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ABSTRACT 
 
MARIELLE E. YOHE: Regulation of the Transforming Immortalized Mammary Protein 
and its Homologs by Auto-inhibition and Tyrosine Phosphorylation 
(Under the direction of John Sondek) 
 
Dbl-related oncoproteins are guanine nucleotide exchange factors (GEFs) specific for 
Rho-family GTPases and typically possess tandem Dbl (DH) and pleckstrin homology (PH) 
domains that act in concert to catalyze exchange.  The exchange activities of many Dbl-proteins 
are regulated by phosphorylation or constitutively activated by truncations preceding their DH 
domains.  However, exact mechanisms of regulation remain poorly understood.  Here we show 
that a sub-group of Dbl-family proteins, including Tim, Ngef, and Wgef, are auto-inhibited by a 
highly conserved helix immediately N-terminal to the DH domain that directly occludes the 
catalytic interface of the DH domain to prevent GTPase activation.  Similar to the distantly 
related Vav isozymes, auto-inhibition is relieved by truncation, mutation, or phosphorylation of 
the auto-inhibitory helix.  Furthermore, substitutions within a highly conserved surface of the DH 
domain designed to disrupt interactions with the auto-inhibitory helix also fully activates the 
exchange process.  Therefore, the regulated auto-inhibition of DH domains by direct steric 
exclusion using short N-terminal segments likely represents a general mode of regulation within 
the large family of Dbl-family proteins.  The C-terminal SH3 domain binding to a poly-
proline region N-terminal to the DH domain of this subgroup of Dbl-family proteins 
provides a unique mechanism of regulated auto-inhibition of exchange activity that is 
functionally linked to the interactions between the auto-inhibitory helix and the DH 
domain. 
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CHAPTER 1: REGULATION OF THE EXCHANGE ACTIVITY OF DBL-
FAMILY PROTEINS 
RhoA, Rac1, and Cdc42 are the best understood of the 22 human Rho-family 
GTPases, which comprise one of five branches of the Ras superfamily of small GTPases 
(1).  Like Ras, Rho proteins function as binary switches that alternate between inactive, 
GDP-bound states and active, GTP-bound states.  Once activated, Rho GTPases directly 
engage numerous downstream effectors to modulate their functions.  Active Rho 
GTPases and their effectors orchestrate actin cytoskeleton rearrangement and gene 
transcription to coordinate diverse cellular processes including adhesion, migration, 
phagocytosis, cytokinesis, neurite extension and retraction, polarization, growth and 
survival (2).  Not surprisingly, aberrant activation of Rho GTPases promotes various 
developmental, immunological and proliferative disorders (3). 
In the development of the nervous system, Rho GTPases integrate extracellular 
signals to direct outgrowth of both axons and dendrites; and the formation and dynamics 
of dendritic spines.  Deletion or mutation of crucial components of the Rho signaling 
pathway renders neurons less responsive to environmental cues, leading to suboptimal 
neuronal connectivity and plasticity (4). 
The activation cycle of Rho GTPases is tightly controlled by three families of 
proteins: GTPase activating proteins (GAPs), guanine nucleotide dissociation inhibitors 
(GDIs) and guanine nucleotide exchange factors (GEFs).  The Dbl-family of proteins 
constitutes the largest group of GEFs specific for Rho GTPases.  Dbl-family proteins are 
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characterized by a Dbl-homology (DH) domain, which contacts the Rho GTPase to 
catalyze nucleotide exchange by promoting and stabilizing an intermediate, nucleotide-
free GTPase state, and an associated pleckstrin-homology (PH) domain, which fine-tunes 
the exchange process by a variety of mechanisms related to the binding of 
phosphoinositides.  The 69 human Dbl-family proteins are divergent in regions outside 
the DH/PH module, and contain additional protein domains that dictate unique cellular 
functions (5). 
The capacity of DH domains to activate Rho GTPases is tightly regulated through 
a multitude of diverse mechanisms ranging from alterations in transcript levels and 
protein expression (6) to subcellular re-distribution (7), post-translation modifications (8) 
and protein degradation (9).  However, despite this large spectrum of regulatory 
mechanisms, in most cases, truncation of Dbl-family proteins often potently activates 
their exchange activities (10).  Currently, there is no general understanding for why 
truncation promotes unregulated exchange.   
The 69 human Dbl-family proteins can be grouped into 17 different sub-families 
based on their domain architecture and the sequence similarity of their DH domains (see 
Figure 1 and (5)).  The regulatory mechanisms for each characterized sub-family are 
reviewed below. 
Fgd subfamily: 
The Fgd subfamily consists of Fgd1 (Faciogenital dysplasia protein 1), Fgd2, 
Fgd3 and Frabin.  Each of these proteins possesses a C-terminal FYVE domain in 
addition to the catalytic DH/PH cassette (5).  FYVE domains, named for the proteins 
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Fab-1, YGL023, Vps27 and EEA1, which also possess this domain, are small, cysteine-
rich, zinc-binding domains known to bind specifically to the phosphoinositide, PI3P (11).   
 
 
Figure 1: Grouping of Dbl-family proteins into subfamilies. 
The 69 human Dbl-family proteins can be grouped into 17 subfamilies based upon their domain 
architecture and the sequence similarity of their DH domains.  Dendrogram adapted from (5). 
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The genes for the members of the Fgd1 subfamily were originally identified as being 
responsible for the development of faciogenital dysplasia, or Aasrskog Scott syndrome, a 
developmental disorder characterized by adverse effects on the formation of skeletal 
structures as well as mental retardation.  Each of these proteins has been shown to 
specifically activate Cdc42 (12-16). 
The best characterized member of this subfamily is Fgd1.  Early studies on the 
regulation of Fgd1 exchange activity showed that while the DH domain alone was 
incapable of inducing filopodia formation in fibroblasts (17), the DH/PH cassette was 
able to transform NIH 3T3 cells (18), suggesting that the PH domain of Fgd1 is necessary 
for it to exchange guanine nucleotide on Cdc42.  Indeed, genetic analysis of a family 
afflicted with faciogenital dysplasia revealed that one mutation responsible for the 
development of this disorder is a missense mutation of a residue in the PH domain known 
to be involved in phosphoinositide binding (19), underscoring the importance of a 
functional PH domain for proper regulation of Fgd1.  However, microinjection of the N-
terminus of Fgd1 into fibroblasts prevented the formation of Fgd1-induced filopodia (20), 
indicating that this Dbl-family protein, like many others, may be auto-inhibited by 
regions N-terminal to the DH domain. 
Alterations in sub-cellular localization also play a role in the regulation of Fgd1 
exchange activity.  A proline-rich region in the N-terminus of Fgd1 is necessary and 
sufficient for its proper localization to the plasma membrane and the Golgi (20).  This 
region has also been shown to interact with cortactin and Actin Binding Protein 1 (Abp1) 
(21).  The interaction between Fgd1 and these two actin binding proteins localizes Fgd1 
to the subcortical actin cytoskeleton in migrating cells.  Mutations that prevent this 
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interaction mislocalize Fgd1 and lead to a decrease in cell motility, indicating that sub-
cellular localization is critical for Fgd1 function (21).  Finally, Fgd1 has been shown to 
be regulated by changes in its protein expression level.  Fgd1 is poly-ubiquitinated and 
targeted for degradation by FWD1/β-TrCP, an F-box E3 ubiquitin ligase.  Mutant Fgd1, 
in which both serines in the FWD1 recognition site have been substituted with alanine, is 
more stably expressed in cells and confers an increase in cell motility (22). 
While the regulation of Fgd2 and Fgd3 exchange activity has yet to be studied, 
the exchange activity of Frabin is also regulated by its sub-cellular localization.  While 
the isolated DH/PH cassette is capable of catalyzing exchange on Cdc42 in vitro, an N-
terminal portion of Frabin, which is capable of binding F-actin and crosslinking actin 
filaments, is required for Frabin to induce the formation of microspikes in fibroblasts 
(15,23), indicating that Frabin must be localized to the actin cytoskeleton to function in 
vivo.  However, the products of PI3 kinase are also required for Frabin activity in cells.  
PI3 kinase has been shown to be necessary for Frabin to induce invadopodia in 
RPMI7951 human melanoma cells (24), and for Frabin to localize to the plasma 
membrane during human biliary cell infection by Cryptosporidium parvum (25).  The 
Fgd1 subfamily of Dbl-family proteins, then, is regulated by several distinct mechanisms, 
including N-terminal auto-inhibition, alteration of sub-cellular localization and alteration 
in levels of expressed protein. 
Frg subfamily: 
The Frg subfamily of Dbl-family proteins consists of Frg (Fgd1-related GEF, also 
known as FIR or Farp2) and CDEP (Chondrocyte-derived ezrin-like domain containing 
protein, also known as Farp) (5).  These proteins each possess an N-terminal FERM  
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GEF: Truncation: Reference: 
Asef Δ SH3 (26) 
CDEP Δ FERM (27) 
Dbl Δ spectrin repeats (28) 
Dbs Δ Sec14 (29) 
Ect2 Δ BRCT repeats (30) 
Fgd1 Δ N-terminus (20) 
GEF-H1 Δ N- and C-terminus (31) 
ITSN Δ SH3 domains (32) 
LARG Δ coiled-coil (33) 
Lbc Δ C-terminus (34) 
Net1 Δ N-terminus (35) 
Ngef Δ N-terminus (36) 
p114-RhoGEF Δ N- and C-terminus (37) 
p115-RhoGEF Δ coiled-coil (33) 
p190-RhoGEF Δ N- and C-terminus (38) 
PDZ-RhoGEF Δ coiled-coil (33) 
Pem2 Δ SH3 (39) 
P-Rex Δ DEP, PH or PDZ (40) 
RasGRF Δ C-terminus (41) 
Sgef Δ N-terminus (42) 
Tiam1 Δ PH and TSS (43) 
Tim Δ N-terminus (44) 
Vav Δ CH (45) 
 
Table 1: Dbl-family GEFs that are activated by truncation mutations. 
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domain and a C-terminal PH domain in addition to the DH/PH cassette.  FERM domains, 
named for Band 4.1, Ezrin, Radixin and Moesin, are thought to bind to both 
phosphoinositides and adhesion proteins, and in so doing, serve as a link between 
membrane dynamics and the actin cytoskeleton.   
The exchange activity of Frg is activated primarily by direct, Src-dependent 
tyrosine phosphorylation of Frg, which activates its exchange potential towards Cdc42.  
Several different signaling pathways lead to Src phosphorylation of Frg.  For example, 
endothelin A, acting through its G-protein coupled receptor, leads to Src phosphorylation 
of Frg (46).  In addition, the binding of nectins, the calcium-independent Ig-like adhesion 
molecules that initiate the formation of adherens junctions, to their partners on 
neighboring cells leads to Src-mediated phosphorylation of Frg (47).  However, signaling 
pathways downstream of nectin ligation also lead to activation of the small GTPase Rap1, 
which is also able to activate Frg, through an as yet undetermined mechanism (48).  
Finally, the interaction of CD47, an Ig superfamily member, with its ligand, SH2-domain 
containing protein tyrosine phosphatase, leads to activation of Src and phosphorylation of 
Frg, which promotes the formation of dendritic filopodia and spines (49). 
CDEP has not yet been shown to be a substrate for Src phosphorylation.  
However, truncation of the N-terminal FERM domain of CDEP has been shown to 
activate its exchange potential towards RhoA (27).  In addition, CDEP is regulated at the 
transcriptional level.  Parathyroid hormone, binding to its G-protein coupled receptor, 
leads to the formation of the second messenger, cyclic AMP, which induces the 
expression of CDEP in maturing chondrocytes (27).  The two Frg subfamily members, 
then, are regulated in different ways.  Frg is regulated primarily by tyrosine 
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phosphorylation, while CDEP is regulated by auto-inhibition and alterations in levels of 
its transcript. 
Ras-GRF subfamily: 
The Ras-GRF subfamily consists of two highly related isozymes, Ras-GRF1 (Ras 
guanine nucleotide releasing factor) and Ras-GRF2 (5).  Both Ras-GRF1 and Ras-GRF2 
are expressed predominantly in the neuronal cells of the central nervous system.  Like the 
Sos proteins, Ras-GRF1 and 2 are able to catalyze exchange of guanine nucleotides on 
both GTPases of the Ras family, through a C-terminal Cdc25 domain, and the Rho 
family, through an N-terminal DH/PH cassette.  In addition to the Cdc25 and DH/PH 
domains, Ras-GRF proteins also contain an N-terminal, non-DH-associated PH domain, 
and an IQ motif.  While the exchange potential of Ras-GRF toward Ras is strongly 
activated by calcium binding to the IQ motif, the regulation of the exchange potential of 
Ras-GRF towards Rac1, the cognate GTPase of the DH/PH cassette, is less well 
understood (41). 
Several lines of evidence suggest that regulation of Ras-GRF exchange activity 
towards Rac1 is regulated by heterotrimeric G-proteins.  First, the Rac activity of Ras-
GRF is increased in response to LPA (lysophosphatidic acid) (50), which acts through a 
G-protein coupled receptor (GPCR).  In addition, Ras-GRF has been shown to function 
as a Rac1-specific GEF when it is immunoprecipitated from cells that are also expressing 
Gβγ (51). 
Ras-GRF exchange activity is regulated independently of heterotrimeric G-
proteins as well.  For example, Ras-GRF is tyrosine phosphorylated in a Src-dependent 
manner downstream of signaling from the platelet-derived growth factor (PDGF) 
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receptor, and that phosphorylation increases its exchange activity toward Rac (51).  
Truncation of the C-terminus of Ras-GRF also activates its exchange potential toward 
Rac (41).  Ras-GRF exchange activity is also regulated by dimerization.  Both Ras-GRF1 
and Ras-GRF2 form homo- and hetero-dimers through their DH domains, and these 
dimerization events are required for their transformation activity (52).  Finally, the N-
terminal region of Ras-GRF has been shown to interact with both microtubules (53) and 
activated H-Ras (41), although the consequences of these interactions on the exchange 
potential of Ras-GRF towards Rac have yet to be determined.  The mechanisms by which 
the Rac-specific exchange activity of Ras-GRF isozymes are regulated, then, are 
incompletely understood.  However, these mechanisms include activation downstream of 
cell surface receptors such as GPCRs and RTKs and other intermolecular interactions. 
Sos subfamily: 
The Sos subfamily is made up of the highly related isozymes, Sos1 (Son of 
sevenless) and Sos2 (5).  Sos was originally identified in Drosophila as an exchange 
factor for Ras in the Sevenless pathway of eye development.  Like the RasGRF isozymes, 
the Sos isozymes are exchange factors for Rac1, through their N-terminal DH/PH 
cassettes, and Ras, through their C-terminal Cdc25 domains (54).   
Unlike the RasGRF isozymes, the molecular context in which the Sos isozymes 
function as a GEF for Rac as opposed to Ras has been well described.  The proline-rich 
C-terminus of Sos is able to interact with the SH3 domain of the adaptor, Grb2.  The SH2 
domain of Grb2 localizes the Sos/Grb2 to auto-phosphorylated receptor tyrosine kinases 
at the cell membrane.  This membrane localization enables Sos to catalyze exchange of 
guanine nucleotides on Ras (54).  In contrast, Sos can also form a poly-proline mediated 
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complex with two scaffold proteins, Eps8 and E3b1.  When Sos is in this context, it is 
able to activate Rac as opposed to Ras (55,56).  The transition between the Sos/Grb2 and 
Sos/Eps8/E3b1 complex is mediated by p66-Shc, an adaptor protein that competes with 
Grb2 for Sos binding and causes the dissociation of the Sos/Grb2 complex (57).   
The Sos isozymes are also unique in that they have been shown to be clearly 
regulated by the product of PI3 kinase, PI(3,4,5)P3.  The exchange activity of Sos is auto-
inhibited via steric occlusion of the DH domain by the adjacent PH domain (58).  The 
Sos PH domain has a higher affinity for binding PI(3,4,5,)P3 than it does for PI(3,4)P2 or 
PI(4,5)P2 (59).  However, when the PH domain is bound to PI(4,5)P2 it sterically 
occludes the GTPase binding site of the DH domain, but when the PH domain is bound to 
PI(3,4,5)P3, it is not able to bind to the DH domain, and the exchange activity of Sos for 
Rac is activated (60).  Interestingly, the regulatory subunit of PI3 kinase is able to interact 
with a phosphorylated form of E3b1, and further increase the Rac activity of Sos when it 
is bound to Eps8/E3b1 (61). 
Like many other Dbl-family proteins, Sos is activated by tyrosine 
phosphorylation.  Activation of receptors tyrosine kinase such as the EGFR and PDGFR 
leads to tyrosine phosphorylation of Sos in an Abl-dependent manner.  Phosphorylation 
by Abl increases the exchange potential of Sos toward Rac1, although Sos must both be 
tyrosine phosphorylated and bound to Eps8/E3b1 to be fully active (62).  Finally, Sos 
activity towards Rac is activated downstream of signaling from Robo, the repulsive 
guidance receptor in the nervous system that binds to the ligand, Slit.  The mechanism by 
which Sos is activated in this case has yet to be determined (63).  The Sos family  
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Figure 2: Regulation of Rac-specific exchange activity of Sos by intermolecular interactions. 
Sos bound to Grb2 is Ras-specific and localized to the plasma membrane.  The activity of p66-Shc causes 
dissociation of Sos from Grb2.  Sos is then able to bind to the complex of E3b1 and Eps8.  This trimeric 
complex is then able to catalyze exchange of guanine nucleotide on Rac. 
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isozymes, then, are regulated by alterations in their sub-cellular localization, lipid binding 
to their PH domains, and tyrosine phosphorylation (see Figure 2).   
Ect2 Subfamily: 
The Ect2 subfamily consists of the protein product of the epithelial cell 
transforming gene 2, as well as its uncharacterized isozyme (protein accession number 
XP294019) (5).  A truncated form of Ect2 was originally identified in a screen for 
mitogenic, signal-transducing genes in epithelial cells (64).  Ect2 has subsequently been 
shown to be the main guanine nucleotide exchange factor active during mitosis (65).  Its 
N-terminus is composed of a novel domain with homology to the yeast cyclin protein, 
Clb6; followed by two BRCT (BRCA1 C-terminal repeat) motifs, which are common in 
checkpoint and repair proteins.  The DH/PH cassette, shown to be specific for RhoA (66), 
is located in the C-terminus of the molecule.  A nuclear localization sequence is found in 
the center of the molecule, in the so-called S domain, between the BRCT repeats and the 
DH domain (30). 
The exchange activity of Ect2 is strongly auto-inhibited by its N-terminus.  The 
BRCT repeats are able to form a direct, intramolecular interaction with the DH domain to 
prevent activation of RhoA by Ect2 (30,67).  In fact, expression of the N-terminus of 
Ect2 in trans inhibits Ect2 to such an extent that accumulation of active RhoA and 
cytokinesis is blocked (64,65).  The extreme C-terminus of Ect2, however, is necessary 
for cellular transformation by Ect2 expression (30,66). 
Ect2 is localized to the nucleus in interphase cells, where it is inactive (64).  
However, when a cell enters metaphase, Ect2 translocates to the mitotic spindle, and is 
found at the cleavage furrow during the anaphase and telophase stages of mitosis (64).  
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Its localization to the central spindle and astral microtubules near the equatorial cortex in 
the cleavage furrow is mediated by an interaction with centralspindlin (68), a protein 
complex composed of the mitotic kinesin, MK1p2 and MgcRacGAP, a GTPase 
activating protein for Rac (69).  An intact PH domain, as well as the BRCT repeats, is 
necessary for proper localization of Ect2 to the cleavage furrow during mitosis (69).  
When Ect2 is localized to the cleavage furrow, its exchange activity is increased through 
an allosteric interaction with p0071, an armadillo-repeat containing protein related to 
p120-catenin (70). 
Ect2 is also regulated at the expression level.  Expression of Ect2 is induced at the 
S to M transition during the cell cycle, and is induced by several growth factors, 
including KGF, EGF and PDGF (30).  In contrast, like other genes responsible for cell 
cycle progression, Ect2 gene expression is down-regulated through the actions of the 
tumor suppressor and cell cycle checkpoint proteins, p53 and Rb (71,72).  Expression of 
Ect2 is also regulated at the protein level, since Ect2 interacts with an ubiquitin ligase, 
UBE3A (73).  The importance of proper regulation of Ect2 expression is underscored by 
the fact that amplification of the Ect2 gene is seen in esophageal squamous cell 
carcinoma (74). 
Finally, Ect2 is regulated by phosphorylation.  Ect2 is phosphorylated at the G2 to 
M transition of the cell cycle, and that phosphorylation event is required for Ect2 
exchange activity (64).  In particular, during metaphase, Ect2 is phosphorylated at Thr 
814 by Cyclin dependent kinase 1 (Cdk1).  The mitotic kinase, Plk, binds to Ect2 thus 
phosphorylated, and subsequently phosphorylates Ect2 at Thr 412, activating its 
exchange potential (75).  The Ect2 proto-oncogene, then, is regulated by a variety of  
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Figure 3: Ect2 is regulated by auto-inhibition, phosphorylation and nuclear sequestration. 
During interphase, Ect2 is sequestered in the nucleus, where it is inactive.  However, when the cell enters 
mitosis and the nuclear envelope breaks down, Ect2 is phosphorylated and activated by mitotic kinases.  
Active Ect2 then translocates to the cleavage furrow, where it is able to activate RhoA. 
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mechanisms, including auto-inhibition, alteration in sub-cellular localization, tyrosine 
phosphorylation and alteration in expression levels (see Figure 3). 
Tim subfamily: 
The Tim subfamily is made up of Tim (Transforming Immortalized Mammary), 
Ngef (Neuronal-specific GEF), Wgef (Weakly similar to RhoGEF5), Sgef (SH3 domain-
containing GEF), Vsm-RhoGEF (Vascular smooth muscle cell specific GEF), and 
neuroblastoma (5).  Tim and its closest homologs all possess a divergent N-terminus of 
low complexity followed by a DH/PH cassette and a C-terminal Src homology 3 (SH3) 
domain.  SH3 domains are known to interact with poly-proline containing ligands, 
however, no such binding partners have yet been identified for members of the Tim 
subfamily. 
Ngef is expressed primarily in the brain, is localized to chromosome 2q37, and is 
transforming in cell culture (36,76).  The mouse homolog of Ngef, ephexin, is expressed 
in the central nervous system during development and was originally cloned based upon 
its ability to interact with the EphA4 receptor tyrosine kinase.  Ephexin activates RhoA, 
Rac1 and Cdc42 in cell-based assays; mediates ephrinA-induced growth cone collapse 
(77); and is phosphorylated by Src family kinases downstream of EphA4 receptor 
activation (76).  When ephexin is not tyrosine phosphorylated, it activates RhoA, Rac1 
and Cdc42; but when ephexin is tyrosine phosphorylated; it activates RhoA exclusively 
(78).  Most recently, ephexin has been shown to be phosphorylated in its N-terminus by 
Cdk5 downstream of EphA4 receptor activation.  Phosphorylation of ephexin by Cdk5 
also activates its exchange potential towards RhoA (79).  The precise mechanism by 
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which ephexin undergoes its specificity switch and the mechanisms by which Cdk5 and 
Src coordinate to modulate ephexin activity are poorly understood. 
Vsm-RhoGEF, which is specifically expressed in vascular smooth muscle cells, 
also associates with the intracellular domain of EphA4.  EphA4 signaling leads to 
phosphorylation of Vsm-RhoGEF and activation of the RhoA specific exchange activity 
of this protein (80).  Sgef is localized to human chromosome 2q25.2, an amplification 
unit in prostate tumors (81), and generates a novel dorsal ruffling phenotype through 
activation of RhoG (42).  Wgef is expressed primarily in liver, heart and kidney, and 
activates RhoA, Rac1 and Cdc42 in cell-based activity assays (82).   
Tim was originally identified based upon its capacity to induce transformation of 
NIH 3T3 cells upon truncation (83), and while there are multiple transcripts of TIM 
(44,83), endogenous Tim is expressed as a 60-kDa protein.  mRNA transcripts encoding 
Tim are ubiquitously expressed in numerous tissues and cancer-derived cell lines; 
corresponding protein expression has been verified in various cell lines (44,83).  The 
gene encoding human Tim has been localized to chromosomal region 7q33 -7q35, which 
has been implicated in rearrangements contributing to both acute myelogenous leukemia 
and breast carcinoma (84).  The regulation of Tim and its orthologs, Ngef and Wgef, will 
be described in later chapters.
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GEF: Binding Partner: Domain required: Sub-cellular 
localization: 
Activity at this 
location: 
Reference: 
Ect2 centralspindlin PH domain Cleavage 
furrow 
Increased (68) 
Fgd1 Actin binding protein 
1; cortactin 
N-terminal proline 
rich region 
Actin 
cytoskeleton 
Increased (21) 
Frabin Unknown N-terminus Actin 
cytoskeleton 
Increased (15) 
GEF-H1 Microtubules Zn++ finger Mitotic 
spindle 
Decreased (85) 
Net1 N/A N-terminal NLS Nucleus Decreased (86) 
Tiam1 Par3/Par6/aPKC RBD Junctions Unknown (87) 
Tiam1 Arp 2/3 PH-TSS Actin rich 
regions of 
plasma 
membrane 
Unknown (88) 
Tuba ZO-1 Unknown Tight 
junctions 
Unknown (89) 
Table 2: Regulation of Dbl-family GEFs by alteration of their sub-cellular localization. 
 
 18
Intersectin subfamily: 
The intersectin subfamily consists of ITSN1 (intersectin1) and its ortholog, 
ITSN2, which is largely unstudied (5).  A short splice isoform of ITSN was originally 
characterized as a scaffold protein that functions in receptor-mediated endocytosis, 
consisting of two EH domains (Eps15 homology), a coiled-coil region and five tandem 
SH3 domains.  The EH domains, which are related to EF hand motifs, helix-loop-helix 
structural motifs that coordinate calcium and function in protein-protein interactions, 
target ITSN-S to clathrin-coated pits.  Additionally, the SH3 domains bind to the 
molecular motor for endocytosis, the GTPase, dynamin (90,91).   
A longer, neuronal-specific, isoform of ITSN was identified, ITSN-L, which 
contains a DH/PH cassette in its C-terminus.  ITSN-L is an exchange factor specific for 
Cdc42 (32).  While the PH domain of ITSN-L binds to a broad spectrum of 
phosphoinositides, the binding of phospholipids does not affect the in vitro exchange 
activity of ITSN-L (92).  Similarly, ITSN-L is not stimulated by PI3 kinase activity, the 
DH domain alone exhibits the same in vitro exchange activity as the DH/PH tandem (93) 
and the PH domain makes no contacts with Cdc42 as judged by the crystal structure of 
the DH/PH cassette bound to Cdc42 (94).  Multiple lines of evidence, then, show that the  
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GEF: Dimerization domain: Reference: 
β-Pix Leucine zipper (95) 
Dbl DH (96) 
LARG Coiled-coil (33) 
Lbc Coiled-coil (97) 
p115-RhoGEF Coiled-coil (33) 
PDZ-RhoGEF Coiled-coil (33) 
RasGRF DH (52) 
 
Table 3: Dbl-family GEFs that form homo-dimers. 
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exchange activity of ITSN-L is not regulated through the binding of phospholipids to its 
PH domain. 
The exchange activity of ITSN, however, is regulated by auto-inhibition.  The 
SH3 domains of ITSN-L inhibit its in vitro exchange activity by sterically occluding the 
DH domain to prevent binding of nucleotide free Cdc42.  The binding of the SH3 
domains to the DH domain occurs in a manner independent of the poly-proline binding 
pocket.  However, the binding of proteins, such as N-WASP, which coordinates the 
formation of actin filaments (32) and Numb, an adaptor protein important in dendritic 
spine morphogenesis (98), to the SH3 domains leads to an increase in the exchange 
activity of ITSN-L.  Although the SH3 domains mediate ITSN-L auto-inhibition, they are 
also required for cellular transformation by ITSN-L.  The first SH3 domain binds to Sos, 
which leads to activation of the small GTPase, Ras, and subsequent cellular 
transformation (99). 
Like many other Dbl-family members, the exchange activity ITSN-L also may be 
regulated by phosphorylation.  The kinase domain of the ligand-bound tyrosine kinase, 
EphB2, interacts with the N-terminus of intersectin.  Although phosphorylation of ITSN-
L by EphB2 has not yet been studied, the interaction of ITSN-L with EphB2 increases the 
exchange activity of ITSN-L (100).  Therefore, while ITSN subfamily members are not 
regulated through the binding of phospholipids, they are regulated by auto-inhibition and 
phosphorylation.   
Net1 subfamily: 
The Net1 subfamily consists of Net1 (neuroepithelial transforming protein) and 
Xpln (exchange factor found in platelets, leukemic, and neuronal tissues).  These two 
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proteins are among the smallest of the Dbl-family, and contain no known domains 
outside of the conserved DH/PH cassette (5).  While Net1 specifically activates RhoA 
and not Rac1 or Cdc42 (101), Xpln activates RhoA and RhoB but not RhoC (102). 
A truncated version of Net1 was originally identified as an oncogene in a genetic 
screen from a cDNA expression library derived from a human neuroepithelial cell line 
(35).  Indeed, the N-terminus of Net1 inhibits its exchange activity (101), albeit through a 
unique mechanism.  Net1 contains two nuclear localization signals (NLS) in its N-
terminus.  Removal of these sequences allows Net1 to localize to the cytoplasm, where it 
is able to activate RhoA.  The PH domain of Net1 is necessary and sufficient for its exit 
from the nucleus, presumably through interactions with other proteins that contain a 
nuclear export sequence (10).  The extreme C-terminus of Net1 forms a consensus PDZ-
domain binding site, which has been shown to be critical for the transformation potential 
of Net1, although no binding partners for this motif have been identified to date (103). 
Although binding partners for the PH domain and PDZ-binding motif of Net1 
have yet to be identified, Net1 has been shown to bind to several other proteins.  The 
Xenopus ortholog of Net1, xNet1, interacts with Dishevelled, a protein scaffold critical 
for Wnt signaling.  Net1 also interacts with the protein scaffold, CNK1, which leads the 
RhoA activated by Net1 to activate only the JNK signaling pathway (104).  Finally, Net1 
is phosphorylated by Pak1 on several serine residues, which decreases its exchange 
activity (105). 
In contrast to Net1, the mechanisms by which the exchange activity of Xpln is 
regulated are largely unknown.  Xpln is not activated by truncation of its N- or C-
terminus, although it is transforming (102).  In addition, the two NLS in the N-terminus  
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Figure 4: Net1 is regulated by nuclear sequestration. 
The nuclear localization sequence on the N-terminus of Net1 targets it to the nucleus, where it is inactive.  
The mechanisms that allow Net1 to exit from the nucleus to the cytosol, where it is able to activate RhoA, 
are unclear.  Net1, therefore, represents a Dbl-family GEF that is activated in cellular assays by N-terminal 
truncation, but is not auto-inhibited. 
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of Net1 are not conserved in Xpln, and as a consequence Xpln is largely expressed in the 
cytosol (86).  Members of the Net1 subfamily, then, are unique in that they are not 
regulated by auto-inhibition.  Net1, but not Xpln, is regulated by sequestration in the 
nucleus (see Figure 4). 
p115-RhoGEF subfamily: 
The p115-RhoGEF subfamily is composed of p115-RhoGEF, PDZ-RhoGEF and 
LARG (for leukemia-associated Rho GEF).  Each of these proteins possesses an N-
terminal RGS (regulator of G-protein signaling) domain, a DH/PH cassette and a C-
terminal coiled-coil domain.  PDZ-RhoGEF and LARG also contain a PDZ domain in 
their extreme N-terminal region, which enables these proteins to interact with the C-
termini of various proteins with which p115-RhoGEF is unable to interact, as is discussed 
below (5).  p115-RhoGEF and PDZ-RhoGEF were originally identified based upon their 
ability to interact with Gα13 (106,107), while LARG, in contrast, was identified as a 
fusion partner with Mixed Lineage Leukemia (MLL) protein in an AML patient (108).   
All three of these proteins have been shown to be exchange factors specific for 
RhoA (5).  In addition, all three of these proteins have been shown to oligomerize 
through their C-terminal coiled-coil domain (33).  This oligomerization leads to a 
decrease in exchange activity.  Finally, all three of these proteins have been shown to 
interact directly with activated Gα12 and Gα13 (106-108). 
The best characterized member of this subfamily is p115-RhoGEF.  The RGS 
domain of p115-RhoGEF has been shown to bind to and act as a GAP (GTPase 
accelerating protein) for Gα12 and Gα13.  However, only Gα13 has been shown to directly 
activate the exchange potential of p115-RhoGEF for RhoA, although truncation of the 
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RGS domain is activating (107).  Endogenous p115-RhoGEF is localized to the cytosol in 
serum-starved cells, but translocates to the plasma membrane upon stimulation with LPA 
(109).  LPA acts through a GPCR to activate Gα12 and Gα13.  Palmitoylated and 
activated Gα12 and Gα13 are able to induce translocation of p115-RhoGEF (110).  
Interestingly, both the RGS domain and the PH domain are necessary for p115-RhoGEF 
translocation to the membrane in response to LPA treatment, indicating that the PH 
domain is also a potential binding site for Gα subunits (111). 
The PDZ domain of PDZ-RhoGEF and LARG mediates an interaction of these 
Dbl-proteins with the C-terminus of Plexin-B2, a transmembrane receptor that transduces 
both attractive and repulsive signals mediated by the axon-guidance ligands, the 
semaphorins.  Plexin B signaling leads to activation of the exchange potential of PDZ-
RhoGEF and LARG through an as yet undefined mechanism (112).  An association of 
the small GTPase, Rnd1, with the C-terminus of Plexin B increases the interaction of 
plexin B with PDZ-RhoGEF, leading to an increase in Rho activation in cells where all 
three of these proteins are expressed (113).  In addition, PDZ-RhoGEF and LARG are 
able to associate with the C-terminus of the LPA receptor, a GPCR that catalyzes the 
activation of Gα12/13 subunits (114), and LARG is able to interact with the C-terminus of 
IGF1-R (115).  Both of these interactions are mediated through the PDZ domain of these 
GEFs and the consequences of the interactions on the exchange potential of the GEFs 
have yet to be determined. 
The GEFs in the p115-RhoGEF subfamily are also regulated by phosphorylation 
events.  Signaling from the thrombin receptor leads to PKC activation, and activated PKC 
is able to phosphorylate and activate p115-RhoGEF (116).  In addition, Tec, a non-
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receptor tyrosine kinase that contains a PH domain, phosphorylates LARG and increases 
its exchange activity (117).  In both of the above cases, Gα subunits are still required to 
unleash the full exchange potential of the phosphorylated GEF.  In contrast, 
phosphorylation of the p115-RhoGEF subfamily GEFs by the p21-activated kinases 
(Paks) does not activate their exchange potential.  Pak1 is able to phosphorylate p115-
RhoGEF, and not PDZ-RhoGEF or LARG.  This phosphorylation has no effect on the 
exchange activity of p115-RhoGEF (118).  Pak4, in contrast, binds to the C-terminus of 
PDZ-RhoGEF, phosphorylates the GEF and decreases its exchange activity (119).  In 
conclusion, members of the p115-RhoGEF subfamily can be activated by C-terminal 
truncation, not N-terminal truncation as has been described for many other Dbl-family 
members.  Also, orthologs of p115-RhoGEFs are activated downstream of signaling from 
Gα12/13-coupled receptors, and are inhibited by phosphorylation on serine or threonine 
residues. 
Lbc subfamily: 
The Lbc subfamily is made up of Lbc (Lymphoid blast crisis, also known as 
AKAP-Lbc, for A-kinase anchoring protein, or Brx), GEF-H1 (also known as Lfc, for 
Lbc’s first cousin), p190-RhoGEF, and p114-RhoGEF.  Each of these proteins is 
composed of an extended N-terminus with no known domain architecture, a DH/PH 
cassette, and a C-terminal coiled-coil domain.  All four proteins have been shown to be 
RhoA specific exchange factors.  Of the four proteins in this subfamily, Lbc and GEF-H1 
are the best studied (5).   
p190-RhoGEF was identified in a yeast-two-hybrid screen for proteins that 
interact with c-Jun amino-terminal kinase interacting protein 1 (JIP-1) (120).  The full-
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length protein is auto-inhibited with respect to the isolated DH/PH cassette.  The protein 
is localized to the cytoplasm, distinct microdomains of the plasma membrane and 
microtubules.  The C-terminus of p190-RhoGEF mediates the interaction with 
microtubules by directly binding to tubulin, although this interaction does not affect the 
exchange activity of p190-RhoGEF (38). 
Stimulation of cells expressing p114-RhoGEF with thrombin, LPA or 
acetylcholine leads to Rho activation.  Activation of Rho in this context is thought to be 
due to Gβγ binding to the DH/PH cassette of p114-RhoGEF and activating its exchange 
potential.  Importantly, the isolated DH/PH cassette is more active than full-length p114-
RhoGEF in catalyzing exchange of guanine nucleotides on RhoA (37). 
Onco-Lbc was identified in a screen for oncogenes in a cDNA library isolated 
from a patient in the acute phase of chronic myelogenous leukemia (CML) (121).  Onco-
Lbc was shown to be transforming in NIH 3T3 cells and capable of inducing tumor 
formation in immunocompromised mice (122).  Onco-Lbc is the result of a fusion event 
between the gene for proto-Lbc and an unrelated sequence, which led to the introduction 
of a nonsense mutation immediately following the PH domain (97).  Proto-Lbc is auto-
inhibited with respect to onco-Lbc in a variety of cellular assays, and both the DH and 
PH domains of onco-Lbc are necessary for its activity (34,123,124).  Onco-Lbc localizes 
to actin stress fibers, and the PH domain is necessary for this localization pattern (34).  
Full-length Lbc, like its cousins, p115-RhoGEF, PDZ-RhoGEF, and LARG, is able to 
interact with Gα12 and is able to form homo-dimers through its C-terminal coiled-coil 
domain.  Homo-dimerization maintains the basal activity level of full-length Lbc 
(97,125).   
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A splice isoform of Lbc, known as Brx, is able to bind to and act as a 
transcriptional co-activator for various steroid hormone receptors, including both of the 
estrogen receptors, the retinoic acid receptor β and the glucocorticoid receptor (126,127).  
The consequences of these interactions on the exchange activity of Lbc have yet to be 
determined.  Lbc is able to interact with the regulatory subunit of protein kinase A (PKA) 
(128).  In turn, activated PKA phosphorylates Lbc on serine 1565.  This phosphorylation 
event enables 14-3-3 to bind to Lbc, which inhibits the exchange activity of Lbc (129).  
Interestingly, binding of the metastasis suppressor, nucleoside diphosphate kinase nm23-
H2 also inhibits the exchange activity of Lbc (130). 
The oncogenic form of GEF-H1, which is N-terminally and C-terminally 
truncated with respect to the wild-type protein, was originally identified in a screen for 
oncogenes expressed in a leukemia cell line (31,131).  GEF-H1 is unique among the 
members of the Lbc subfamily in that it contains a zinc finger motif in its N-terminus.  
Microtubules are able to interact with GEF-H1 directly by binding to the zinc finger 
motif.  The interaction stabilizes the microtubules, but inhibits the exchange activity of 
GEF-H1 towards RhoA (132), potentially by stabilizing an auto-inhibitory interaction 
between the zinc finger motif and the PH domain (133).  The interaction with 
microtubules, and thus the activity of GEF-H1, is regulated by the cell cycle.  For 
example, GEF-H1 is cytosolic and active during interphase, but bound to the mitotic 
spindle during mitosis (85,134).  Enteropathogenic E. coli is able to take advantage of 
this feature of GEF-H1 regulation in order to lead to an activation of RhoA in the cell.  
The type III effector Esp6/Orf3 is injected into cells, which triggers the destruction of 
microtubules, thus activating GEF-H1 and causing the formation of stress fibers (135).  
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GEF-H1 is also able to associate with tight junctions in epithelial cells and regulate 
paracellular permeability.  The association with tight junctions is mediated by GEF-H1 
binding through its PH domain to the F-actin binding protein, cingulin.  This interaction, 
like the interaction with microtubules, decreases the RhoA exchange activity of GEF-H1 
(133). 
The exchange activity of GEF-H1 is also regulated by phosphorylation.  Pak1 
phosphorylates GEF-H1 on Ser 885, which has no direct effect on the exchange activity 
of GEF-H1.  However, phosphorylation on Ser 885 creates a binding site for 14-3-3, 
which inhibits GEF-H1 exchange activity (9).  The Class II Pak, Pak4, is also able to 
phosphorylate GEF-H1; in this case, Ser 810 is the target residue for phosphorylation.  
However, this phosphorylation causes a release of GEF-H1 from the microtubules into 
the cytoplasm (136).  Finally, transcription of the GEF-H1 mRNA is regulated in several 
cases: mutant p53, which causes trans-activation of genes not induced by wild-type p53, 
up-regulates the transcription of GEF-H1 (137), while treatment of cells with Gleevac 
leads to a decrease in GEF-H1 expression (138).  As a group, members of the Lbc 
subfamily are regulated similarly to the highly related p115-RhoGEF subfamily 
members.  However, GEF-H1 is also uniquely down-regulated by interactions with 
microtubules as well as phosphorylation-dependent interactions with 14-3-3 proteins.   
Vav subfamily: 
The Vav subfamily is made up of three Dbl-family proteins, Vav1, Vav2 and 
Vav3.  Each of these proteins is composed of eight structural domains: a calponin 
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GEF: Kinase: Sites of 
Phosphorylation: 
Effect on 
Exchange Activity: 
Upstream Signal: Reference: 
β-Pix Pak1 S525, T526 Increased bFGF, NGF (139) 
β-Pix PKA S516, T526 Unknown Endothelin 1 (140) 
β-Pix Src/FAK Y442 Increased (Rac) EGF (141) 
Dbl ACK1 ND (Y) Increased Unknown (142) 
Dbs Src ND (Y) Increased Epinephrine/ 
Norepinephrine 
(143) 
Dbs Unknown ND (Y) Increased Neurotrophin 3 (144) 
Ect2 Cdk1 T814 None G2 to M transition (64) 
Ect2 Plk T412 Increased G2 to M transition (75) 
Ephexin Src Y87 Increased (Rho) Ephrin A (78) 
Ephexin Cdk5 S139 Increased (Rho) Ephrin A (79) 
FRG Src ND (Y) Increased Endothelin A; 
nectin 
(46,47) 
GEF-H1 Pak1 S885 Decreased (14-3-3) Unknown (9) 
GEF-H1 Pak4 S810 Increased (release 
from microtubules) 
 (136) 
Kalirin Unknown ND (Y) None Ephrin B (145) 
LARG Tec ND (Y) Increased Unknown (117) 
Lbc PKA S1565 Decreased (14-3-3) Unknown (129) 
p115-RhoGEF PKC ND (S/T) Increased Thrombin (116) 
p115-RhoGEF Pak1 ND (S/T) Decreased Unknown (118) 
PDZ-RhoGEF Pak4 ND (S/T) Decreased Unknown (119) 
P-Rex1 PKA ND (S/T) Decreased Epinephrine/ 
norepinephrine 
(146) 
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GEF: Kinase: Sites of 
Phosphorylation: 
Effect on 
Exchange Activity: 
Upstream Signal: Reference: 
RasGRF Src ND (Y) Increased PDGF (147) 
Sos Abl ND (Y) Increased EGF; PDGF (62) 
Tiam1 CaMKII ND (T) Increased LPA, PDGF, 
endothelin, 
bombesin, 
bradykinin 
 
Tiam1 ROCK T1662 Decreased Unknown (148) 
Tiam1 Src ND (Y) Increased Unknown (149) 
Tiam1 TrkB Y829 Increased BNDF (150) 
Trio Abl ND (Y) Unknown Unknown (151) 
Vav Multiple Y142, Y160, Y172 
(Vav1 numbering) 
Increased Multiple (152) 
Vsm-RhoGEF Unknown ND (Y) Increased Ephrin A (80) 
 
 
Table 4: Regulation of Dbl-family GEFs by phosphorylation. 
ND denotes not determined; Y, S and T are tyrosine, serine and threonine, respectively. 
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homology (CH) domain, an acidic region, a DH domain, a PH domain, a cysteine-rich 
zinc-finger (CRD) domain, and an SH2 (Src homology 2) domain flanked by two SH3 
domains.  CH domains are potential actin-binding domains found in a variety of 
cytoskeletal and signal transduction proteins, while SH2 domains are known to bind 
phospho-tyrosine containing ligands (11).  Vav1 is expressed primarily in hematopoetic 
cells, where it plays a role in B and T cell development, although it is ectopically 
expressed in some primary pancreatic adenocarcinomas (153).  Vav2 and Vav3 have near 
ubiquitous expression patterns (152). 
Regulation by intramolecular auto-inhibitory interactions has been studied 
extensively for Vav1.  An NMR structure of the Vav1 DH domain and the C-terminal 
portion of the acidic region revealed that a helix N-terminal to the DH domain folds back 
to occlude the GTPase binding surface.  Inhibition is relieved by phosphorylation of a 
tyrosine 174 within this helix, which disrupts the interactions of the helix with the DH 
domain.  The DH domain is subsequently solvent exposed, able to bind GTPases and thus 
able to catalyze exchange (154).   
While this auto-inhibitory helix functions to regulate Vav proteins in vivo, the 
complete mechanism of Vav regulation may be more complex.  Vav is phosphorylated on 
two tyrosine residues in the acidic region, Y142 and Y160, in addition to Y174 
highlighted above.  Mutation of all three of these residues to phenylalanine activates the 
transformation potential and in vitro exchange potential of Vav1, but not to the same 
extent as truncating the CH domain (8).  The CH domain, then, is required for the 
orientation of the auto-inhibitory helix on the surface of the DH domain in the context of 
full-length Vav1.  In addition, the CH domain contributes to the auto-inhibition of Vav  
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Figure 5: Vav1 is regulated by intramolecular interactions and phosphorylation. 
A portion of the acidic region of Vav1, which has the consensus sequence φ Y x x φ (where φ denotes a 
hydrophobic amino acid residue and x denotes any amino acid residue), forms a helical structure that binds 
to the most conserved surface of the DH domain, preventing GTPase binding.  Tyrosine phosphorylation, 
by the Src family kinase Lck, among others, disrupts the interaction of this auto-inhibitory helix with the 
DH domain.  The DH domain is then able to bind and exchange guanine nucleotide on small GTPases such 
as Rac. 
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proteins by forming an intramolecular interaction with the CRD (45).  Multiple diverse 
upstream signals lead to activation of Vav proteins.  For example, cell surface receptors 
of the tyrosine kinase, cytokine, adhesion and G-protein coupled families are all able to 
induce downstream phosphorylation and activation of Vav proteins (152,155).   
Vav proteins may also be regulated through binding of phospholipids to the PH 
domain.  This mode of regulation is thought to be mediated by the PH domain binding to 
and occluding the GTPase binding site of the DH domain.  Binding to the DH domain is 
enhanced by the PH domain binding to PI(4,5)P2 and eliminated by the PH domain 
binding to PI(3,4,5)P3 (156).  However, a recent single particle electron microscopy study 
of full length Vav3 failed to provide any structural evidence for this mechanism, 
indicating that Vav proteins may be regulated primarily through phospholipid 
independent mechanisms (157).   
The function of the C-terminal SH2-SH3-SH2 domain grouping of the Vav 
proteins appears to be cell-type specific.  However, these domains have been shown to be 
important for the localization of Vav proteins, and their proper engagement of both 
upstream kinases and downstream effectors (45).  The regulation of Vav proteins, then, is 
complex and is not facilitated simply by phosphorylation of Y174 (see Figure 5). 
Pix subfamily: 
The Pix subfamily consists of α-Pix (Pak interacting exchange factor, also known 
as Cool-2) and β-Pix (also known as p85-SPR or Cool-1) (5).  Both of these proteins 
were identified by three independent laboratories based upon their ability to bind to p21-
activated kinase (Pak) (158-160).  Both α- and β-Pix are made up of an N-terminal SH3 
domain, which binds to a non-canonical poly-proline region in either Pak or the E3 
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ubiquitin ligase, Cbl (Casistas B-lymphoma); followed by the DH/PH cassette; a binding 
region for the ArfGAP, Git (G-protein coupled receptor kinase interactor); and a leucine 
zipper domain (161).  The N-terminus of α-Pix is longer than that of β-Pix, and contains 
a CH domain.  Disruption of the CH domain in α-Pix is linked to the development of 
certain X-linked forms of mental retardation (162). 
Initial studies into the regulation of the exchange activity of the Pix proteins gave 
conflicting results.  First, it was shown that the leucine zipper domain of β-Pix mediated 
its homo-dimerization in vitro and in vivo.  Over-expression of a β-Pix construct lacking 
this dimerization motif prevented PDGF from stimulating membrane ruffle formation in 
fibroblasts, indicating that dimerization was necessary for β-Pix exchange activity on Rac 
(95).  However, it was also shown that the SH3-DH-PH domains of α- and β-Pix were 
able to stimulate exchange on Cdc42 in vitro (163).  These seemingly paradoxical results 
were explained by the discovery that the specificity of the Pix proteins is coupled to the 
monomer-dimer equilibrium.  As a dimer, α-Pix activates Rac specifically, and the DH 
domain of one molecule of α-Pix is assisted by the PH domain of its partner to catalyze 
exchange on Rac.  However, as a monomer, α-Pix is able to activate either Rac or Cdc42, 
but only when either Pak or Cbl is bound to the SH3 domain (161).  The binding of a 
complex of Pak and Gβγ to the SH3 domain of α-Pix leads to dissociation of the α-Pix 
dimer, and activation of the ability of α-Pix to stimulate exchange on Cdc42.  In contrast, 
the binding of GTP-bound Cdc42 to the DH domain of one of the molecules in the α-Pix 
dimer activates the ability of its partner to stimulate exchange on Rac.  The mechanisms 
by which Pak/Gβγ and activated Cdc42 affect the exchange potential of α-Pix are 
unknown, but are presumed to be allosteric (164). 
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Figure 6: Pix proteins are regulated by protein-protein interactions. 
In the basal state, α-Pix exists as a homodimer, capable of activating Rac1.  The binding of activated 
Cdc42 to one DH domain of the homodimer increases the ability of the other DH domain to activate Rac1 
(top).  However, binding of a complex of Pak1 and Gβγ to the SH3 domain of α-Pix causes dissociation of 
the homodimer and enables α-Pix to activate Cdc42 (bottom). 
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In addition to being regulated by non-enzymatic protein-protein interactions as 
described above, Pix proteins are also regulated by phosphorylation.  In PC12 cells, 
bFGF or NGF binding to their receptors leads to activation of the Ras-Raf-MEK-ERK 
MAP kinase signaling cascade.  Activation of this signal transduction pathway stimulates 
Pak to phosphorylate β-Pix on S525 and T526, residues in the Git binding domain, and 
activates the exchange potential of β-Pix toward Rac (139).  Interestingly, in human 
mesangial cells, endothelin 1 binding to its receptor leads to the activation of Gαs, 
stimulation of adenylyl cyclase, and formation of cyclic AMP.  The increase in cellular 
cyclic AMP stimulates protein kinase A to phosphorylate β-Pix on S516 and T526, 
although the effect of this phosphorylation on the exchange activity of β-Pix is unknown 
(140).  Finally, β-Pix is tyrosine phosphorylated downstream of signals from the EGF 
receptor in a Src-and FAK- dependent manner.  This phosphorylation, at Y442, in the Cbl 
and activated Cdc42 binding region, leads to an increase in the exchange potential of β-
Pix towards Cdc42 but not Rac (141).  The molecular mechanism by which 
phosphorylated Pix proteins have increased exchange potentials relative to their de-
phosphorylated counterparts is currently unknown.  Also unknown is whether or not 
phosphorylation impacts the dimerization or the specificity of the Pix proteins (see Figure 
6). 
Tiam subfamily: 
The Tiam subfamily consists of Tiam1 (for T-cell invasion and metastasis gene 1) 
and Tiam2 (also known as Stef, for Sif and Tiam1-like exchange factor) (5).  Tiam1 was 
originally identified in a genetic screen based upon its ability to induce T-lymphoma cells 
to invade fibroblast monolayers (165), and was shown to be an exchange factor specific  
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GEF: Ligand: Effect on exchange 
activity: 
Reference: 
Asef PI(3,4,5)P3 Changes 
localization 
(166) 
Dbl PI(4,5)P2, 
PI(3,4,5)P3 
Decreases (7) 
Dbs PI(4,5)P2 None (92) 
Dbs Rac1⋅GTP Increases (167) 
GEF-H1 Cingulin Decreases (133) 
Kalirin (N) TrkA Unknown (168) 
p115-RhoGEF Gα13 Increases (111) 
P-Rex PI(3,4,5)P3 Increases (169) 
Sos PI(4,5)P2 Decreases (170) 
Sos PI(3,4,5)P3 Increases (170) 
Tiam1 PI(3)P None (92) 
Trio (N) Filamin None (171) 
Vav PI(4,5)P2 Decreases (156) 
Vav PI(3,4,5)P3 Increases (156) 
Table 5: Regulation of Dbl-family proteins through intramolecular interactions with the DH-
associated PH domain. 
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for Rac1 (172).  Both Tiam1 and Tiam2 are made up of an N-terminal PH domain, a 
coiled-coil region, a Ras-binding domain (RBD) and a PDZ domain, followed by the 
catalytic DH/PH cassette (5).  PDZ domains are homology regions named for Post 
synaptic density 95, Discs large, and Zo-1, the first proteins discovered to have this 
domain, and they function in mediating protein-protein interactions (11).  The coiled-coil 
region is also known as the TSS (Tiam1 and Stef similarity region) (43).  In addition to 
its role in invasion and metastasis, Tiam1 has been found to be mutated in human renal 
cell carcinoma (173) and is significantly over-expressed in prostate carcinoma (174). 
The presence of multiple PEST sequences in the extreme N-terminus of Tiam1 
has led to the hypothesis that Tiam1 is regulated primarily at the level of protein stability.  
PEST sequences, which are motifs containing the primary sequence proline – glutamic 
acid – serine – threonine, target proteins to the proteasome for degradation.  In fact, these 
PEST sequences do lead to increased turnover of Tiam1 protein upon Rac activation 
(175).  For this reason, a mutant version of Tiam1 in which these sequences have been 
truncated, C1199, has historically been used to study Tiam1 activity in cells.  This 
truncation, while affecting Tiam1 protein stability, does not otherwise affect Tiam1 
exchange activity.  In fact, Tiam1 is inhibited in trans by expression of the N-terminal 
PH domain and coiled-coil domain (43), indicating that the full-length protein, as well as 
the C1199 construct, is auto-inhibited.  Tiam1 is cleaved by caspases during apoptosis, 
resulting in a protein product that is deficient in plasma membrane localization and Rac 
exchange activity (176).  Tiam1 expression is also regulated at the transcriptional level, 
since transcription of the Tiam1 mRNA is up-regulated through the activity of the 
transcription factor, E1A (177).   
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The regulation of Tiam1 exchange activity by phosphoinositide binding is 
complex and incompletely understood, due in part to the fact that Tiam1 contains two PH 
domains, each of which could bind phosphoinositides.  Tiam1 is known to translocate to 
the membrane upon treatment of cells with PDGF and LPA and this re-localization is 
dependent upon the N-terminal, non-DH-associated, PH domain (178).  Membrane 
localization is essential for Tiam1 activity in cells, and the N-terminal PH domain can be 
functionally replaced by the myristoylated, membrane-localization domain of c-Src 
(179).  Tiam1 activity in cells is also dependent upon PI3 kinase activity (180), an effect 
which is mediated by the N-terminal PH domain.  The binding of the N-terminal PH 
domain to PI(4,5)P2 mediates Tiam1 association with the plasma membrane of 
astrocytoma cells, while the binding of this domain to PI(3,4,5)P3 stimulates the 
exchange activity of Tiam1 (181).  The N-terminal PH domain may affect Tiam1 
localization through binding to other proteins, as well as phospholipids, since this domain 
has been shown to interact with the protein scaffold, spinophilin (182).   
Ascorbyl stearate, a PH-domain binding ligand, is able to stimulate the exchange 
activity of N-terminally truncated Tiam1 in cells.  This effect that is due to ligand binding 
to the DH-associated PH domain, not the N-terminal PH domain (183).  In contrast, the 
DH-associated PH domain was shown to bind specifically to PI(3)P with weak affinity, 
and this binding did not affect the exchange activity of Tiam1 in vitro (92).  A mutation 
that rendered this PH domain unable to bind to PI(3)P impaired the ability of Tiam1 to 
activate Rac1 in cells, although the membrane targeting of this mutant Tiam1 was 
unaffected (184).   
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GEF: G protein: Effector 
domain: 
Consequences on 
exchange activity: 
Reference: 
α-Pix βγ SH3 Increases (Cdc42) (164) 
Dbl βγ N-terminus Unknown (185) 
LARG βγ RGS Increases (108) 
p114-RhoGEF βγ Unknown Increases (37) 
p115-RhoGEF α12/13 RGS/PH Increases (107) 
p63-RhoGEF αq/11 C-terminus Increases (186) 
PDZ-RhoGEF α12/13 RGS Increases (106) 
P-Rex βγ DH/PH Increases (169) 
RasGRF βγ Unknown Increases (Rac) (51) 
Table 6: Dbl-family GEFs that function as effectors for heterotrimeric G-protein subunits. 
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Multiple lines of evidence support the hypothesis that Tiam1 exchange activity is 
regulated by phosphorylation.  Tiam1 was shown to be phosphorylated on multiple 
threonine residues upon stimulation of cells with LPA, PDGF, endothelin-1, bombesin 
and bradykinin, but not EGF (187).  These phosphorylations were mediated by a 
signaling pathway involving Gαq, phospholipase γ1 (PLCγ1), and protein kinase C 
(PKC), leading to activation of calcium- and calmodulin-dependent protein kinase II 
(CaMKII), which is able to phosphorylate Tiam1 directly.  Phosphorylation of Tiam1 by 
CaMKII led to a two-fold increase in the exchange activity of Tiam1 in vitro (188).  In 
contrast, phosphorylation of Tiam2 by p160-Rho kinase on Thr 1662 leads to a decrease 
in its activity (148). 
Tiam1 is also phosphorylated on multiple tyrosine residues in a Src-dependent 
manner, which increases the exchange activity of Tiam1 (149).  Additionally, Tiam1 is 
able to interact with either the receptor tyrosine kinase, EphA2, or its ligand, ephrin B1, 
when the receptor and ligand are interacting.  This interaction leads to an increase in 
Tiam1 exchange activity, although the phosphorylation state of Tiam1 in this case has yet 
to be examined (189).  The EphB receptor tyrosine kinases have been shown to interact 
with both Tiam1 and the NMDA (N-methyl-D-aspartic acid) receptor in developing brain 
and regions of the adult brain undergoing synaptic remodeling.  NMDA receptor 
stimulation induces Tiam1 phosphorylation and increases the exchange activity of Tiam1 
in a CaMKII dependent manner, and this signaling pathway is required for NMDA 
receptor induced dendritic spine morphogenesis (190).  Finally, stimulation of cells with 
BNDF leads to an association of Tiam1 with the receptor for BNDF (brain-derived 
neurotrophic factor, TrkB (neurotrophic tyrosine kinase receptor, type B).  TrkB directly 
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phosphorylates Tiam1 at a tyrosine residue in the RBD, Y829, and this phosphorylation 
leads to an increase in Tiam1 exchange activity (150).   
The presence of an RBD in the N-terminus of Tiam1 as well as the fact that 
Tiam1 is required for cellular transformation by activated versions of the Ras GTPases 
(191) has led to the hypothesis that Tiam1 is a Ras-effector protein.  Ras effectors bind to 
Ras in a GTP-dependent manner and are activated by this binding event.  Activated Ras 
has been shown to bind to the RBD of Tiam1, and Ras binding was shown to increase the 
exchange activity of Tiam1 in cells (192).  However, the RBD of Tiam1 is unable to 
interact with H-Ras, Rap1B or M-Ras in vitro (193).  Rap1A, though, has been shown to 
interact with the DH/PH cassette of Tiam1 (194).  Several other PH domains are able to 
act as effector binding modules for small GTPases, including the PH domain of PLCβ 
(195), so the DH-associated PH domain, and not the RBD as originally thought, may be 
the binding site for activated Ras proteins in Tiam1. 
Recently, Tiam1 and 2 have been shown to be part of the complex of Par3, Par6, 
atypical PKC and Cdc42 (Par refers to partitioning defective), which has been shown to 
be important for the development of epithelial and neuronal cell polarity.  Par3 interacts 
directly with the proteins of the Tiam subfamily, through its PDZ array interacting with 
the RBD of the Tiam protein.  This interaction serves to spatially restrict Tiam1 for 
activation of Rac in the proper location, rather than specifically activating the exchange 
potential of Tiam1 (87,196).  Similarly, the N-terminal PH domain and coiled-coil region 
of Tiam1 interact with the p21-Arc subunit of the Arp2/3 complex, an interaction that 
serves to spatially restrict Tiam1 to actin rich regions of the plasma membrane (88).   
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GEF: G protein: Effector domain: Consequences on 
exchange activity: 
Reference: 
α-Pix Cdc42 DH Increases (164) 
Dbs Rac PH Increases (167) 
RasGRF H-Ras N-terminus Unknown (41) 
Scambio Rac PH Unknown (197) 
Sos H-Ras Ras exchanger 
motif (Rem) 
Unknown (for Rac 
activity) 
(198) 
Tiam1 Rap1a PH (DH-
associated) 
Unknown (194) 
Vav2 Rap1a PH Unknown (194) 
     
Table 7: Dbl-family GEFs that function as effectors for small GTPases. 
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Tiam proteins, then, are regulated by diverse signaling mechanisms, potentially 
due to the fact that they are composed of multiple signaling domains.  They are repressed 
by proteolytic cleavage and activated by lipid binding, phosphorylation, and binding to 
activated forms of Ras family members. 
Asef subfamily: 
The Asef subfamily consists of Asef1 (APC-stimulated exchange factor), Asef2, 
and Pem2 (Posterior end mark, also known as collybistin).  All three of these exchange 
factors are composed of an extended N-terminus with no known domain structure, 
followed by an SH3 domain and the DH/PH cassette (5).  Additionally, all three of these 
exchange factors stimulate exchange of guanine nucleotide exclusively on Cdc42 
(199,200).   
Pem2 was originally cloned based upon its ability to interact with gephyrin, a 
protein scaffold that binds to and clusters inhibitory glycine receptors in the post-synaptic 
density of neurons (201).  Pem2 is expressed predominantly in the brain, and two splice 
isoforms have been identified.  The splice isoform that contains the SH3 domain is less 
active in an in vitro exchange assay than a splice isoform in which the SH3 domain is 
truncated, indicating that the exchange activity of Pem2 is negatively regulated by its 
SH3 domain (39).  The interaction with gephyrin is mediated by the PH domain of Pem2, 
however, the crystal structure of the DH/PH cassette bound to Cdc42 revealed that the 
PH domain of Pem2 does not contact the GTPase during the exchange reaction (39).  
Therefore, the ability of gephyrin to modulate the exchange activity of Pem2 is unknown.   
Asef was originally identified as a binding partner for the armadillo array of APC 
(Adenomatous Polyposis Coli), the protein product of a tumor suppressor gene mutated 
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in many forms of colorectal cancers.  Like that of Pem2, the exchange activity of Asef 
has been shown to be negatively regulated by a region N-terminal to the DH domain, a 
region that includes the APC binding site.  APC binding to Asef allosterically activates 
the exchange factor (26).  Although truncated forms of Asef are not transforming, over-
expression of Asef decreases E-cadherin-mediated cell-cell adhesion and promotes cell 
migration in epithelial cells.  Indeed, both Asef and truncated versions of APC are 
required for the migration, and presumably the subsequent invasion and metastasis, of 
colorectal tumor cells (202).  The exchange activity of Asef2, which is expressed in a 
larger variety of tissues than Asef1, is also auto-inhibited by its N-terminus, and 
stimulated by APC binding (199).  A crystal structure of an auto-inhibited form of Asef1 
reveals that its SH3 domain binds to its DH domain in a manner different from that 
shown for SH3 domains binding to poly-proline containing ligands, and that this binding 
sterically occludes the GTPase binding surface of the DH domain, preventing Cdc42 
binding and activation (203). 
Most recently, the PH domain of Asef1 was shown to interact specifically with 
the product of PI3 kinase, PI(3,4,5)P3.  The PH domain of Asef1 is critical for its 
localization to sites of cell-cell contact at the plasma membrane of epithelial cells.  The 
capacity of PI(3,4,5)P3 to activate the exchange potential of Asef was not assessed (199).  
However, the members of the Asef family are regulated in two unique ways: they are 
repressed through a novel auto-inhibitory interaction between the SH3 and DH domains 
and activated through a novel interaction with the armadillo array of APC. 
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GEF: Mechanism: Signal: Reference: 
CDEP Increased transcription Parathyroid hormone (27) 
Dbl Ubiquitin-mediated 
proteolysis 
CHIP (204) 
Ect2 Increased transcription Mitogens 
(KGF, EGF, PDGF) 
(30) 
Ect2 Decreased transcription p53, Rb (71) 
Ect2 Ubiquitin-mediated 
proteolysis 
UBE3A (73) 
Fgd1 Ubiquitin-mediated 
proteolysis 
FWP1/βTrCP (22) 
Tiam1 Caspase-mediated cleavage apoptosis (176) 
Tiam1 Increased transcription E1A (177) 
Table 8: Regulation of Dbl-family GEFs by alteration of protein expression or mRNA transcription. 
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P-Rex subfamily: 
The P-Rex subfamily consists of two highly related isozymes: P-Rex1 (for 
PI(3,4,5)P3-dependent Rac exchanger) and P-Rex2 (5).  P-Rex1 protein was originally 
purified from porcine neutrophils based upon its ability to stimulate Rac in response to 
PI(3,4,5)P3, and its gene was subsequently cloned (169).  The two isozymes have very 
similar domain architectures: they consist of a DH/PH cassette, two DEP domains (a 
homology region named for Disheveled, EGL-10 and Pleckstrin, the first proteins shown 
to contain this domain), two PDZ domains, and a C-terminal inositol phosphate – 4 – 
phosphatase domain (InsPx-4-P) (169,205,206).  The InsPx-4-P domain has not been 
shown to display phosphatase activity, and is truncated in an alternate splice isoform of 
P-Rex2, P-Rex2B.  The expression profiles of the two P-Rex subfamily members are 
quite different, however.  P-Rex1 is expressed exclusively in neutrophils and in the brain.  
P-Rex2A is expressed in skeletal muscle, heart, kidney, placenta, intestine and lung, 
while P-Rex2B expression is limited to cardiac tissues (205,206). 
P-Rex subfamily members are exchange factors specific for Rac and this 
specificity is in part conferred by the β3-β4 loop of the PH domain making direct 
contacts with Rac that are not conserved in Rho or Cdc42 (207).  The regulation of 
exchange activity of the P-Rex subfamily members, however, is complex and 
incompletely understood.  The exchange activity of P-Rex proteins is stimulated by 
PI(3,4,5)P3, which binds directly to the P-Rex PH domain (40,169).  In addition, P-Rex 
proteins are stimulated through an interaction between Gβγ subunits and the DH domain 
(40,169).  Neither Gα subunits, nor Gβγ dimers that contain Gβ5, Gγ1 or Gγ11 are able to 
stimulate P-Rex exchange activity (146).  The DEP, PDZ and PH domains, however, play 
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a role in the auto-inhibition of P-Rex activity, since their deletion stimulates exchange 
activity (40).  The precise molecular mechanism behind this auto-inhibition has yet to be 
determined. 
P-Rex has been identified as a component of several additional signaling 
pathways.  First, P-Rex is localized to the leading process of migrating neurons in the 
intermediate zone of the developing cortex, where its exchange potential is activated 
downstream of NGF (nerve growth factor) binding to its receptor, TrkA.  P-Rex is not 
phosphorylated in this signaling pathway, however.  The pathway by which P-Rex is 
activated in this context depends on Ras activation of PI3 kinase, leading to production of 
PI(3,4,5)P3.  The activated Rac produced by P-Rex leads to an increase in neuronal 
motility (208).  P-Rex has been shown to be phosphorylated by protein kinase A (PKA) 
downstream of signaling from the β2-adrenergic receptor.  PKA phosphorylation of P-
Rex decreases both the basal activity of P-Rex and the ability of P-Rex to be stimulated 
by Gβγ (146).  Finally, in migrating neutrophils, endogenous P-Rex translocates to the 
plasma membrane at the leading edge in response to GPCR stimulation with such ligands 
as fMLF and C5a.  At the leading edge, P-Rex co-localizes with both Rac2 and F-actin, 
and interestingly, this translocation requires tyrosine kinase activity (209).  Although a 
role for P-Rex regulation by tyrosine phosphorylation is emerging, P-Rex subfamily 
members represent the best characterized Dbl-family proteins regulated by PI(3,4,5)P3 
and Gβγ.   
Tuba subfamily: 
The Tuba subfamily consists of Tuba, an uncharacterized protein (accession 
number XP376334), and Obscurin.  The regulation of exchange activity of these proteins 
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is relatively unexplored.  Tuba is ubiquitously expressed and is composed of four N-
terminal SH3 domains, a DH domain, a BAR domain (named for Bin, Amphiphysin and 
RVS, the first proteins shown to have this region of homology) and two C-terminal SH3 
domains (5).  BAR domains have been shown to bind and deform lipid bilayers and to 
mediate dimerization between proteins that contain this domain.  In the case of Tuba, the 
BAR domain serves to functionally replace the PH domain, and binds specifically to 
PI(4,5)P2 (210).  Among the human Dbl-family proteins, Tuba, and its uncharacterized 
ortholog, are the only two that do not possess a PH domain immediately C-terminal to the 
catalytic DH domain.  The isolated DH/BAR cassette of Tuba has been shown to 
specifically activate Cdc42 in vitro (211). 
Tuba’s N-terminal array of SH3 domains, like that of Intersectin, interacts with 
dynamin.  The C-terminal SH3 domains bind to various regulators of the actin 
cytoskeleton, such as WAVE-1, Mena and N-WASP.  In epithelial cells, Tuba is 
localized to the tight junction, where it interacts with ZO-1.  Tuba may play a role in 
junctional organization in this context (89).  In fibroblasts, over-expression of Tuba leads 
to actin-dependent membrane ruffling in the absence of growth factors (210). 
Obscurin, like Tuba, is a very large protein, and is composed of multiple 
immunoglobulin-like domains, an SH3 domain, a DH/PH cassette and a C-terminal 
immunoglobulin-like domain (5,212).  Obscurin was originally identified based upon its 
ability to interact with small ankyrin1, a protein that is an integral component of the 
sarcoplasmic reticulum (SR) membrane.  Additionally, Obscurin interacts with the 
contractile apparatus of smooth muscle cells by binding both Titin and sarcomeric actin.  
Obscurin, then, may function to mediate the organization of smooth muscle myofibrils 
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and the SR (213).  The exchange activity of Obscurin, like that of Tuba, however, has yet 
to be explored. 
Dbl subfamily: 
The Dbl subfamily is composed of the founding member of the Dbl family of 
proteins, Dbl (for diffuse B-cell lymphoma); a highly related protein, Dbs (for Dbl’s big 
sister); two proteins with two DH/PH cassettes, Trio and Kalirin; and two relatively 
uncharacterized proteins, Scambio and p63-RhoGEF (also known as GEFT).  Although 
these proteins are highly homologous with respect to the primary structure of their DH 
and PH domains (5), they are divergent in the regions outside of the DH/PH cassette, and 
therefore their domain architectures will be discussed individually below. 
Onco-Dbl was originally isolated in a screen for oncogenes in a cDNA library 
derived from a B-cell lymphoma cell line (214).  Proto-Dbl was later shown to be an N-
terminally extended form of onco-Dbl, indicating that Dbl is regulated by auto-inhibition 
(215).  In fact, Dbl is composed of an N-terminal spectrin domain (a structural motif 
found in proteins involved in cytoskeletal regulation), followed by the DH/PH cassette.  
The sequences N-terminal to the DH domain bind directly to the PH domain, and are 
inhibitory to the exchange activity of Dbl when expressed in trans (28).  The N-terminal 
sequences are also important for proper localization of Dbl inside the cell: proto-Dbl is 
localized to the perinuclear region, while the isolated DH/PH cassette colocalizes with 
the actin cytoskeleton (28). 
Like many of the other Dbl-proteins, Dbl itself is regulated through 
phosphoinositide binding.  The PH domain of Dbl binds to both PI(4,5)P2 and 
PI(3,4,5)P3.  Phosphoinositide binding impairs the ability of Dbl to activate Cdc42 
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(7,216).  Mutation of the PH domain such that it is no longer able to bind 
phosphoinositides has no effect of the in vitro exchange activity of Dbl (7).  However, a 
functional PH domain is required for localization of Dbl to both the actin cytoskeleton 
and the plasma membrane.  This localization is essential for both the ability of Dbl to 
transform cells and to activate RhoA in cells (7,216,217).  Whether the PH domain 
modulates the localization of Dbl through binding to phosphoinositides or to another 
protein is unknown. 
The exchange activity of Dbl is modulated by signaling molecules in addition to 
phosphoinositides.  The N-terminus of Dbl is able to interact directly with Gβγ subunits, 
although the capacity of Gβγ to modulate the exchange activity of Dbl has not been 
assessed (185).  In addition, the non-receptor tyrosine kinase ACK1 (for activated 
Cdc42-associated kinase) induces the tyrosine phosphorylation of Dbl.  This 
phosphorylation increases the exchange activity of Dbl towards Cdc42 and RhoA both in 
vitro and in cells (142).  Finally, like the members of the RasGRF and Pix subfamilies, 
Dbl has been shown to form homodimers, mediated by the DH domain.  Dimerization is 
required for the exchange and transformation activities of Dbl (96). 
Interestingly, the exchange activity of Dbl is also regulated through modulation of 
the protein’s stability in the cell.  Early studies revealed that onco-Dbl was more stably 
expressed than proto-Dbl, and therefore that sequences in the N-terminus of the protein 
were important for rapid turnover of Dbl protein (218).  Further work indicated that the 
heat shock cognate protein 70 (Hsc70) is able to interact with both the PH and the 
spectrin domains of Dbl, serving to hold Dbl in its auto-inhibited conformation (219).  
Additional components of the Hsc70/Dbl complex include another chaperone, heat shock 
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protein 90 (Hsp90) and CHIP (C-terminus of Hsc70 interacting protein), an E3 ubiquitin 
ligase.  Proto-Dbl was shown to be a substrate for poly-ubiquitination by CHIP, and this 
ubiquitination targets proto-Dbl for degradation by the proteasome (see Figure 7).  Since 
onco-Dbl lacks the spectrin domain, it is unable to interact with Hsc70 and CHIP, and is 
therefore stabilized in the cell (204). 
Dbs, like Dbl, was isolated in a genetic screen for protein products that induce 
transformation of NIH 3T3 cells (220).  Dbs is a larger protein than Dbl, in that it 
contains an N-terminal Sec14 domain (a lipid binding domain) in addition to the spectrin 
and DH/PH domains that the two proteins have in common (5).  Although Dbs is able to 
activate RhoA and Cdc42 in vitro (5), its ability to transform cells depends only on its 
activation of RhoA (221).  Originally, it was thought that Dbs is not regulated by auto-
inhibition (220), however, subsequent studies have shown that the Sec14 domain inhibits 
Dbs-mediated cellular transformation by direct interaction with the PH domain (29). 
The activity of Dbs is precisely regulated through binding to phospholipids.  
Initial studies showed that the PH domain of Dbs is critical for its transformation 
abilities, but that a membrane localization signal could functionally replace the PH 
domain (222).  This hypothesis was called into question when it was discovered that the 
PH domain of Dbs binds to PI(4,5)P2 when it is presented in a small unilamellar vesicle 
made up primarily of other anionic lipids, but with an affinity thought to be too low to 
drive translocation of Dbs to the plasma membrane (92).  Interestingly, while the ability 
of the PH domain to bind phospholipids was critical for the proper subcellular 
localization of Dbs and the ability of Dbs to transform cells, phospholipid binding does 
not affect the in vitro exchange activity of Dbs (223).  These seemingly disparate  
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Figure 7: Regulation of Dbl by alterations in its cellular stability. 
Heat shock cognate proteins (Hsc) 70 and 90 bind to both the spectrin and PH domains of Dbl, holding it in 
an auto-inhibited conformation.  Binding of the E3 ubiquitin ligase, CHIP, to Hsc70 targets Dbl for 
proteasomal degradation (left).  However, activation of various signal pathways leads to relief of Dbl auto-
inhibition (right). 
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observations concerning the ability of the PH domain to dictate the subcellular 
localization of Dbs can be resolved by the observation that a version of the DH/PH 
cassette that is chemically modified to become a dimer is capable of being driven to the 
plasma membrane.  Mutations in either PH domain of the engineered dimer prevent 
interaction with the membrane, but not nucleotide exchange in vitro (224).  The PH 
domain in the full-length Dbs protein, then, is potentially able to drive Dbs to the plasma 
membrane in partnership with the Sec14 domain, which is able to bind the di-
phosphorylated phosphoinositides (29). 
The crystal structure of Dbs bound to its cognate GTPase, Cdc42, revealed a 
unique role for the PH domain.  The PH domain of Dbs makes contacts with Cdc42 
directly, assisting the DH domain in catalyzing guanine nucleotide exchange (225).  The 
interactions between the PH domain in Dbs and Cdc42 were shown to be critical for Dbs-
mediated cellular transformation (223).   
Like that of Dbl, the exchange activity of Dbs is modulated downstream of 
several signaling pathways.  For instance, signaling downstream of the α1B adrenergic 
receptor, a Gαq coupled receptor, activates the exchange potential of Dbs toward Cdc42, 
but not RhoA, in a Src-dependent manner (143).  In addition, the PH domain of Dbs is 
able to serve as an effector binding domain for the activated form of the small GTPase, 
Rac1.  This interaction increases the ability of Dbs to transform cells and activate RhoA 
in the context of the cellular milieu (167).  Neurotrophin-3, acting through its receptor, 
TrkC, on the surface of Schwann cells leads to the phosphorylation of Dbs and activation 
of its exchange potential toward Cdc42, and a subsequent increase in the migratory 
capacity of these cells (144).  Finally, the exchange potential of Dbs toward RhoA is 
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negatively regulated through an interaction between Dbs and the protein scaffold Ccpg1 
(cell cycle progression protein 1) (226).  Although Ccpg1 is able to interact with Dbs, 
Cdc42 and Src, the phosphorylation state of Dbs was not assessed in this study (see 
Figure 8). 
Scambio, which gets its name from the Italian word for exchange, is made up of a 
DH/PH cassette with extended N- and C-termini that have limited homology to other 
Dbl-family proteins.  Scambio is highly expressed in the heart and in skeletal muscle 
tissues, and is capable of stimulating exchange on both RhoA and RhoC.  Its regulatory 
mechanisms are largely uncharacterized, but similar to Dbs, Scambio is able to interact 
with active Rac1 (197). 
p63-RhoGEF is a relatively small Dbl-family member, consisting of a DH/PH 
cassette with N- and C-terminal extensions that show limited homology to other Dbl-
family proteins (5).  p63-RhoGEF was shown to have exchange activity for RhoA, and is 
expressed in excitable tissues, such as cardiac muscle, skeletal muscle and the brain 
(227).  An alternate splice isoform of p63-RhoGEF, named GEFT, which lacks the N-
terminal extension, was shown to promote dendritic outgrowth and spine morphogenesis 
in hippocampal neurons (228,229).  GEFT was originally characterized as a Rac1 and 
Cdc42 specific exchange factor (228), but the most recent experimental evidence 
indicates that GEFT and p63-RhoGEF are encoded by the same gene and are both RhoA 
specific (230).   
Recently, the exchange activity of p63-RhoGEF was shown to be activated 
downstream of signaling from Gαq/11-coupled receptors.  Additionally, Gαq was shown to 
interact with the C-terminal half of p63-RhoGEF.  These results suggest that p63- 
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Figure 8: Targeting of Dbs to the plasma membrane requires two lipid binding domains. 
In the cytoplasm, Dbs is held in an auto-inhibited conformation through an intramolecular interaction 
between the Sec14 domain and the PH domain.  Auto-inhibition is relieved by an unknown mechanism.  
Activated Dbs, however, is targeted to the plasma membrane by interactions between both the Sec14 and 
the PH domains with membrane phosphoinositides.  Activated Rac1 binding to the PH domain of Dbs helps 
to properly position this domain for contact with the cognate GTPases of Dbs, enabling efficient exchange. 
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RhoGEF may function as an effector protein for Gαq/11, although the molecular 
mechanisms by which this occurs have yet to be uncovered (186).  Finally, p63-RhoGEF 
expression is regulated at the transcriptional level during skeletal muscle regeneration.  
The transcription of p63-RhoGEF messenger RNA is increased during myogenesis and 
decreased during adipogenesis (231). 
Trio is composed of an N-terminal Sec14 domain, an array of spectrin repeats, a 
DH/PH domain specific for Rac and RhoG, an SH3 domain, a DH/PH domain specific 
for RhoA, an additional SH3 domain, an immunoglobulin-like domain and a C-terminal 
serine/threonine kinase domain (5).  Trio is so named because of the three functional 
enzymatic domains it possesses: two DH/PH cassettes and a kinase domain.  While the 
genomes of invertebrates possess only one Trio isoform (dTrio in Drosophila 
melonogaster and UNC-73 in C. elegans), mammalian genomes possess two: Trio and the 
highly related Kalirin.  Although both Trio and Kalirin are expressed in neurons, Trio is 
also expressed multiple other tissues (232). 
Trio was identified by several independent labs simultaneously.  One group 
identified Trio based upon its ability to interact with the cytoplasmic domain of the LAR 
transmembrane protein tyrosine phosphatase (232).  The significance of that interaction 
remains unclear.  Multiple groups, however, identified dTrio as in integral component of 
signaling pathways regulating photoreceptor axon guidance in the developing eye.  In this 
context, Trio is localized to the plasma membrane of photoreceptor growth cones and the 
activity of its N-terminal DH/PH cassette is negatively regulated by the Sec14 and 
spectrin domains (233). 
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The expression of full-length Trio, but not the isolated DH/PH cassettes, has been 
shown to induce extension of neurites in an NGF-independent manner in the PC12 
pheochromocytoma cell line.  This effect is entirely mediated by the activation of RhoG 
by the N-terminal DH/PH cassette of Trio.  In addition, the exchange activity of the N-
terminal DH/PH cassette of Trio is required for induction of neurites by NGF in these 
cells (234).  The function of the C-terminal DH/PH cassette remains unclear.  However, 
the RhoA specific DH domain plus fifteen amino acid residues not found in Trio (termed 
Tgat, for Trio related transforming gene in ATL tumor cells) was recently identified as 
an oncogene (6). 
Multiple roles have been proposed for the PH domain associated with the Rac-
specific DH domain of Trio.  First, the N-terminal PH domain interacts with the actin 
filament cross-linking protein, filamin.  This interaction is required for Trio to induce 
membrane ruffling, but does not modulate the Rac-specific exchange activity of Trio 
(171).  Interestingly, the PH domain of the N-terminal DH/PH cassette is required for 
efficient exchange on Rac1, while the PH domain of the C-terminal DH/PH cassette 
inhibits exchange on RhoA (6,235). 
Genetic and biochemical experiments in Drosophila show that both Trio and the 
non-receptor tyrosine kinase, Abl, interact with the cytoplasmic domain of Frazzled, 
which is the cell-surface receptor for Netrin (151,236).  Although Trio was shown to be 
tyrosine phosphorylated in these experiments (151), the residues phosphorylated and the 
consequences of the phosphorylation event on the exchange activity of Trio were not 
determined.  Finally, Trio, like Kalirin, as will be discussed below, is regulated by pre-
mRNA splicing.  An alternate splice isoform of Trio, termed Solo, is expressed in 
 59
Purkinje neurons.  Solo is composed of the Sec14 domain, the spectrin domains, the first 
DH/PH cassette, and the SH3 domain of Trio followed by a short membrane anchoring 
domain, and is localized to early endosomes, where it mediates Rac activation (237). 
The domain architecture of Kalirin is basically identical to that of Trio, however, 
the N- and C-terminal DH/PH cassettes of the human Kalirin protein were identified 
independently and named Duo and Duet, respectively.  Kalirin was originally identified 
as a binding partner for the cytoplasmic domain of peptidyl-α-amidating-mono-
oxygenase, a transmembrane enzyme essential for synthesis of neuropeptides.  Kalirin 
was named for the Kali, a Hindu goddess with many hands, because of its multiple 
enzymatic domains (238).   
Multiple splice isoforms of Kalirin are expressed at different points in the 
development of the rat nervous system.  Kalirin7, which terminates in a PDZ-binding 
motif unique to this splice isoform immediately following the N-terminal, Rac-specific 
DH/PH cassette is localized to punctate structures along the shaft of developing neurites 
(239) and is the splice isoform of Kalirin that is expressed in the adult rat (240).  The 
PDZ-binding motif interacts with multiple PDZ domain-containing proteins, including 
PSD-95, and serves to properly localize Kalirin7 (241).   
The longer splice isoforms of Kalirin, Kalirin9 and Kalirin12, are expressed 
during embryonic development (240).  Kalirin9 contains all of the domains of full-length 
Kalirin up to and including the second, RhoA specific DH/PH cassette, and is localized to 
both the cell bodies and the processes of neurons.  Kalirin12, which also contains the 
kinase domain, is localized to only the cell bodies of neurons (239).  Interestingly, over-
expression of the first DH/PH cassette in primary cortical neurons led to shorter neurites, 
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both axons and dendrites, while over-expression of the second DH/PH cassette led to an 
increase in axon length (240).  However, the first DH/PH cassette, by activating RhoG, 
induces superior cervical ganglion fiber outgrowth, indicating a possible cell-type 
specific difference in the effects of expression of the first DH/PH cassette (242). 
Kalirin may play a role in signal transduction from several different receptor 
tyrosine kinases.  First, EphB2 binding to its ligand ephrin B leads to the tyrosine 
phosphorylation of both over-expressed and endogenous Kalirin.  While tyrosine 
phosphorylation doesn’t alter the exchange activity of Kalirin, it does lead to the 
recruitment of Kalirin to EphB2 containing clusters on the plasma membrane (145).  
Additionally, Kalirin is required for NGF-induced neurite outgrowth in PC12 cells.  
Kalirin, through its N-terminal PH domain, binds to the cytoplasmic kinase domain of the 
NGF receptor, TrkA.  Although Kalirin binding increases the kinase activity of TrkA, we 
do not yet know if Kalirin is phosphorylated or activated by TrkA (168). 
The exchange activity of the first DH/PH cassette of Kalirin, however, is 
regulated by auto-inhibition.  The SH3 domain, located between the two DH/PH 
cassettes, is able to form intramolecular interactions with multiple proline-containing 
sequences.  Truncation of these poly-proline motifs leads to an increase in the Rac-
specific exchange activity of the full-length protein.  In addition, the SH3 domain is able 
to directly bind, and potentially sterically occlude, the N-terminal DH/PH cassette of 
Kalirin (243).  In summary, the mechanisms of regulation for Dbl subfamily members is 
complex, but in most cases is related to the function of the DH-associated PH domain. 
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Concluding Remarks: 
The mechanisms of regulation of Dbl-family proteins, as described in the 
preceding sections, are diverse.  This situation is not surprising considering the disparity 
in the domain architectures of the various subfamilies of Dbl-family proteins.  However, 
some generalizations can be drawn.  First, many Dbl-family proteins are activated by 
truncation mutations (see Table 1).  In fact, this mechanism of regulation is so common 
that the isolated DH/PH of many Dbl-family proteins has been used in functional assays 
as a constitutively active mutant.  However, there are multiple mechanisms by which a 
truncation mutation is auto-activating.  Most commonly, activation by truncation 
indicates that a particular Dbl-protein is regulated by intramolecular auto-inhibitory 
interactions.  The Vav isozymes are the best understood examples of Dbl-family proteins 
that are regulated by auto-inhibition.  In this case, an auto-inhibitory helix immediately 
N-terminal to the DH domain is able to sterically occlude the GTPase binding site on that 
catalytic domain.  However, a review of Dbl-family protein regulation indicates that 
multiple different domains are able to bind to either the DH or the PH domain and 
sterically occlude the cognate GTPase from the catalytic interface.  In many cases, the 
precise molecular interactions that lead to auto-inhibition of Dbl-family proteins remain 
to be discovered, and we do not yet know if other Dbl-family proteins are auto-inhibited 
by motifs that bear sequence homology to the auto-inhibitory helix of Vav.   
Truncation of the N-terminus of the Dbl-family protein Net1, however, is 
activating in cellular assays because truncation removes Net1’s nuclear localization 
signal, and prevents this GEF from being sequestered in the nucleus where it cannot 
activate its cognate GTPase.  Dbl-family GEFs need to translocate from the cytoplasm to 
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the plasma membrane in order to be active, however, other Dbl-family proteins that are 
sequestered in a sub-cellular location where they are inactive or that are active in a 
particular domain of the plasma membrane are shown in Table 2.  Prevention of 
intermolecular interactions, such as the formation of homo-dimers mediated by the C-
terminal leucine zipper domain of p115-RhoGEF is yet another mechanism by which 
truncation can yield an activated GEF.  The Dbl-family proteins known to form homo- 
and hetero-dimers are shown in Table 3. 
The second most common mechanism by which Dbl-family proteins are regulated 
is phosphorylation.  Multiple kinases, including tyrosine or serine/threonine kinases, as 
well as receptor or non-receptor kinases are able to phosphorylate Dbl-family proteins 
(see Table 4).  These phosphorylation events can directly activate the exchange activity 
of the GEF, as in the case of the tyrosine phosphorylation of Vav proteins, or directly 
inactivate the GEF, as in the case of PKA phosphorylation of P-Rex.  In addition, 
phosphorylation can lead to creation of a binding site for a phospho-specific protein-
protein interaction.  GEF-H1 phosphorylation by Pak1, followed by its inhibitory 
interaction with 14-3-3 can be characterized in this way.   
Another mechanism by which Dbl-family proteins are regulated is through 
ligands binding to the DH-associated PH domain.  These interactions are presumed to 
target the Dbl-family protein to the plasma membrane, where it is able to activate a 
prenylated GTPase.  However, in many cases these interactions also mediate efficient 
exchange by properly orienting the DH-associated PH domain, which has significant 
conformational heterogeneity.  In this scenario, the DH and PH domains of Dbl proteins 
function as a coincidence detector designed to integrate information regarding local 
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fluctuations in both GTPase concentrations and membrane composition.  These 
interactions are summarized in Table 5.   
Dbl-family proteins are able to be regulated by, and thus serve as effectors for 
both heterotrimeric G proteins (Table 6) and small GTPases (Table 7).  The molecular 
details of these interactions and the ubiquity of this regulatory mechanism are currently 
unknown. 
Although many mechanisms that increase the exchange activity of Dbl-family 
GEFs have been identified, very few mechanisms for returning the activity level to a 
basal state are known.  One such mechanism is ubiquitin-mediated targeting of Dbl-
family proteins to the proteasome.  This mechanism has been shown to be important for 
the regulation of Dbl itself, as well as other GEFs in this family (Table 8).  Interestingly, 
although many Dbl-proteins are activated by phosphorylation events, the phosphatases 
that might down-regulate Dbl-protein activity have yet to be identified. 
This review of Dbl-family protein regulation strikingly highlights the fact that 
there are multiple mechanisms of regulation for each individual GEF.  By requiring 
multiple inputs, the cell is able to achieve highly specific spatio- and temporal regulation 
of GEF activity, underlying the importance of proper regulation of these proteins for 
homeostasis. 
 
CHAPTER 2: AUTO-INHIBITION OF THE DBL-FAMILY PROTEIN TIM BY 
AN N-TERMINAL HELICAL MOTIF 
Introduction: 
RhoA, Rac1, and Cdc42 are the best understood of the 22 human Rho-family 
GTPases, which comprise one of five branches of the Ras superfamily of small GTPases 
(1).  Like Ras, Rho proteins function as binary switches that alternate between inactive, 
GDP-bound states and active, GTP-bound states.  Once activated, Rho GTPases directly 
engage numerous downstream effectors to modulate their functions.  Active Rho 
GTPases and their effectors orchestrate actin cytoskeleton rearrangement and gene 
transcription to coordinate diverse cellular processes including adhesion, migration, 
phagocytosis, cytokinesis, neurite extension and retraction, polarization, growth and 
survival (2).  Not surprisingly, aberrant activation of Rho GTPases promotes various 
developmental, immunological and proliferative disorders (3). 
The Dbl-family of guanine nucleotide exchange factors (GEFs) are the largest 
group of proteins directly responsible for the activation of Rho GTPases.  Dbl-family 
proteins are characterized by a Dbl-homology (DH) domain, which contacts the Rho 
GTPase to catalyze nucleotide exchange, and an associated pleckstrin-homology (PH) 
domain, which fine-tunes the exchange process by a variety of mechanisms related to the 
binding of phosphoinositides.  The 69 human Dbl-family proteins are divergent in 
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regions outside the DH/PH module, and contain additional domains that presumably 
dictate unique cellular functions (5). 
The capacity of DH domains to activate Rho GTPases is tightly regulated through 
a multitude of diverse mechanisms ranging from alterations in transcript levels and 
protein expression (6) to subcellular re-distribution (7), post-translation modifications (8) 
and protein degradation (9).  However, despite this large spectrum of regulatory 
mechanisms, in most cases, truncation of Dbl-family proteins often potently activates 
their exchange activities (10).  Currently, there is no general understanding for why 
truncation promotes unregulated exchange.   
In order to better understand potential mechanisms that regulate Dbl-family 
proteins, we have chosen to study the relatively small, human Dbl-member, Tim 
(Transforming Immortalized Mammary).  Tim was originally identified based upon its 
capacity to induce transformation of NIH 3T3 cells upon truncation (83), and while there 
are multiple transcripts of TIM (44,83), endogenous Tim is expressed as a 60-kDa 
protein, consisting of a short N-terminal region (~70 residues) followed by a DH/PH 
cassette and an adjacent C-terminal SH3 domain.  All conserved homologs of Tim 
preserve this domain architecture.  mRNA transcripts encoding Tim are expressed in 
numerous tissues and cancer-derived cell lines; corresponding protein expression has 
been verified in various cell lines (44,83).  The gene encoding human Tim has been 
localized to chromosomal region 7q33 -7q35, which has been implicated in 
rearrangements contributing to both acute myelogenous leukemia and breast carcinoma 
(84).  Nonetheless, while Tim was originally identified as an oncogene, its in vivo 
functions and regulation are unknown.  Indeed, although Tim was cloned from a cDNA 
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expression library derived from a human mammary epithelial cell line, Tim expression is 
down-regulated in breast carcinoma cell lines and aggressive primary breast carcinoma 
cells express versions of Tim in which the catalytic DH domain is either truncated or 
mutated, suggesting a possible tumor suppressor function for Tim (244). 
Here we show that the exchange potential of Tim towards RhoA is inhibited by a 
short N-terminal region with high helical propensity that directly interacts with the DH 
domain to prevent access of Rho GTPases to the DH domain.  Truncation, mutation or 
phosphorylation of this putative helix fully relieves this auto-inhibition.  Addition of the 
putative helix in trans to truncated Tim restores auto-inhibition.  Furthermore, a 
substitution within the DH domain designed to disrupt interactions with the N-terminal 
helix also relieves auto-inhibition.  These results show that Tim, like the distantly related 
Vav isozymes, is activated by unintentional truncation and regulated phosphorylation. 
Experimental Procedures: 
Protein Expression and Purification: 
Full-length and truncated versions of human Tim were PCR-amplified and ligated 
into pET-21a (Novagen) between NdeI and XhoI.  The cDNA for Tim was a gift of Dr. 
David Siderovski (UNC). 
Tim constructs were expressed in the E. coli strain Rosetta (DE3) (Novagen).  
Cell cultures were grown at 37ºC in LB/ampicillin (100 μg/mL), and induced with 1 mM 
isopropyl-β-D-thiogalactopyranoside (IPTG) for 5 h at 27ºC.  Cell pellets were 
resuspended in 20 mM HEPES, pH 7, 1 mM EDTA, 2 mM DTT, 10 % glycerol (buffer 
A) containing 20 mM NaCl, lysed using an Emulsiflex C5 cell homogenizer (Avestin), 
and clarified by centrifugation at 40,000 g for 45 min at 4ºC.  Clarified supernatant was 
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loaded on a Fast Flow S column (Pharmacia) equilibrated with buffer A and eluted with a 
linear gradient of 20-500 mM NaCl.  Tim protein eluted at approximately 300 mM NaCl 
and was loaded onto an S-200 size exclusion column (Pharmacia) equilibrated with 
buffer A containing 300 mM NaCl.  Fractions containing monomeric Tim were pooled, 
concentrated, and stored at -80ºC.  Mutations were introduced into wild-type Tim using 
the Quikchange site-directed mutagenesis kit (Stratagene) as per the manufacturer’s 
instructions, and these mutant proteins were expressed and purified as described above.  
DNA sequences of all expression constructs were verified by automated sequencing.  
RhoA was purified as described (94,225,245). 
Baculoviruses encoding both the wild-type and kinase inactive (K297A) versions 
of the kinase domain of c-Src (Mus musculus) were generated from pFastBacHT vectors 
(gifts of Dr. David Siderovski, UNC) using the Bac-to-Bac method (Invitrogen). 
HighFive insect cells were infected with the baculovirus at a multiplicity of infection of 
1.0. After 48 h of incubation at 27°C, cells were harvested by low speed centrifugation, 
resuspended and lysed in 20 mM HEPES, pH 7.5, 500 mM NaCl, 2 mM MgCl2, 10% 
glycerol (buffer B) with 10 mM imidazole, and clarified by centrifugation at 100,000 g 
for 45 min.  The clarified supernatants were diluted to a final volume of 150 ml and 
loaded onto a nickel-charged metal chelating column (Pharmacia) equilibrated with 
buffer B containing 10 mM imidazole, washed with buffer B containing 50 mM 
imidazole and eluted with buffer B containing 400 mM imidazole.  Eluted Src was 
extensively dialyzed versus buffer B with 150 mM NaCl and 1 mM EGTA, concentrated, 
and stored at -80ºC.   
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The kinase domain of EphA4 was PCR-amplified from the full-length cDNA (gift 
of N. Mochizuki, National Cardiovascular Center Research Institute, Suita, Osaka, 
Japan), ligated into pGEX4T2 (Amersham Biosciences) in frame with an N-terminal GST 
tag, and expressed in BL21(DE3) E. coli as described above.  Cell pellets were 
resuspended in 20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 2 mM DTT, 10% 
glycerol (buffer C), lysed and clarified as described above.  Clarified lysate was loaded 
onto a glutathione-sepharose column (Pharmacia).  EphA4 protein was washed and eluted 
in buffer C containing 10 mM glutathione.  The GST tag was removed with TEV 
protease and protein was loaded on an S-200 column equilibrated with buffer C.  Eluted 
EphA4 was concentrated and stored at -80ºC.   
Guanine Nucleotide Exchange Assays: 
Fluorescence spectroscopic analysis of N-methylanthraniloyl (mant)-GTP 
incorporation into RhoA was carried out as described (246).  In brief, assay mixtures 
containing 20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT and 100 μM 
mant-GTP (Molecular Probes) and 2 μM RhoA were allowed to equilibrate with 
continuous stirring.  After equilibration, 50 nM Tim was added and nucleotide loading 
was monitored as the decrease in the tryptophan fluorescence (λex = 295 nm, λem = 335 
nm) of RhoA or the increase in the mant-GTP fluorescence (λex = 360 nm, λem = 440 nm) 
as a function of time using a Perkin-Elmer LS 55 spectrophotometer.  Rates of guanine 
nucleotide exchange were determined by fitting the data to a single exponential decay 
model with GraphPad Prizm.  Data were normalized to yield percent GDP released and 
assays were performed in duplicate. 
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Cell Culture and Transformation Assays: 
NIH 3T3 mouse fibroblasts were maintained in DMEM supplemented with 
penicillin/streptomycin and 10% calf serum (Hyclone).  HEK 293T cells and SYF 
fibroblasts were maintained in DMEM supplemented with penicillin/streptomycin and 
10% fetal bovine serum (Sigma).  PCR-amplified Tim constructs were ligated into 
pcDNA 3.1 Hygro (Invitrogen) between EcoRI and XhoI such that an expressed HA-tag 
was encoded at the N-terminus of each construct.  Mutations were introduced into wild 
type Tim as described above. 
Cell lines stably expressing Tim were established by transfecting NIH 3T3 cells 
with 1 μg of each pcDNA construct using LipofectAMINE Plus (Invitrogen) according to 
the manufacturer’s protocol.  Three days post-transfection the cells were subcultured into 
growth medium supplemented with 300 μg/mL of hygromycin B.  Mass populations of 
multiple, drug resistant colonies (>50) were pooled together for focus formation analyses.  
Western blot analysis with an anti-HA antibody (Covance) was performed to verify Tim 
expression in the cell lines. 
For the secondary focus formation assays, equal numbers of cells from each cell 
line were seeded into 60 mm dishes.  The growth medium of each dish was replaced with 
fresh hygromycin-supplemented medium every three days.  14 days after seeding, the 
dishes were stained with crystal violet and the foci were quantified by visual inspection.  
Individual experiments were performed in duplicate and independently carried out three 
times. 
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GTPase Activation Assays: 
Affinity purifications of RhoA were carried out as described (66).  In brief, the 
Rho binding domain (RBD) of Rhotekin (amino acids 7-89) was expressed as a GST 
fusion protein in BL21 (DE3) cells and immobilized on glutathione-coupled Sepharose 
4B beads (Amersham Biosciences).  HEK 293T cells were transiently transfected with 1 
μg of various pcDNA-Tim constructs using LipofectAMINE 2000 (Invitrogen) according 
to the manufacturer’s protocol.  Immediately post-transfection, these cells were serum 
starved in DMEM supplemented with 0.1% FBS and incubated for 16 hours.  Cells were 
washed in ice cold PBS and lysed in lysis buffer (50 mM Tris pH 7.5, 500 mM NaCl, 30 
mM MgCl2, 0.1% SDS, 0.5% sodium deoxycholate, 1.0% Triton X-100 and protease 
inhibitors).  Lysates were clarified by centrifugation at 16,000 g for 10 min.  Total protein 
concentration of the lysates was determined by a colorimetric assay (Bio-Rad).  1 mg of 
clarified HEK 293T lysate was incubated with 120 μg GST-Rhotekin-RBD beads for 1 
hour at 4°C.  The beads were washed three times in wash buffer (25 mM Tris pH 7.5, 30 
mM MgCl2, 40 mM NaCl and protease inhibitors).  Total and affinity-purified lysates 
were subjected to SDS-PAGE and Western blot analysis using an anti-RhoA (Santa Cruz 
Biotechnology) monoclonal antibody.  Each experiment was performed a minimum of 
three times.  Precipitation of Tim with recombinant G17A RhoA was performed 
essentially as described (102). 
In vitro kinase assay: 
30 μg of purified Tim protein was incubated with 250 ng of recombinant Src or 
EphA4 kinase domain in kinase buffer (100 mM Tris, pH 7.5, 125 mM MgCl2) 
supplemented with 100 μM ATP and 5 μCi [γ-32P] ATP for 60 min at 30°C.  Samples 
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were subjected to SDS-PAGE and autoradiography.  Control substrate peptide was 
obtained from Upstate. 
Immunoprecipitation: 
The cDNAs for various Src constructs in pUSEamp were obtained from Upstate.  
SYF fibroblasts were transfected with 10 μg Src and 5 μg Tim using Superfect (Qiagen) 
according to the manufacturer’s protocol.  24 hours post-transfection, the cells were 
serum starved in DMEM supplemented with 0.1% FBS and incubated for 16 hours.  Cells 
were washed in ice-cold PBS and lysed in lysis buffer.  Lysates were clarified by 
centrifugation at 16,000 g for 10 min.  1 mg of clarified SYF lysate was incubated with 
25 μg anti-HA affinity matrix (Roche) for 1 hour at 4°C.  The beads were washed three 
times in lysis buffer.  Total and affinity purified lysates were subjected to SDS-PAGE 
and Western blot analysis using anti-phosphotyrosine (Transduction Laboratories), anti-
Src (Upstate), anti-HA (Covance), and anti-β actin (Sigma) antibodies.  The experiment 
was performed three times.   
Results: 
Specificity of the Guanine Nucleotide Exchange Activity of Tim: 
Previous studies by our lab have shown that Tim catalyzes exchange of guanine 
nucleotides on RhoA, but not on Rac1 or Cdc42 (94).  This specificity of exchange 
activity is due to the fact that Tim possesses a basic residue in helix α5 of the DH 
domain, which is able to form an energetically favorable salt-bridge interaction with 
glutamate 54 of RhoA.  Rac1 and Cdc42 do not have an acidic residue in the position 
analogous to E54 of RhoA, and thus cannot make this contact with Tim (94).  However, 
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recent work in which Tim is over-expressed in various mammalian cell types suggests 
that Tim may catalyze exchange on more than one Rho family GTPase.  For example, 
expression of Tim in COS-7 or NIH 3T3 cells leads to a loss of actin stress fibers and the 
formation of membrane ruffles, dorsal ruffles, and filopodia, suggesting that Tim may 
activate Rac1, RhoG or Cdc42 but not RhoA in these cell types (244).  However, 
expression of Tim in COS-7 cells leads to activation of RhoA, and not Rac1 or Cdc42, in 
pulldown experiments using GST-tagged versions of the Rho binding domains of the Rho 
effector, Rhotekin, and the Rac1 and Cdc42 effector, Pak (44).  In the same study, Tim 
expression in NIH 3T3 cells led to activation of JNK, SRF and AP-1 regulated 
transcription, suggesting that Tim activates multiple GTPases in this cell type.  However, 
in the same work, Tim expression in Swiss 3T3 cells led to cell rounding, while Tim 
expression in HeLa cells led to an increase in vinculin-enriched focal adhesions, 
suggesting that Tim activates RhoA in these cell types.   
In an attempt to resolve these conflicting data, and to test the hypothesis that Tim 
activates multiple GTPases, we performed a fluorescence-based guanine nucleotide 
exchange assay on a library of Rho-family GTPases (Figure 9).  In this assay, Tim 
robustly activated each of the members of the RhoA subfamily of Rho GTPases, RhoA, 
RhoB, and RhoC.  However, Tim failed to activate the members of the Rac1 (Rac1, 
Rac2, Rac3 and RhoG) or Cdc42 (Cdc42, TCL and TC10) subfamilies.  These data 
suggest that Tim directly activates members of the RhoA subfamily of GTPases, but may 
activate indirectly additional GTPases when over-expressed in various cell types. 
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Regulation of Tim by regions preceding its DH domain: 
Tim was originally identified by its capacity to transform NIH 3T3 cells upon N-
terminal truncation (83).  Since many Dbl-family proteins are activated by similar 
truncations, we undertook a detailed analysis of the structural determinants within the N- 
 
 74
Figure 9: Tim is specific for RhoA, RhoB and RhoC. 
The exchange of GDP bound to various Rho GTPases and catalyzed by Tim was measured using a standard 
fluorescence-based assay (245,246).  The relative fluorescence units (RFU) resulting from mant-GTP 
loading onto each GTPase are shown for Tim catalyzed (red curves) and intrinsic (black curves) exchange 
reactions.  The GTPases were purified and assessed for GTP-loading stimulated by EDTA as previously 
described (195). 
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terminal region of Tim required for its auto-inhibition.  Using purified proteins, full-
length Tim (wt, Figure 10A) enhanced the rate of exchange of guanine nucleotide bound 
to RhoA by a modest five-fold relative to the equivalent, spontaneous reaction (-).  In 
contrast, truncation of the first 22 residues of Tim (Δ22) greatly enhanced the normalized 
loading of nucleotide by more than thirty-fold.   
Constitutive RhoA activation promotes cellular transformation, and consistent 
with the in vitro exchange data, stable expression in NIH 3T3 cells of Tim (Δ22) 
promoted robust formation of foci relative to background (vector) and full-length Tim 
(wt) (Figure 10B).  The combined results from the in vitro exchange assays and cellular 
transformation assays indicate that Tim is auto-inhibited by its N-terminus and that 
deletion of the first 22 residues of Tim relieves this auto-inhibition to promote robust 
guanine nucleotide exchange on RhoA in vitro as well as significant transformation of 
NIH 3T3 cells. 
To produce a high-resolution map of the residues within the N-terminal portion of 
Tim necessary for auto-inhibition, this region was subjected to alanine-scanning 
mutagenesis and the resulting purified mutant proteins were tested for their capacity to 
activate RhoA in vitro (Figure 11A).  This analysis identified residues 15 through 22 of 
Tim as necessary for its auto-inhibition in vitro.  Stable expression of these substituted 
forms of Tim in NIH 3T3 cells indicated an approximate direct correlation between the 
capacity of Tim to activate RhoA in vitro and the transformation potential of the mutated 
forms of Tim (Figure 11B).  One exception to this rule, Y22A, significantly relieved the 
auto-inhibition of Tim in vitro, but failed to activate Tim’s transforming potential.  It was 
reasoned that in the cellular environment secondary intermolecular interactions might  
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Figure 10: Full-length Tim is auto-inhibited by its N-terminal region. 
(A)  The exchange of GDP bound to RhoA and catalyzed by Tim was measured using a standard 
fluorescence-based assay (245,246).  Fold-activation is relative to the spontaneous loading of guanine 
nucleotide and represents the average of two independent reactions for each trace.  Equal amounts (2 µg) of 
purified proteins used in the exchange assays are shown at right following SDS-PAGE and staining with 
Coomassie brilliant blue.  Also shown is a schematic of the domain architecture of Tim with the site of N-
terminal truncation indicated.  (B)  N-terminally truncated Tim potentiates transformation of NIH 3T3 
cells.  Data represent the averages of three independent experiments carried out in duplicate.  ** denotes p 
< 0.01, as determined by a pairwise t-test assuming equal variances.  Inset illustrates representative plates 
of foci.  Right panel verifies approximately equal expression of Tim variants used in the focus formation 
assays.   
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serve to stabilize the auto-inhibited state.  These secondary stabilizing interactions would 
be lacking in the in vitro exchange assays using purified components such that even 
modest perturbation to the auto-inhibition of Tim (e.g. Y22A) would appear relatively 
enhanced.  To explore this possibility, Tyr 22 was subsequently mutated to Glu (Y22E) 
with the anticipation that the added negative charge would further perturb auto-inhibitory 
interactions.  The identical substitution was separately created at Tyr 19, and the resulting 
mutant proteins were analyzed as above.  Both potentially phosphomimetic substitutions 
led to robust in vitro activation of RhoA and correspondingly large increases in the 
transformation potential of Tim.  To the best of our knowledge, these data represent the 
first report of a full-length Dbl-family protein that is activated by single substitutions to 
the same extent as activation by N-terminal truncation.   
To determine if residues 15 through 22 of Tim are sufficient for its auto-
inhibition, we created a peptide comprising this region and performed an in vitro guanine 
nucleotide exchange assay in which this peptide (WT, Figure 12A) was added to Tim 
(Δ22) in trans.  The exchange activity of Tim (Δ22) alone was greatly enhanced with 
respect to full-length Tim, as was also shown in Figure 9A.  However, the exchange 
activity of Tim (Δ22) in the presence of the wild type peptide was reduced to that of full-
length, auto-inhibited Tim.  To determine if the observed inhibition was specific for this 
peptide, we also created a peptide in which the tyrosine residue corresponding to Tyr 19 
in full-length Tim was converted to glutamic acid (MT, Figure 12A).  Substitution of Tyr 
19 with glutamic acid in the context of full-length Tim led to Tim activation in both the 
in vitro exchange assay and the cellular transformation assay (Figure 11).  We therefore 
expected that a peptide incorporating this substitution would have no effect on the  
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Figure 11: A short region within Tim is responsible for auto-inhibition. 
(A)  The N-terminal portion of Tim was subjected to scanning mutagenesis and the purified proteins were 
assayed for their capacity to catalyze the exchange of guanine nucleotides on RhoA.  Fold-activation is 
relative to the spontaneous loading of nucleotide onto RhoA (-) and represents the average of two 
independent assays for each mutant.  Equal amounts (2 µg) of purified proteins used in the exchange assays 
are shown in the lower panel following SDS-PAGE and staining with Coomassie brilliant blue (a 
composite of several gels is shown).  (B)  Equivalent forms of Tim were stably expressed in NIH 3T3 cells 
(lower panel, composite western blot) and assayed for foci formation (upper panel).  Data represent the 
averages of three independent experiments carried out in duplicate.  * denotes p < 0.05, ** denotes p < 
0.01, as determined by a pairwise t-test assuming equal variances.   
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exchange potential of Tim (Δ22).  This hypothesis was borne out experimentally, since 
the exchange potential of Tim (Δ22) in the presence of the mutant peptide was identical 
to that of Tim (Δ22) alone.  Importantly, neither peptide had an effect on the intrinsic rate 
of exchange on RhoA.  These data strongly suggest that residues 15 through 22 are both 
necessary and sufficient for Tim auto-inhibition. 
To confirm that the N-terminal region is necessary for Tim inhibition in the 
context of an intact cell, we performed affinity purifications of active Tim using a GST-
tagged version of nucleotide-free RhoA (RhoA G17A, Figure 12B).  Since Dbl-family 
proteins bind preferentially to nucleotide-free Rho family GTPases, this construct is 
expected to affinity purify any active, RhoA-specific GEF present in a cell lysate.  Wild 
type, HA-tagged Tim, when expressed in serum-starved HEK 293T cells, did not 
appreciably interact with RhoA G17A.  In contrast, both truncated Tim (Δ22) and full-
length Tim possessing the double substitution, Y19E + Y22E were robustly affinity 
purified by the RhoA G17A matrix, suggesting that the immediate N-terminal region of 
Tim, and tyrosines 19 and 22 in particular, lead to Tim auto-inhibition by preventing its 
interaction with RhoA. 
Affinity purifications of active RhoA (Figure 12C) confirmed the direct 
correlation between the capacity of Tim to activate RhoA in vitro and Tim’s transforming 
potential.  For example, while wild-type Tim did not significantly activate RhoA relative 
to empty vector upon transfection into HEK 293T cells, both truncated Tim (Δ22) and 
full-length Tim possessing the double substitution, Y19E + Y22E, dramatically 
stimulated the loading of GTP onto RhoA.  These data strongly suggest that the increased  
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Figure 12: The N-terminal region is necessary and sufficient for Tim auto-inhibition. 
(A)  Tim (Δ22) was incubated with either a peptide corresponding to the N-terminal auto-inhibitory region 
(WT, biotin-SQLLYQEYSDV-amide) or a mutant peptide (MT, biotin-SQLLEQEYSDV-amide) at room 
temperature for 20 minutes.  The resulting complexes were assayed for their ability to stimulate loading of 
mant-GTP onto RhoA.  The peptide concentrations were 100 μM.  (B)  The activity of Tim constructs 
transiently expressed in quiescent HEK 293T cells was assessed by a pulldown assay using GST-tagged 
nucleotide-free RhoA as the affinity purification matrix.  Levels of active Tim were determined by 
immunoblotting the pulldown samples.  Immunoblots of the total cell lysate (2.5% input shown) show 
approximately equal expression of the Tim constructs.  (C)  The ability of Tim constructs to stimulate 
GTP-loading on RhoA in HEK 293T cells was assessed by affinity precipitation of active RhoA with 
rhotekin.  Levels of RhoA-GTP were determined by immunoblotting the affinity-precipitated samples and 
were compared to RhoA pools in the total cell lysate (1% input shown).  In the same experiment, HA-
tagged Tim variants were checked for approximately equal expression by immunoblotting.    
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transformation potential of mutant forms of Tim is directly caused by their increased in 
vivo exchange activities.   
Regulation of Tim by Tyrosine Phosphorylation: 
Based upon primary and secondary amino acid sequence analyses, the auto-
inhibitory region within Tim is strongly predicted to be helical (residues 16 – 26; (247)) 
and tyrosines 19 and 22 within this region are predicted to be excellent substrates for  
phosphorylation by Src-family non-receptor tyrosine kinases (248).  Since the activation 
of many Dbl-family GEFs is associated with phosphorylation (155), the potential 
regulation of Tim by phosphorylation was tested both in vitro and in vivo (Figure 13).  
First, it was confirmed that indeed, full-length, purified Tim was an excellent substrate 
for purified Src, with kinetics and extent of phosphorylation resembling control reactions 
with a standard, control peptide (Figure 13A and data not shown).  Furthermore, 
phosphorylation was confined to the N-terminal region of Tim, since Src was incapable 
of phosphorylating Tim (Δ22).  Residues 19 and 22 are the only tyrosines encompassed 
within this deletion, and both residues are phosphorylated by Src since substitution at 
both sites (Y19A + Y22A) is required to prevent the phosphorylation of full-length Tim.  
Intriguingly, single substitution at either Tyr 19 or 22 enhances phosphorylation at the 
other tyrosine, indicating that the two sites might be functionally linked.  One simple 
interpretation for these data posits that substitution at either tyrosine significantly disrupts 
intramolecular interactions associated with auto-inhibition such that the remaining 
tyrosine is more accessible for phosphorylation by Src.   
A logical extension of this scenario is that phosphorylation at tyrosines 19 and 22 
might be physiologically relevant for relieving the auto-inhibition of Tim in vivo.  
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Consequently, it was shown that constitutively active (CA) but not kinase dead (KD) Src 
was capable of phosphorylating Tim in vivo upon co-expression in SYF fibroblasts 
designed to lack endogenous Src-family kinases (Figure 13B).  In the same vein, Src 
robustly activated Tim in vitro using purified components (Figure 13C).  In this setting, 
maximal activation required ATP consistent with the idea that phosphorylation of Tim by 
Src relieves auto-inhibition of Tim to promote activation of RhoA.  Taken together, these 
data strongly suggest that the in vivo phosphorylation of Tim within its auto-inhibitory 
region by Src might be a physiologically relevant means of activating the exchange 
potential of Tim and linking as yet unidentified upstream cellular events with the 
activation of RhoA.   
Src without ATP also activated Tim (Figure 13C), suggesting that the binding of 
Src to Tim partially disrupted the auto-inhibition of Tim.  However, the possibility exists 
that Src remained bound to ATP during the purification of the kinase domain, and that 
additional ATP is not required for this kinase domain to phosphorylate Tim.  To test this 
hypothesis, we incubated Tim with increasing amounts of purified Src kinase domain and 
performed a phosphotyrosine blot (Figure 14A).  Auto-phosphorylation of the kinase 
domain, and phosphorylation of Tim, only occurred when ATP was included in the 
reaction, suggesting that the purified Src kinase domain is not bound to ATP.  To confirm 
that Src binding to Tim, in the absence of phosphorylation, activates Tim, we also 
performed an exchange assay in which Tim was incubated with a kinase inactive 
(K297A) version of Src (Figure 14B).  Kinase inactive Src was also able to activate Tim, 
indicating that formation of a complex between Src and Tim, decoupled from 
phosphorylation, is sufficient to partially activate the exchange capacity of Tim.  We  
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Figure 13: Src phosphorylates Tim and activates its exchange activity. 
(A)  Src specifically phosphorylates two tyrosines (19 and 22) within the auto-inhibitory helix of Tim.  
Purified forms of Tim (lower panel) were incubated with recombinant Src and radioactive ATP for various 
times prior to SDS-PAGE and auto-radiography was used to assess levels of phosphorylation (upper panel).  
Deletion of the entire inhibitory region (Δ22), or tandem substitution of Tyr 19 and 22 abrogates 
phosphorylation.  (B)  Src phosphorylates Tim in vivo.  SYF fibroblasts were transiently cotransfected with 
HA-Tim and constitutively active (CA) or kinase-dead (KD) Src constructs.  HA-Tim was 
immunoprecipitated from cell lysates, and immunoblotted to determine the extent of phosphorylated Tim.  
The experiment was performed three times and a representative example is shown.  Phosphorylation of Tim 
by Src (C) or EphA4 (D) promotes the capacity of Tim to catalyze nucleotide exchange on RhoA.  Full-
length Tim was incubated with combinations of kinase and ATP as indicated for thirty minutes prior to 
addition of the mixtures to exchange reactions.  Fold-activation is relative to the spontaneous loading of 
nucleotide onto RhoA (black trace) and represents the average of two independent runs for each condition. 
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have been unable to isolate a complex of Tim and Src by co-immunoprecipitation 
experiments from cells over-expressing both of the proteins (data not shown), suggesting 
that their interaction is transient in vivo where endogenous concentrations of ATP favor 
completion of the phosphorylation reaction. 
The Tim homologs, ephexin and Vsm-RhoGEF, interact with and are tyrosine 
phosphorylated downstream of the EphA4 receptor tyrosine kinase (77,80).  To test the 
hypothesis that Tim is directly phosphorylated by EphA4, we performed in vitro kinase 
assays with recombinant kinase domain of EphA4.  Tim was robustly phosphorylated by 
the kinase domain of EphA4 (data not shown), indicating that Tim is phosphorylated by 
EphA4 directly.  Additionally, EphA4 activated Tim in vitro (Figure 13D).  In this case, 
the kinase in the absence of ATP did not activate Tim, suggesting that the interaction 
between EphA4 and Tim is transient compared to the interaction between Tim and Src.  
These data suggest that binding of ligand to the EphA4 receptor may lead to the 
phosphorylation and activation of Tim. 
Disrupting auto-inhibition by mutating the DH domain: 
The above experiments have shown that Tim is auto-inhibited by a small, 
conserved region with high helical propensity and that this auto-inhibition can be relieved 
by truncation, mutation, or phosphorylation of the auto-inhibitory region.  This situation 
is reminiscent of regulation of the Vav isozymes whereby a short helix immediately 
preceding the DH domain lies down on the most conserved surface of the DH domain to 
prevent Rho GTPases from engaging this same surface for effective nucleotide exchange 
(154).  Phosphorylation of the inhibitory helix in the Vav isozymes by Src and related 
non-receptor tyrosine kinases stimulates exchange in vitro and in vivo (249-253) and is  
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Figure 14: The Src kinase domain activates Tim in the absence of phosphorylation. 
(A)  ATP is required for the phosphorylation of Tim by recombinant Src produced in baculovirus-infected 
HighFive cells.  Various combinations of Tim and Src were incubated for 30 minutes at 37 ºC prior to SDS-
PAGE and immunoblot analysis.  (B)  Kinase-inactive Src activates Tim.  Full-length Tim was incubated 
with combinations of kinase-inactive Src as indicated for thirty minutes prior to addition of the mixtures to 
exchange reactions.  Fold-activation is relative to the spontaneous loading of nucleotide onto RhoA (black 
trace) and represents the average of two independent runs for each condition.  Equal amounts of the 
purified Src proteins are shown in the lower panel following immunoblot analysis. 
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required for some physiological functions of Vav (254).  If a similar mechanism is 
operative for Tim, then it might be possible to mutate specific residues within the DH 
domain to disrupt interactions with the auto-inhibitory helix without affecting GTPase 
binding, and in this way constitutively activate Tim.  Such residues within the DH 
domain would be expected to be conserved, equivalent to sites that contact the auto-
inhibitory helix of Vav1, and yet not critical for the interaction of the DH domain with 
GTPases.  Appropriate analyses of the available sequence and structure data (Figure 15A 
and references within) identified several sites that fit these criteria, and Tim was mutated 
with individual substitutions (Y111L and S114A) to test this hypothesis.  Tim (Y111L) 
was destabilized, insoluble and inactive in vitro (data not shown).  In contrast, Tim 
(S114A) is stable, soluble, and able to activate RhoA in vitro (Figure 15B) approximately 
four-fold more efficiently than wild-type Tim.  Importantly, under identical conditions, 
S114A is relatively silent within the context of Tim lacking the auto-inhibitory helix 
(Δ22), indicating that the intrinsic exchange mechanism of Tim is unaffected by S114A.  
The ability of this mutant (Δ22 + S114A) to catalyze exchange, however, is inhibited by 
addition of 100 μM of the peptide corresponding to the N-terminal putative helical motif 
(residues 15-25) of Tim used in Figure 12A (data not shown).  This result indicates that 
the S114A substitution does not completely abolish the interaction between the N-
terminal auto-inhibitory motif of Tim and the DH domain pocket and is consistent with 
the partial relief of inhibition of exchange caused by the S114A substitution within the 
context of full-length Tim (Figure 15A).   
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Figure 15: Mutations within the DH domain designed to disrupt the interaction with the auto-
inhibitory helix lead to auto-activation. 
(A)  Surface representations of the Vav1 DH domain (PDB accession 1F5X, murine Vav1 residues 198-
372) that illustrate (left) the positions of highly conserved residues among DH domains from 70 human 
Dbl-family sequences as determined by ClustalX (bright red is most conserved); (center) the sites of 
contact (≤ 5 Å; blue) between the Vav1 DH domain and the Vav1 auto-inhibitory helix (residues 170-179); 
and (right) the sites and degree of conservation of interactions observed within the structures of 
Tiam1•Rac1, Intersectin•Cdc42, Dbs•RhoA and Larg•RhoA that occur between Rho GTPases and DH 
domains (≤ 3.5 Å between residues, bright green is fully conserved) mapped onto the surface of the DH 
domain of Vav1.  Surface representations were produced using the programs ProtSkin (255) and PyMOL 
(256) and reveal a region of high sequence conservation in a pocket that contacts the auto-inhibitory helix 
but does not contact Rho GTPases.  Thr 212 of Vav1 is indicated and the equivalent residue (Ser 114) in 
Tim has been mutated to disrupt auto-inhibition as shown below.  (B)  Relative to the spontaneous loading 
of guanine nucleotide onto RhoA (- , black trace) auto-inhibition of full-length Tim (wt, red trace) is 
relieved by mutation within its DH domain (S114A, green trace) while the exchange activity of truncated, 
constitutively active Tim (Δ22, magenta trace) is relatively unaffected by the equivalent mutation (Δ22 + 
S114A, blue trace).  The traces corresponding to spontaneous loading, full-length Tim and Tim (Δ22) are 
reproduced from Figure 10 for reference.  Proteins used in the exchange assays are shown at right.  (C)  
The S114A mutation increases the ability of Tim transiently expressed in quiescent HEK 293T cells to 
associate with nucleotide-free RhoA.  The activity level of Tim constructs was assessed as described in 
Figure 12.  Levels of active Tim were determined by immunoblotting the pulldown samples.  Immunoblots 
of the total cell lysate (2.5% input shown) show approximately equal expression of the Tim constructs.  (D)  
Mutation in the DH domain (S114A) increases the ability of Tim to induce foci when expressed in NIH 
3T3 cells.  Data represent the averages of three independent experiments carried out in duplicate.  The 
lower panel shows approximately equal expression of the Tim constructs. 
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Consistent with the in vitro exchange data, though, Tim (S114A) behaved 
similarly to truncated Tim (Δ22) in its ability to interact with nucleotide free RhoA 
(Figure 15C) and its ability to induce formation of foci (Figure 15D).  Consequently, it is 
possible to decouple the auto-inhibitory and exchange functions of Tim through mutation 
of its DH domain.   
Discussion: 
Figure 16 presents a model for the relief of auto-inhibition of Tim.  In this model, 
an auto-inhibitory helix packs against the conserved pocket of the DH domain in the 
basal, inactive state to prevent Rho GTPases from accessing the surface of the DH 
domain necessary for guanine nucleotide exchange.  Activation of Src leads to 
phosphorylation of the auto-inhibitory helix, which disrupts the interactions between the 
auto-inhibitory helix and the DH domain, thereby freeing the DH domain to interact with 
cognate GTPases and activate them by nucleotide exchange.  If the auto-inhibitory helix 
is truncated, or otherwise mutated such that it can no longer bind to the DH domain, Tim 
will be constitutively activated.  Likewise, if residues within the conserved binding patch 
of the DH domain are mutated such that it is no longer able to bind the auto-inhibitory 
helix, Tim will be constitutively activated.   
Tim clusters with five other human Dbl-family proteins: neuroblastoma, Sgef, 
Wgef, Ngef, and Vsm-RhoGEF, based on high sequence identity among DH domains and 
overall domain architecture that includes an SH3 domain carboxyl-terminal to the 
canonical DH/PH module.  While not readily evident using standard sequence alignment 
algorithms such as PSI-BLAST, all members of this sub-group possess a putative auto-
inhibitory region N-terminal to the DH domain with high sequence identity to the short  
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Figure 16: Model of Tim auto-inhibition. 
(A)  Regulation of Tim exchange activity by sequences N-terminal to the DH domain.  The auto-inhibitory 
helix packs against the conserved pocket of the DH domain, preventing the binding and consequent 
activation of the cognate Rho GTPase.  Tyrosine phosphorylation leads to the removal of the auto-
inhibitory helix from the DH domain.  Tim can now bind Rho to catalyze the exchange of guanine 
nucleotide.  (B)  Mechanisms of constitutive activation of Tim proteins.  The auto-inhibitory helix is 
truncated, or otherwise mutated such that it can no longer bind to the DH domain.  Alternatively, residues 
within the conserved binding patch of the DH domain are mutated such that it is no longer able to bind the 
auto-inhibitory helix, leading to a constitutively active GEF.  In each of these scenarios, the end result is 
loss of auto-inhibition leading to constitutive activation of Tim.   
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auto-inhibitory region mapped in Tim (data not shown).  Consequently, it is likely that 
other members of this subgroup are regulated in a manner similar to Tim.  In fact, the 
mouse homolog of Ngef, ephexin, is tyrosine phosphorylated in an N-terminal motif with 
significant sequence identity to the auto-inhibitory helix within the Tim subgroup of Dbl 
proteins.  However, phosphorylation of ephexin alters its exchange profile.  Specifically, 
unphosphorylated ephexin activates RhoA, Rac1 and Cdc42; but when tyrosine 
phosphorylated, ephexin exclusively activates RhoA (78).  The mechanism by which this 
specificity switch occurs is currently unknown and not encompassed within the model 
presented here for the activation of Tim. 
The mechanism of auto-inhibition of Tim presented above is reminiscent of the 
mechanism of auto-inhibition of the Vav isozymes.  In fact, the auto-inhibitory helix of 
Tim shows high sequence homology to the auto-inhibitory helix of Vav1 (data not 
shown).  The structure of an extended fragment of the DH domain of Vav1 highlights the 
steric occlusion of the DH domain through interaction with an N-terminal helix to 
prevent GTPase binding and guanine nucleotide exchange (154).  This inhibition is 
relieved upon phosphorylation of Tyr 174 within the inhibitory helix, which disrupts the 
interaction of the inhibitory helix with the DH domain and allows Rho GTPases to access 
the catalytic surface of the DH domain for effective guanine nucleotide exchange.  While 
this regulatory mechanism is operative in vivo for the three Vav isozymes, complete 
regulation of Vav isozymes is more complex.  For example, Vav1 is additionally 
phosphorylated at Tyr 142 and 160 within a highly acidic region, and substitution of all 
three tyrosines to phenylalanine greatly enhances the transformation potential of full-
length Vav1 relative to any single substitution.  However, a mutant of Vav1 truncated to 
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remove its N-terminal calponin homology (CH) domain, but not the phosphorylated 
tyrosines, is also transforming, suggesting that the CH domain stabilizes interactions of 
the auto-inhibitory helix with the DH domain within the context of full-length Vav1 (8).  
In addition, the CH domain contributes to the auto-inhibition of Vav proteins by 
interacting with a cysteine-rich domain C-terminal to the DH/PH cassette (45,157).  
Furthermore, Vav proteins may also be regulated allosterically through the binding of 
phospholipids to the PH domain, although this concept remains controversial (156,170).  
Thus, the regulated activation of the Vav isozymes is more complex than what we have 
shown above for Tim since the activation of the Vav isozymes cannot be attributed solely 
to the phosphorylation of tyrosine residues N-terminal to the DH domain.   
The human genome encodes 58 receptor tyrosine kinases (RTKs), and more than 
half of the RTKs are known to activate at least one of the Rho family members.  At least 
16 of the 69 human Dbl-family proteins are known to interact with and/or be 
phosphorylated by RTKs, thus serving as a link between ligation of RTKs and Rho 
activation (155).  For instance, FRG, a Dbl-family protein specific for Cdc42, is activated 
upon phosphorylation by Src downstream of signals arising from both the endothelin A 
receptor (46) and nectins (47).  Similarly, the exchange activity of Dbs for Cdc42 is 
enhanced upon the phosphorylation of Dbs by Src downstream of the α1B adrenergic 
receptor (143).  Activated TrkB directly binds to and activates Tiam1 (150), which is also 
known to be phosphorylated and activated by Src (149).  In each case mentioned above, 
the mechanisms by which phosphorylation increases exchange activity have yet to be 
determined.  Clearly, one fruitful avenue of research will be to assess mechanistically 
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how these phosphorylations enhance exchange; one likely mechanism is that 
phosphorylation perturbs auto-inhibition as described here.   
The Rho GTPases have long been thought to play a role in tumorigenesis.  
However, in contrast to Ras GTPases, animal studies and studies of human tumors have 
yet to further our understanding of the role of Rho GTPases in promoting tumorigenesis.  
In fact, constitutively active, GTPase-deficient mutants of Rho GTPases have yet to be 
found in human tumors.  However, several Rho GTPases, including RhoA, RhoC and 
Rac1, are over-expressed in human tumors, leading to the hypothesis that Rho GTPases, 
unlike Ras GTPases, must undergo cycling of GTP loading to be oncogenic (3,257).  
Consistent with this idea, Dbl-family Rho GEFs are more potent oncogenes than their 
substrate GTPases.  Although many Dbl-family proteins, including Tim, were identified 
as proto-oncogenes in expression library screens using DNA or RNA derived from 
human cancer cells, these activation events have proven to be experimental artifacts.  Of 
the 69 human Dbl-family proteins, only Tiam1 has been shown to be mutated in human 
tumors (5), although Vav1 is ectopically expressed in some primary pancreatic 
adenocarcinomas (153) and neuroblastomas (258).  The mutations characterized in this 
study, both in the auto-inhibitory helix and in the DH domain, represent potential 
mechanisms by which Tim and other Dbl-family proteins might be activated in human 
tumors.  Identification of such mutations in human tumors would further define the role 
of Rho GTPases in tumorigenesis. 
If versions of Tim mutated in either the auto-inhibitory helix or in the region of 
the DH domain thought to interact with the auto-inhibitory helix should be isolated from 
human tumors, then Tim would represent an attractive target for rational drug design.  
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The peptide inhibitor shown in Figure 11A could serve as the basis for design of 
peptidomimetic inhibitors of aberrant Tim activation of Rho.  Several inhibitors of small 
GTPase activation have been previously identified.  TRIPα was isolated as a random 
peptide aptamer that selectively binds to the second DHPH cassette of the RhoGEF Trio 
and inhibits the exchange activity of Trio in vitro and in PC12 cells through an unknown 
mechanism (259).  Additionally, the small molecule NCS23766 was identified in 
structure-based virtual screen for compounds that might fit into a pocket on the surface of 
Rac1.  Residues in this pocket contact Tiam1 during the exchange reaction.  This 
compound selectively inhibits Rac1 binding to Rac1-specific GEFs in vitro and prevents 
PDGF induced Rac activation in cells (260,261).  Finally, brefeldin A inhibits the 
activation of the small GTPase Arf1 by its exchange factors by binding to and stabilizing 
a complex of Arf1-GDP and the catalytic Sec7 domain (262).  The Tim peptide, then, is a 
unique GEF inhibitor in that its mechanism of action is identical to that of the auto-
inhibitory helix of the wild-type protein. 
In summary, we have shown that the Dbl-family protein, Tim, is a RhoA, RhoB 
and RhoC-specific GEF that is auto-inhibited by a putative helix N-terminal to the DH 
domain, which directly binds the DH domain to sterically exclude Rho GTPases and 
prevent their activation.  This auto-inhibition is relieved by truncation, mutation, or 
phosphorylation of the auto-inhibitory helix, or by mutation of the conserved surface of 
the DH domain to disrupt interactions with the auto-inhibitory helix.  Since inhibition of 
Tim can be restored by addition of the auto-inhibitory helix in trans, the auto-inhibitory 
helix is necessary and sufficient for maintenance of a basal state of Tim activation. 
CHAPTER 3: REGULATION OF NEURONAL-SPECIFIC GEF BY AUTO-
INHIBITION AND PHOSPHORYLATION 
Introduction: 
In the development of the nervous system, Rho GTPases integrate extracellular 
signals to direct outgrowth of both axons and dendrites; and the formation and dynamics 
of dendritic spines.  Active RhoA leads to a decrease in growth cone motility, a decrease 
in neurite elongation, and an increase in actomyosin-dependent contraction of the 
developing neuron.  Active Rac1, in contrast, leads to an increase in lamellae formation, 
and an increase in the initiation, elongation, branching complexity and dynamics of 
dendrites.  Like Rac1, active Cdc42 leads to an increase in dendritic branch formation, as 
well as an increase in filopodia and neurite formation.  In addition, conditional in vivo 
deletion of Cdc42 has revealed that this GTPase is required for establishment of apical-
basal polarity and maintenance of ventricular zone neuronal progenitor cells (263,264).  
Deletion or mutation of crucial components of the Rho signaling pathway, then,  renders 
neurons less responsive to environmental cues, leading to compromised neuronal 
connectivity and plasticity (4). 
Many Dbl-family proteins, which activate Rho GTPases by catalyzing the 
exchange of GDP for GTP, are associated with neurological disorders.  Fgd1 was 
originally identified as a gene that is deleted in patients with faciogenital dysplasia, a 
developmental disorder characterized by skeletal defects as well as mental retardation 
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(12).  In addition, a truncation mutation of αPix/COOL2 has been identified in forms of 
X-linked mental retardation (162), while intersectin is associated with certain forms of 
Downs syndrome (265).  Finally, a loss of function of Alsin is associated with juvenile 
onset amyotrophic lateral sclerosis (ALS) (266).   
Other Dbl-family proteins are known to play a role in neuronal development, 
although a link between these GEFs and a neurological disorder has yet to be discovered.  
For example, Kalirin has been shown to affect neurite outgrowth, and neuronal and 
dendritic spine morphogenesis (145).  In addition, P-rex was shown to be involved in 
neurotrophin-derived signaling and neuronal migration (208).  FRG (also known as 
FARP2 or FIR) is expressed in the ventricular zone during mouse brain development and 
may play a role in neurogenesis, asymmetric cell division, neuronal migration and neurite 
remodeling (267).  Plexin A1 binds to the N-terminal FERM domain of FRG, and 
activation of plexin A1 by its ligand, semaphorin 3A leads to an increase in the exchange 
activity of FRG and subsequent growth cone collapse (268).  Finally, Tiam1 binding to 
the polarity protein, Par3, spatially restricts this Dbl-family GEF to dendritic spines.  This 
restricted localization is required for dendritic spine morphogenesis (87). 
Although many Dbl-family proteins are known to be involved in many different 
facets of neuronal development, the mechanisms by which these proteins are regulated in 
this context are largely unknown.  We have recently shown that Tim, a small Dbl-family 
protein, is also auto-inhibited by a putative helix N-terminal to the DH domain, which 
directly binds the DH domain to sterically exclude Rho GTPases and prevent their 
activation.  This auto-inhibition is relieved by truncation or mutation of the auto-
inhibitory helix, or by a mutation in the conserved surface of the DH domain that disrupts 
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interactions with the auto-inhibitory helix.  Src and EphA4 phosphorylate Tim on two 
tyrosines in the auto-inhibitory helix, Tyr 19 and Tyr 22, which activates the exchange 
potential of Tim.  Finally, a peptide comprising the auto-inhibitory helix is able to inhibit 
a truncated version of Tim in trans (269). 
Tim consists of an SH3 domain C-terminal to the DH and PH domains and this 
domain architecture is shared with a small group of Dbl-family members including: 
Wgef, Sgef, Vsm-RhoGEF, neuroblastoma and Ngef.  In contrast to Vav and other Dbl-
family members, relatively little is known about the physiological importance and 
molecular regulation of this sub-group.  For example, Ngef is expressed primarily in the 
brain, is localized to chromosomal region 2q37, and is transforming in cell culture 
(36,76).  The mouse ortholog of Ngef, ephexin, is expressed in the central nervous system 
during development and was originally cloned based upon its ability to interact with the 
EphA4 receptor tyrosine kinase.  Ephexin activates RhoA, Rac1 and Cdc42 in cell-based 
assays; mediates ephrinA-induced growth cone collapse (77); and is phosphorylated by 
Src family kinases downstream of EphA4 receptor activation (76).  When ephexin is not 
tyrosine phosphorylated, it activates RhoA, Rac1 and Cdc42; but when ephexin is 
tyrosine phosphorylated; it activates RhoA exclusively (78).  Most recently, ephexin has 
been shown to be phosphorylated in its N-terminus by Cdk5 downstream of EphA4 
receptor activation (79).  The precise mechanism by which ephexin undergoes its 
specificity switch and the mechanisms by which Cdk5 and Src coordinate to modulate 
ephexin activity are poorly understood. 
Here we show that Ngef is also regulated by phosphorylation of the auto-
inhibitory helix.  Truncation, mutation or phosphorylation of the auto-inhibitory helix 
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activates the exchange potential of Ngef toward RhoA, Rac1 and Cdc42 in vitro and in 
vivo.  However, in contrast to Tim, Ngef is phosphorylated by Src on only one of the 
tyrosines in the auto-inhibitory helix, and Ngef is not phosphorylated by EphA4.  
Additionally, a subset of cortical progenitor cells expressing a phosphomimetic mutant of 
Ngef are able to differentiate into neurons but do not extend neurites.  This phenotype is 
effectively reversed by inhibition of the Rho effector, p160-Rho kinase.  These results 
extend our knowledge of the regulation of Dbl-family proteins as a whole, and Ngef in 
particular.   
Materials and Methods: 
Protein Expression and Purification: 
Full-length and truncated versions of human Ngef were PCR-amplified and 
ligated into pET-21a (Novagen) between NdeI and XhoI in frame with a C-terminal, non-
cleavable hexahistidine tag.  The cDNA for Ngef was obtained as I.M.A.G.E. clones 
(ATCC) (Accession number: Q8N5V2). 
Ngef constructs were expressed in the E. coli strain BL21 (DE3) (Novagen).  Cell 
cultures were grown at 37ºC in LB/ampicillin (100 μg/mL), and induced with 1 mM 
isopropyl-β-D-thiogalactopyranoside (IPTG) for 5 h at 27ºC.  Cell pellets were 
resuspended in 20 mM Tris, pH 8, 300 mM NaCl, 10% glycerol (buffer A) with 10 mM 
imidazole, lysed using an Emulsiflex C5 cell homogenizer (Avestin), and clarified by 
centrifugation at 40,000 g for 45 min at 4ºC.  Clarified supernatants were loaded on a 
nickel-charged metal chelating column (Pharmacia) equilibrated with buffer A containing 
10 mM imidazole, washed with buffer A containing 50 mM imidazole and eluted with 
buffer B containing 400 mM imidazole.  Eluted proteins were subsequently loaded onto 
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an S-200 size exclusion column equilibrated with 20 mM Tris pH 7.5, 150 mM NaCl, 2 
mM DTT, 1 mM EDTA and 5 % glycerol.  Fractions containing monomeric Ngef were 
pooled, concentrated and stored at -80ºC.  Mutations were introduced into wild-type Ngef 
using the Quikchange site-directed mutagenesis kit (Stratagene) as per the manufacturer’s 
instructions, and these mutant proteins were expressed and purified as described above.  
DNA sequences of all expression constructs were verified by automated sequencing.  
RhoA, Cdc42 and Rac1 were purified as described (94,225,245).  The kinase domains of 
Src and EphA4 were also purified as described (269). 
Guanine Nucleotide Exchange Assays: 
Fluorescence spectroscopic analysis of N-methylanthraniloyl (mant)-GTP 
incorporation into RhoA was carried out as described (246).  In brief, assay mixtures 
containing 20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT and 100 μM 
mant-GTP (Molecular Probes) and 2 μM RhoA were allowed to equilibrate with 
continuous stirring.  After equilibration, 400 nM Ngef was added and nucleotide loading 
was monitored as the decrease in the tryptophan fluorescence (λex = 295 nm, λem = 335 
nm) of RhoA as a function of time using a Perkin-Elmer LS 55 spectrophotometer.  Rates 
of guanine nucleotide exchange were determined by fitting the data to a single 
exponential decay model with GraphPad Prizm.  Data were normalized to yield percent 
GDP released and assays were performed in duplicate. 
Fluorescence spectroscopic analyses of mant-GTP release from Cdc42 and Rac1 
were also carried out as described (246).  In brief, assay mixtures containing 20 mM Tris 
pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 20 μM GTP and 250 nM Rac1 or 
Cdc42 preloaded with mant-GTP were allowed to equilibrate with continuous stirring.  
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After equilibration, 400 nM Ngef was added and mant-GDP release was monitored as the 
decrease in mant-GTP fluorescence (λex = 360 nm, λem = 440 nm) as a function of time.  
Rates of guanine nucleotide exchange were determined as described above. 
Cell Culture and Mammalian Expression Constructs: 
NIH 3T3 mouse fibroblasts were maintained in DMEM supplemented with 
penicillin/streptomycin and 10% calf serum (Hyclone).  COS-7 cells were maintained in 
DMEM supplemented with penicillin/streptomycin and 10% fetal bovine serum (Sigma).  
PCR-amplified Ngef constructs were ligated into pcDNA 3.1 Hygro (Invitrogen) between 
EcoRI and XhoI such that an expressed HA-tag was encoded at the N-terminus of each 
construct.  In addition, PCR-amplified HA-tagged Ngef constructs were also ligated into 
the pCIG vector (270), which contains (cDNA) – IRES – eGFP under the control of a 
CMV promoter and a chicken β-actin promoter, between EcoRI and XhoI.  Mutations 
were introduced into wild type Ngef as described above. 
Transformation Assays: 
Cell lines stably expressing Ngef were established by transfecting NIH 3T3 cells 
with 1 μg of each pcDNA construct using LipofectAMINE Plus (Invitrogen) according to 
the manufacturer’s protocol.  Three days post-transfection the cells were subcultured into 
growth medium supplemented with 300 μg/mL of hygromycin B.  Mass populations of 
multiple, drug resistant colonies (>50) were pooled together for focus formation analyses.  
Western blot analysis with an anti-HA antibody (Covance) was performed to verify Ngef 
expression in the cell lines.  The secondary focus formation assay was performed 
essentially as described (269). 
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GTPase Activation Assays: 
Affinity purifications of Rho A, Rac1 and Cdc42 were carried out as described 
(66,271).  In brief, the Rho binding domains (RBD) of Pak (amino acids 70-132) and 
Rhotekin (amino acids 7-89) were expressed as a GST fusion proteins in BL21 (DE3) 
cells and immobilized on glutathione-coupled Sepharose 4B beads (Amersham 
Biosciences).  COS-7 cells were transiently transfected in 100 mm dishes with 12 μg of 
various pCIG-Ngef constructs using LipofectAMINE 2000 (Invitrogen) according to the 
manufacturer’s protocol.  Immediately post-transfection, these cells were serum starved 
in DMEM supplemented with 0.1% FBS and incubated for 16 hours.  Cells were washed 
in ice cold PBS and lysed in lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 30 mM 
MgCl2, 1.0% Triton X-100 and protease inhibitors).  Lysates were clarified by 
centrifugation at 16,000 rpm for 10 min.  Total protein concentration of the lysates was 
determined by a colorimetric assay (Bio-Rad).  1 mg of clarified COS-7 lysate was 
incubated with 120 μg GST-Pak-RBD beads for 1 hour at 4°C.  The beads were washed 
three times in lysis buffer.  Total and affinity-purified lysates were subjected to SDS-
PAGE and Western blot analysis using anti-Cdc42 (Transduction Laboratories) 
monoclonal antibodies.  Each experiment was performed two or three times. 
Activated GEF assays: 
The activated GEF assays were performed essentially as described (102).  In brief, 
nucleotide-free mutants of RhoA (G17A), Rac1 (G15A) and Cdc42 (G15A) were 
expressed as GST-fusion proteins in BL21 (DE3) cells and immobilized on glutathione-
coupled Sepharose 4B beads (Amersham Biosciences).  COS-7 cells were transiently 
transfected in 100 mm dishes with 12 μg of various pCIG-Ngef constructs using 
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LipofectAMINE 2000 (Invitrogen) according to the manufacturer’s protocol.  
Immediately post-transfection, these cells were serum starved in DMEM supplemented 
with 0.1% FBS and incubated for 16 hours.  Cells were washed in ice cold PBS and lysed 
in lysis buffer (20 mM Hepes pH 7.5, 150 mM NaCl, 2 mM MgCl2, 1.0% Triton X-100 
and protease inhibitors).  Lysates were clarified by centrifugation at 16,000 rpm for 10 
min.  Total protein concentration of the lysates was determined by a colorimetric assay 
(Bio-Rad).  0.5 mg of clarified COS-7 lysate was incubated with 120 μg GST-GTPase 
beads for 1 hour at 4°C.  The beads were washed three times in lysis buffer.  Total and 
affinity-purified lysates were subjected to SDS-PAGE and Western blot analysis using 
anti-HA (Covance) monoclonal antibodies.  Each experiment was performed two or three 
times. 
In vitro kinase assay: 
30 μg of purified Ngef protein was incubated with 250 ng of recombinant Src or 
EphA4 kinase domain in kinase buffer (100 mM Tris, pH 7.5, 125 mM MgCl2) 
supplemented with 100 μM ATP 30 min at 37°C.  Samples were subjected to SDS-PAGE 
and Western blot analysis using anti-phosphotyrosine monoclonal antibodies (BD 
Transduction laboratories).  
Animals: 
Mice (BalbC) were used according to a protocol approved by the Institutional 
Animal Care and Use Committee at the University of North Carolina at Chapel Hill and 
in accordance with guidelines put forth by the National Institutes of Health.  Time-
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pregnant females were maintained by overnight breeding with males of the same strain, 
and noon following breeding was considered to be the E0.5 time-point.   
Dissociated Cortical Cultures: 
Electroporation of dorsal telencephalic progenitors was performed essentially as 
described (270).  In brief, various pCIG2 constructs were injected into the lateral 
ventricles of isolated E15.5 embryonic mouse heads using a Picospritzer III (General 
Valve) microinjector.  The whole head was electroporated using an EXM 830 
electroporator and gold-coated electrodes (BTX).  After removal of the skin, skull, pia, 
thalamus, hippocampus and basal ganglia, the resulting cortices were dissociated using a 
papain-based method as previously described (272).  5 X 104 of these cells were plated 
onto glass coverslips coated with poly-L-lysine and laminin, and the cultures were 
maintained in serum free media (neurobasal media with B27, N2, L-glutamine and 
penicillin/streptomycin supplements) for 4 days prior to being fixed in 4% 
paraformaldehyde.   
Confocal Microscopy: 
Cultured cortical progenitor cells were immunostained as previously described.  
The primary antibodies used include: mouse anti-Tuj1 (βIII tubulin) (Sigma), mouse anti-
HA (Covance) and mouse anti-nestin (BD Biosciences).  Direct fluorescence (GFP, 
Alexa-546 conjugated phalloidin, Molecular Probes) and indirect fluorescent 
immunostaining (Alexa-546 conjugated secondary antibodies, Molecular Probes)was 
observed using a LEICA TCS-SL laser scanning confocal microscope mounted on a DM-
IRE2 inverted microscope stand and equipped with an argon laser (488 nm), green 
helium-neon laser (546 nm), red helium-neon laser line (633 nm) and X-Y motorized 
 104
Märzhäuser stage.  For quantification of axonal length, the tile scan function was used to 
assemble multiple 20X fields.  Axon length was then measured using ImageJ 
(rsb.info.nih.gov).  In the time-lapse studies, dissociated cortical progenitor cells were 
imaged at a frequency of one picture every five minutes for 40 minutes before and an 
hour and 40 minutes after the addition of 20 μM Y-27632 (Calbiochem). 
Results: 
The exchange activity of Ngef toward its cognate GTPases is regulated by auto-
inhibition and tyrosine phosphorylation. 
We have previously shown that the Dbl-family protein, Tim, is auto-inhibited by a 
short, putative helix N-terminal to its DH domain.  Tim shares domain architecture and 
high sequence identity with five other human Dbl-family proteins: neuroblastoma, Sgef, 
Wgef, and Vsm-RhoGEF and Ngef.  All members of this sub-group possess a putative 
auto-inhibitory region N-terminal to the DH domain with high sequence identity to the 
short auto-inhibitory region mapped in Tim (Figure 17A).  Consequently, it is likely that 
other members of this subgroup are regulated in a manner similar to Tim, and this 
hypothesis was tested for Ngef.   
The mouse homolog of Ngef, ephexin, has been shown to activate RhoA, Rac1 
and Cdc42 in cell-based activity assays (77), and similarly, Ngef activated these GTPases 
in vitro (Figure 17B).  However, this activation required deletion of the putative auto-
inhibitory helix, since a construct lacking this helix showed robust activity (Δ185), while 
the shorter N-terminally truncated form of Ngef (Δ166) and the full-length version (wt) 
were essentially inert in RhoA, Rac1, and Cdc42 exchange assays.  Furthermore, 
substitution of Tyr 179 to Glu (Y179E) within the putative auto-inhibitory helix activated  
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Figure 17: Ngef is regulated by auto-inhibition. 
(A)  The N-terminal portions of Ngef and its closest homologs are highlighted in the multiple sequence 
alignment.  Colored bars underneath the alignment demark regions in Ngef corresponding to the auto-
inhibitory helix (red), an intervening region (green), and the start of the DH domain (yellow).  Tyrosines 
179 and 182 of Ngef are numbered.  The region in Ngef and its close homologs that is strongly predicted to 
be helical using standard algorithms is indicated (α).  The domain architecture of Tim and its closest 
homologs is shown above the alignment.  (B)  Full-length (wt) and truncated (Δ166) forms of Ngef that 
retain the conserved auto-inhibitory helix modestly activate RhoA, Rac1 and Cdc42.  In contrast, Ngef in 
which the auto-inhibitory helix is truncated (Δ185) or mutated (Y179E) have dramatically enhanced 
capacities to catalyze nucleotide exchange on all three GTPases.  Fold-activation (lower panel) is relative to 
the spontaneous loading of guanine nucleotide and represents the average of two independent reactions for 
each condition.  Equal amounts (5 µg) of purified proteins used in the exchange assays are shown at lower 
right following SDS-PAGE and staining with Coomassie brilliant blue.   
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Ngef to the same extent as removing this region by truncation.  Therefore, like Tim, Ngef 
is activated toward its full repertoire of Rho GTPase substrates by removal or substitution 
of a small, conserved segment with high helical propensity located N-terminal to its DH 
domain.  
Similar to the correlation seen with Tim, the in vitro guanine nucleotide exchange 
activity of Ngef tracked with its capacity to transform NIH 3T3 cells (Figure 18).  For 
instance, stably expressing Ngef lacking the auto-inhibitory helix (Δ185) or mutated 
within this region (Y179E) led to an approximately two-fold increase in foci relative to 
either expression of full-length Ngef or the N-terminally truncated version (Δ166) that 
retains the auto-inhibitory region.  The Ngef constructs consistently expressed to varying 
degrees and the results are even more striking if the numbers of foci are normalized for 
Ngef expression.  In this case, Ngef (Y179E) was 4- and 16-fold more efficient at 
promoting foci than Δ166 and full-length Ngef, respectively. 
To confirm that the N-terminal region is necessary for Ngef inhibition in the 
context of an intact cell, we performed affinity purifications of active Ngef using GST-
tagged versions of nucleotide-free RhoA, Rac1 and Cdc42 (RhoA G17A, Rac1 G15A and 
Cdc42 G15A, Figure 19A).  Since Dbl-family proteins bind preferentially to nucleotide-
free Rho family GTPases, these constructs are expected to affinity purify any active GEF 
specific for these GTPases present in a cell lysate.  HA-tagged Ngef (Δ166), when 
expressed in serum-starved COS7 cells, did not appreciably interact with RhoA G17A, 
Rac1 G15A or Cdc42 G15A.  In contrast, Ngef (Δ166+Y179E), in which a key tyrosine 
in the auto-inhibitory helix is mutated was affinity purified by all three of the nucleotide-
free GTPases, suggesting that the region of Ngef immediately N-terminal to its DH  
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Figure 18: Ngef in which the auto-inhibitory helix is truncated (Δ185) or mutated (Y179E) 
potentiates transformation of NIH 3T3 cells.   
Data represents the averages of three independent experiments carried out in duplicate.  An immunoblot 
showing expression levels of the various Ngef constructs is shown at right.  Δ166 and Y179E Ngef 
consistently express less robustly than either wt or Ngef (Δ185).   
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domain, and Y179 in particular, leads to Ngef auto-inhibition by preventing its 
interaction with its cognate GTPases. 
Affinity purifications of active RhoA and Rac1 from the lysates of COS7 cells 
(Figure 19B) confirmed the direct correlation between the capacity of Ngef to activate 
RhoA and Rac1 in vitro and in cells.  Transfection of Ngef (Δ166+Y179E) significantly 
stimulated loading of GTP onto RhoA and Rac1 upon its transfection into COS7 cells 
relative to empty vector.  We were unable to detect an increase in levels of Cdc42⋅GTP 
due to Ngef (Δ166+Y179E) expression (Figure 19B), indicating that either Ngef 
expression does not lead to Cdc42 activation in COS7 cells, or Ngef expression is 
associated with a transient activation of Cdc42 that we are unable to detect by affinity 
precipitation of steady-state levels of activated Cdc42.  Another Dbl-family protein, Dbs, 
has been shown to be a RhoA and Cdc42 specific exchange factor in vitro but its 
expression in NIH 3T3 cells does not lead to an increase in Cdc42⋅GTP as determined by 
affinity purification assays (221).  Interestingly, a peptide corresponding to the auto-
inhibitory helix of Tim (269) effectively inhibits both the RhoA and Cdc42-specific 
exchange activity of Ngef in vitro (Figure 19C), confirming that these two proteins are 
regulated similarly. 
Also like Tim, Ngef containing the auto-inhibitory region (Δ166) was robustly 
phosphorylated by Src in vitro, while further truncation (Δ185) to remove the auto-
inhibitory region led to loss of phosphorylation by Src (data not shown).  Since Tyr 179 
and 182 are the only tyrosines removed by the larger truncation, these data indicate that 
Δ166 Ngef is phosphorylated by Src exclusively within the auto-inhibitory region at 
either one or both of these tyrosines.  Interestingly, mutation of Y179 led to a loss of  
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Figure 19: Ngef in which the auto-inhibitory helix is mutated activates endogenous RhoA and Rac1 
in COS7 cells. 
(A)  The activity of Ngef constructs transiently expressed in quiescent COS7 cells was assessed by a 
pulldown assay using GST-tagged nucleotide-free RhoA, Rac1 or Cdc42 as the affinity purification matrix.  
Levels of active Ngef were determined by immunoblotting the pulldown samples.  Immunoblots of the total 
cell lysate (2.5% input shown) show approximately equal expression of the Ngef constructs (n.s. denotes 
non-specific).  The experiments were performed three times and representative examples are shown.  (B)  
Expression constructs for the phosphomimetic form of Ngef or vector alone were transfected into COS7 
cells, which were subsequently serum starved in DMEM supplemented with 0.1% FCS for 16 hours prior 
to affinity purification of the active forms for RhoA, Rac1 and Cdc42.  The levels of active and total 
GTPases were determined by immunoblotting.  In the same experiment, expression of the HA-tagged Ngef 
variant was verified by immunoblot (n.s. denotes non-specific).  The experiments were performed three 
times and representative examples are shown.  (C)  Ngef (Δ185) was incubated with a peptide 
corresponding to the N-terminal auto-inhibitory region of Tim (WT, biotin-SQLLYQEYSDV-amide) or a 
mutant peptide (MT, biotin-SQLLEQEYSDV-amide) at room temperature for 20 minutes.  The resulting 
complexes were assayed for their ability to stimulate loading of mant-GTP onto RhoA or Cdc42.  The 
peptide concentrations were 100 μM.   
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Ngef phosphorylation by Src (Figure 20A), while mutation of Y182 led to a substantial 
increase in the phosphorylation of Ngef by Src.  These data indicate that both Y179 and 
Y182 are important for the maintenance of Ngef in the auto-inhibited state, but in 
contrast to the situation described for Tim, only Y179 is a substrate for direct 
phosphorylation by Src. 
Relative to its unphosphorylated form, phosphorylation of Ngef (Δ166) by Src led 
to an 8-fold increase in the rate of catalyzed guanine nucleotide exchange using RhoA as 
substrate in vitro (Figure 20B).  Using Cdc42 as substrate, the equivalent enhancement 
was 3-fold (Figure 20C).  Reminiscent of the situation with Tim, Src most likely also 
forms a metastable complex with Ngef, since Src in the absence of ATP was able to 
stimulate guanine nucleotide exchange catalyzed by Ngef (Δ166) approximately 3- and 
1.5-fold for RhoA and Cdc42 substrates, respectively.  These rate enhancements required 
both Ngef and Src since the kinase alone is incapable of stimulating exchange with either 
RhoA or Cdc42 (Figure 20B and C).  Interestingly, and in contrast to Tim, Ngef is neither 
directly phosphorylated nor activated by the kinase domain of EphA4 in vitro (data not 
shown). 
Expression of activated Ngef causes defects in axon extension. 
Previous studies have shown that the unphosphorylated form of the Ngef 
ortholog, ephexin, activates RhoA, Rac1 and Cdc42; but ephexin that is phosphorylated 
at Tyr 87 activates RhoA exclusively (78).  The results that we present above suggest that 
phosphorylated Ngef activates RhoA and Rac1, both in vitro and in fibroblasts, more 
efficiently than unphosphorylated, auto-inhibited Ngef.  Since RhoA and Rac1 are known  
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Figure 20: Phosphorylation by Src directly activates Ngef. 
(A)  Src specifically phosphorylates tyrosine 179 within the auto-inhibitory helix of Ngef.  Purified forms 
of Ngef (lower panel) were incubated with recombinant Src and ATP for thirty minutes prior to SDS-
PAGE and immunoblotting was used to assess levels of phosphorylation (upper panel).  Substitution of Tyr 
179 abrogates phosphorylation.  (B)  Phosphorylation of Ngef by Src promotes the capacity of Ngef to 
catalyze nucleotide exchange on Cdc42 (left) and RhoA (right).  Δ166 Ngef was incubated with 
combinations of kinase and ATP as indicated for thirty minutes prior to addition of the mixtures to 
exchange reactions.   
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Figure 21: E280A Ngef is catalytically inactive. 
The E280A substitution renders Δ185 Ngef inactive on RhoA, Rac1 and Cdc42.  Equal amounts (5 µg) of 
purified proteins used in the exchange assays are shown at lower right following SDS-PAGE and staining 
with Coomassie brilliant blue.   
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to play opposing roles in axon extension (273), we asked if cultured neuronal progenitor 
cells over-expressing the active form of Ngef showed defects in axon extension. 
We measured the length of the presumptive axon in mouse cortical neuronal 
progenitor cells cultured for 4 days in vitro (DIV) and over-expressing either GFP alone 
(pCIG2) or GFP in conjunction with one of three forms of Ngef: auto-inhibited (Δ166), 
constitutively active (Δ166 + Y179E) or exchange inactive (Δ166 + Y179E +E280A).  
The exchange inactive mutation renders Δ185 Ngef, a version of Ngef in which the auto-
inhibitory helix is truncated, completely inactive on RhoA, Rac1 and Cdc42 in vitro, 
although the purified protein is soluble and monomeric (Figure 21).  The E280A mutation 
removes a hydrogen bonding interaction between the catalytic DH domain and switch I 
of the cognate GTPase that has been shown to be critical for GTPase binding in other 
Dbl-family proteins (245).   
Cells expressing either GFP alone or GFP in conjunction with Δ166 Ngef had 
elaborated both an axon and dendritic arbors on the fourth DIV (Figure 22). Interestingly, 
cells expressing GFP and Δ166 + Y179E Ngef displayed two phenotypes.  The majority 
of the cells expressing Δ166 + Y179E extended single axons that were slightly shorter 
than the axons extended from cells expressing Δ166 Ngef or GFP alone.  However, a 
minority of cells expressing Δ166 + Y179E did not extend an axon and displayed a 
rounded, ruffling phenotype.  These cells are differentiated neurons, based on their 
expression of a neuronal-specific tubulin isoform, βIII.  The cause of the development of 
two phenotypes for cells expressing Δ166 +Y179E Ngef is currently unknown.  During 
the developmental time frame of this experiment, the neuronal progenitor cells that 
incorporate plasmid DNA as a result of the electroporation, are a mixed population of  
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Figure 22: Over-expression of an activated form of Ngef affects axonogenesis. 
(A)  Cortical neurons (DIV 4) expressing GFP (green) and various forms of HA-Ngef were immunostained 
for βIII tubulin (blue), a neuron-specific marker, and simultaneously stained with phalloidin (red).  The 
scale bar (upper left) indicates 37 μm.  (B)  Expression of HA-Ngef constructs.  COS7 cells were 
transfected with the indicated HA-Ngef constructs and lysed.  The lysates were analyzed by SDS-PAGE 
and immunoblotting.  The symbol ns indicates a non-specific band that serves as a loading control for this 
experiment.  (C)  Quantification of cells displaying a rounded phenotype.  The total number of cells 
counted for each condition is displayed above the bar corresponding to that condition. 
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cells destined to become a part of both layer 4 and layer 5 of the adult cortex.  Perhaps 
the heterogeneity of the population of cells expressing Δ166 + Y179E Ngef can account 
for the formation of two phenotypes.  Alternatively, the two phenotypes represent 
populations of cells responding differently to an extracellular signal. 
Cells expressing the exchange inactive version of Ngef extended single axons that 
were slightly longer than the axons extended from cells expressing GFP alone, suggesting 
that this mutant form of Ngef forms a non-productive complex with upstream activators, 
such as EphA4 of wild type ephexin, which is present in these cells.  These results are 
consistent with a role for Ngef activity in inhibition of axon outgrowth. 
In order to determine if the only the Rho-specific exchange activity of Ngef 
inhibits axon outgrowth, we attempted to create a mutant of Ngef that is only able to 
activate Rac1.  An interaction between a basic residue in the loop between helices α4 and 
α5 of the DH domain and glutamate 54 of RhoA has been shown to be critical for 
recognition of RhoA (94).  Primary sequence alignment experiments indicated that Ngef 
possesses two basic residues in this loop (K399 and R401), however, mutation of both of 
these residues crippled Ngef exchange activity on RhoA, Rac1 and Cdc42 (data not 
shown).   
Since we were unable to create a mutant of Ngef that did not activate RhoA, we 
attempted to uncouple the effects of activated Ngef and activated RhoA by 
pharmacologically inhibiting a key downstream effector of RhoA, p160-Rho kinase 
(ROCK).  ROCK has been shown to be necessary and sufficient for agonist induced 
neurite retraction and cell rounding, and it can be effectively inhibited in neurons and 
neuronal cell lines with the small molecule Y-27632 (274,275).  Prior to treatment, cells 
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expressing activated Ngef that displayed the rounded phenotype were identified and 
imaged.  These cells were treated with Y-27632 (20 μM) and time-lapse imaged to 
document the elaboration of multiple neurites (Figure 23), indicating that the rounded 
cells are indeed viable and that the RhoA/ROCK signaling pathway is critical for the 
maintenance of the rounded phenotype. 
Discussion: 
For proper nervous system development, nascent neurons must migrate to their 
characteristic locations, extend axons and dendrites in the appropriate directions and form 
synapses with the appropriate partners.  Rho GTPases are an integral part of the signaling 
pathways required for each of the above processes, but their role in the guidance of the 
axonal growth cone to its appropriate partner has not been extensively characterized.  The 
axonal growth cone is a specialized structure present at the distal end of the growing 
axon, which acts as a pathfinder to sense extracellular cues.  This is accomplished by the 
production of a single lamellipodium from the leading edge of the growth cone, which is 
capped by multiple filopodia.  Filopodia play a sensory role, allowing the growth cone to 
search for attractive and repulsive extracellular cues.  Most of the filopodia, which are 
extruded in a constant, stochastic manner, are retracted through myosin-dependent 
contraction of the cortical actin network.  However, should a filopodium become fixed to 
an extracellular ligand and should transmembrane receptors in that filopodium become 
activated, the growth cone is able to use both myosin-dependent traction and the 
extension of a lamellipodium to advance its body toward that ligand (276,277).   
It is currently accepted that active Rac1 and Cdc42 positively influence axonal 
outgrowth, by inducing the formation of lamellipodia and filopodia, respectively.  Active  
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Figure 23: Treatment of Δ166 + Y179E Ngef-expressing cortical progenitors that display the rounded 
phenotype with the ROCK inhibitor, Y-27632, leads to the elaboration of multiple neurites. 
Images of three individual cortical progenitor cells before and after treatment are displayed. 
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RhoA is currently thought to mediate growth cone retraction, through activation of 
downstream effectors that lead to increased myosin-dependent contractility (273,278).   
However, recent evidence suggests that this hypothesis represents an over-simplification 
of the role of Rho GTPases in axon guidance.  For example, active RhoA has been shown 
to be critical for the formation of point contacts, the neuronal equivalent of focal 
adhesions in the fibroblast, that allow the extending growth cone to adhere to the 
extracellular matrix (279).  Rac1 has also been shown to play an important role in growth 
cone collapse (280).  Clearly, the roles of RhoA, Rac1 and Cdc42 in axon pathfinding are 
complex and context-dependent. 
One group of repulsive cues a sensory filopodium from a migrating growth cone 
might encounter, particularly at the midline of the nervous system, is the ephrins.  The six 
GPI-linked ephrin As and three transmembrane ephrin Bs are the ligands for the largest 
family of receptor tyrosine kinases, the EphAs and EphBs, respectively.  The binding of 
ephrins by the Eph receptors induces receptor clustering, auto-phosphorylation and 
activation.  Since the ephrins are themselves transmembrane proteins, signaling is bi-
directional as a result of the ephrin/Eph interaction.  After the initial adhesive interaction 
between a cell expressing an ephrin and a growth cone expressing an Eph receptor, 
downstream signaling pathways that mediate repulsive responses are activated.  The 
ephrin/Eph interaction ultimately results in weakened growth cone attachment to the 
extracellular matrix and retraction of cellular processes such as lamellipodia and 
filopodia.  These repulsive responses are achieved through activation of a 
metalloprotease, which cleaves the ephrin, severing the adhesive interaction; through 
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internalization of membrane patches containing the ephrin/Eph complex; and through the 
actions of Rho GTPases (281). 
Activation of Rho GTPases downstream of transmembrane receptors such as Ephs 
occurs through either inactivation of GAPs or activation of GEFs.  While EphB receptors 
are able to interact with Intersectin (98), Kalirin (145) and Vav2 (282), the best 
characterized interaction between an Eph receptor and a Dbl protein is that of EphA4 and 
ephexin.  Ephexin is tyrosine phosphorylated in an N-terminal motif with significant 
sequence identity to the auto-inhibitory helix described here for Tim.  Phosphorylation of 
ephexin in this motif changes the specificity of this GEF for cognate GTPases.  
Specifically, when ephexin is not tyrosine phosphorylated, it activates RhoA, Rac1 and 
Cdc42; but when ephexin is tyrosine phosphorylated; ephexin activates RhoA exclusively 
(78).  These results, based largely upon examining the cellular morphology of fibroblasts 
transiently transfected with mutants of ephexin and EphA4, are in contrast to those shown 
here.   
We have used in vitro guanine nucleotide exchange assays and cell-based GTPase 
activity assays to show mechanistically that phosphorylation or phospho-mimetic 
mutation of Ngef leads to an activation of the exchange potential for this GEF on all three 
GTPases studied: RhoA, Rac1 and Cdc42.  This discrepancy could be explained in 
several different ways.  First, phosphorylated Ngef may be differentially localized in the 
growth cone to activate Rac1 and Cdc42 in restricted microdomains.  High-resolution 
microscopy studies examining the intracellular localization of phosphorylated Ngef and 
the activated cognate GTPases need to be carried out to examine this idea.  Second, 
ephrinA binding to EphA4 could independently activate an as yet unidentified GAP for 
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Rac1 and Cdc42, such that the net result of this signaling pathway is a preferential 
activation of RhoA.  Finally, activation of Rac1 and Cdc42 by Ngef could play a role in 
growth cone collapse.  Rac1 activity has been shown to be required for growth cone 
collapse since it promotes internalization of the Eph/ephrin complex from the plasma 
membrane (282,283).  Additionally, active Rac1 and Cdc42 are critical for axon 
retraction, branching and defasiculation following growth cone collapse (284).  The role 
of Ngef in these processes has yet to be determined. 
In conclusion, we have demonstrated that Ngef is activated towards its full 
repertoire of cognate GTPases, namely RhoA, Rac1 and Cdc42, by removal, substitution 
or Src-dependent tyrosine phosphorylation of a small, conserved sequence N-terminal to 
its DH domain.  Ngef exchange activity is inhibited by a peptide derived from the auto-
inhibitory sequence of the related protein, Tim, indicating that these two proteins are 
regulated in a near identical manner.  Importantly, we have also shown that the exchange 
activity of Ngef, and its Rho-specific exchange activity in particular, functions to inhibit 
axon outgrowth in developing neurons. 
CHAPTER 4: REGULATION OF THE EXCHANGE ACTIVITY OF TIM BY 
INTRAMOLECULAR INTERACTIONS 
Introduction: 
Src homology 3 (SH3) domains are independently folding modules of 
approximately 60 amino acid residues found in many signaling molecules such as non-
receptor tyrosine kinases and Dbl-family GEFs.  These domains have largely been 
characterized as protein-protein interaction domains, and bind preferentially to proteins 
containing multiple proline residues.  Structural studies of SH3 domains have revealed 
that these domains consist of two three-stranded anti-parallel β-sheets, oriented 
perpendicular to each other.  Two variable regions, the RT- and n-Src loops, contribute 
aromatic residues, which form pockets on the surface of the SH3 domain that are capable 
of accepting a proline residue from the ligand protein, and an acidic residue, which 
typically forms a salt bridge with a basic residue in the ligand protein.  The ligand of SH3 
domains is a left-handed poly-proline type II helix, from which proline containing di-
peptides contact the binding pockets on the surface of the SH3 domain directly (285). 
In addition to their role in intermolecular protein-protein interactions, SH3 
domains also function in intramolecular, auto-inhibitory interactions in a variety of 
signaling proteins.  The SH3 domain was originally identified in the Src family kinases, 
which include Src, Lck, Hck, Blk, Fyn, Lyn, Fgr, Yes and Yrk.  These non-receptor 
tyrosine kinases are composed of an N-terminal region of 9-12 amino acid residues 
 123
important for membrane localization, a variable region, an SH3 domain, an SH2 domain, 
a kinase domain, and a short C-terminal tail.  Src family kinases are held in a basal, 
inactive state by intramolecular interactions that are interrupted downstream of signaling 
from various cell surface receptors such as the EGFR (286).   
Originally it was thought that auto-inhibition of Src family kinases was mediated 
by the SH2 domain of the Src family kinase binding to a phosphorylated tyrosine in its 
own C-terminal tail.  However, structural characterization of Src family kinases in the 
auto-inhibited state have revealed that while the SH2 domain of these proteins does 
indeed bind to the C-terminal tail, auto-inhibition is primarily achieved through the SH3 
domain binding to a poly-proline type II helix found in the poly-peptide that links the 
SH2 domain to the kinase domain.  The interaction between the SH3 domain and the 
SH2-kinase linker region locks the kinase domain in a conformation incapable of binding 
to ATP, and thus incapable of catalyzing the tyrosine phosphorylation of substrate 
molecules (286).  The binding proteins containing poly-proline regions with a higher 
affinity for the SH3 domain of Src family kinases than the internal SH2-kinase linker 
binding site relieves this auto-inhibition.  Poly-proline containing proteins are able to 
relieve Src family kinase auto-inhibition even if the SH2 domain remains bound to the C-
terminal tail.  The function of the interaction between the SH2 domain and the C-terminal 
tail, then, is largely to properly position the SH2-kinase linker region such that it is able 
to bind to the SH3 domain (287,288). 
Auto-inhibition mediated by an intramolecular interaction between an SH3 
domain and a proline-rich region has also been shown for non-receptor tyrosine kinases 
of other families.  For example, the Tec family kinases, Tec, Txk, Bmx, Itk and Btk, are 
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composed of an N-terminal PH and Tec homology (TH) domains, followed by SH3, SH2 
and kinase domains.  Tec family kinases lack the regulatory C-terminal tail found in Src 
family kinases, but do contain two poly-proline regions (289).  The first of these poly-
proline regions, located immediately N-terminal to the SH3 domain, is involved in an 
intramolecular, auto-inhibitory interaction with the SH3 domain (290).  The second poly-
proline region, located in the TH domain, mediates an intermolecular homo-dimerization 
interaction (291,292).  It is thought that formation of Tec family kinase dimers disrupts 
the intramolecular, auto-inhibitory SH3 domain interaction and enables these kinases to 
phosphorylate and activate each other in trans (293).  In addition, the non-receptor 
tyrosine kinase Abl, which contains a variable N-terminal region, an SH3 domain, an 
SH2 domain and a long C-terminal domain without a phospho-tyrosine, is regulated by 
an intramolecular interaction between its SH3 domain and a poly-proline region in the 
kinase domain.  In this case, the auto-inhibitory interaction is stabilized by the N-terminal 
region binding to the SH2 and SH3 domains in a manner similar to the SH2 domain 
binding to the C-terminal tail of Src (294,295). 
The Dbl-family of guanine nucleotide exchange factors (GEFs) are the largest 
group of proteins directly responsible for the activation of Rho GTPases.  Dbl-family 
proteins are characterized by a Dbl-homology (DH) domain, which contacts the Rho 
GTPase to catalyze nucleotide exchange, and an associated pleckstrin-homology (PH) 
domain, which fine-tunes the exchange process by a variety of mechanisms related to the 
binding of phosphoinositides.  The 69 human Dbl-family proteins are divergent in 
regions outside the DH/PH module, and contain additional domains that presumably 
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dictate unique cellular functions.  The additional domains also mediate Dbl-family 
protein auto-inhibition (5). 
Of the 69 human Dbl-family proteins, approximately one third contain an SH3 
domain in addition to the DH/PH module.  Several of these SH3 domain-containing Dbl-
family proteins also contain a proline rich region, indicating that intramolecular 
interactions between an SH3 domain and a poly-proline region may be one mechanism 
by which Dbl-family proteins are auto-inhibited.  In fact, the Rac-specific exchange 
activity of the Dbl-family protein, Kalirin, which contains an SH3 domain between its 
two DH/PH cassettes, is negatively regulated by an intramolecular interaction between 
that SH3 domain and three different poly-proline containing regions in the GEF (243).  
However, the Dbl-family proteins Asef and Intersectin-L, which contain SH3 domains N-
terminal to their DH/PH cassettes, are negatively regulated by SH3 domains directly 
binding to the DH domain in a manner independent of the poly-proline binding site of the 
SH3 domain (203,296).  Dbl-family GEFs, then, are able to be regulated by 
intramolecular interactions involving SH3 domains in both poly-proline dependent and 
independent manners.   
Recently, we have shown that the Dbl-family protein Tim is auto-inhibited by an 
N-terminal helical region that directly occludes the catalytic interface of the DH domain 
to prevent GTPase activation.  Here we show that intramolecular interactions between the 
C-terminal SH3 domain of Tim and a poly-proline region immediately N-terminal to the 
DH domain are similarly auto-inhibitory.  The exchange potential of Tim, then, is 
negatively regulated by two distinct intramolecular interactions, and each of these 
interactions must be disrupted in order to fully activate this Dbl-family protein. 
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Experimental Procedures: 
Protein Purification: 
Mutations were introduced into a pET-21a (Novagen) construct encoding full-
length length or Δ22 Tim using the Quikchange site-directed mutatgenesis kit 
(Stratagene) as per the manufacturer’s instructions.  The PCR-amplified product for Δ57 
Tim was ligated into pET-21a between NdeI and XhoI.  These mutant proteins were 
expressed and purified as described previously (269).  In brief, Tim constructs were 
expressed in the E. coli strain Rosetta(DE3) (Novagen).  Cell cultures were grown at 
37ºC in LB/ampicillin (100 μg/mL), and induced with 1 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) for 5 hours at 27ºC.  Cell pellets were resuspended in 20 
mM HEPES, pH 7, 1 mM EDTA, 2 mM DTT, 10 % glycerol (buffer A) with 20 mM 
NaCl, lysed using an Emulsiflex homogenizer (Avestin), and clarified by centrifugation 
at 40 000 g for 45 min at 4ºC.  Clarified supernatant was loaded on a Fast Flow S column 
(Pharmacia) equilibrated with buffer A and eluted with a linear gradient of 20-500 mM 
NaCl.  Tim protein was next loaded on an S-200 size exclusion column equilibrated with 
buffer A containing 300 mM NaCl.  Fractions containing monomeric Tim were pooled, 
concentrated, and stored at -80ºC.  RhoA was purified as previously described (94). 
Guanine Nucleotide Exchange Assays: 
Fluorescence spectroscopic analysis of N-methylanthraniloyl (mant)-GTP 
incorporation into RhoA was carried out as described (246).  In brief, assay mixtures 
containing 20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT and 100 μM 
mant-GTP (Molecular Probes) and 2 μM RhoA were allowed to equilibrate with 
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continuous stirring.  After equilibration, 50 nM Tim was added and nucleotide loading 
was monitored as the decrease in the tryptophan fluorescence (λex = 295 nm, λem = 335 
nm) of RhoA as a function of time using a Perkin-Elmer LS 55 spectrophotometer.  Rates 
of guanine nucleotide exchange were determined by fitting the data to a single 
exponential decay model with GraphPad Prizm.  Data were normalized to yield percent 
GDP released and assays were performed in duplicate. 
Cell Culture and Transformation Assays: 
NIH 3T3 mouse fibroblasts were maintained in DMEM supplemented with 
penicillin/streptomycin and 10% calf serum (Hyclone).  HEK 293T cells were maintained 
in DMEM supplemented with penicillin/streptomycin and 10% fetal bovine serum 
(Sigma).  PCR-amplified Tim constructs were ligated into pcDNA 3.1 Hygro (Invitrogen) 
between EcoRI and XhoI such that an expressed HA-tag was encoded at the N-terminus 
of each construct.  Mutations were introduced into wild type Tim as described above. 
Cell lines stably expressing Tim were established by transfecting NIH 3T3 cells 
with 1 μg of each pcDNA construct using LipofectAMINE Plus (Invitrogen) according to 
the manufacturer’s protocol.  Three days post-transfection the cells were subcultured into 
growth medium supplemented with 300 μg/mL of hygromycin B.  Mass populations of 
multiple, drug resistant colonies (>50) were pooled together for focus formation analyses.  
Western blot analysis with an anti-HA antibody (Covance) was performed to verify Tim 
expression in the cell lines.  
For the secondary focus formation assays, equal numbers of cells from each cell 
line were seeded into 60 mm dishes.  The growth medium of each dish was replaced with 
fresh hygromycin-supplemented medium every three days.  14 days after seeding, the 
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dishes were stained with crystal violet and the foci were quantified by visual inspection.  
Individual experiments were performed in duplicate and independently carried out three 
times. 
HEK 293T cells were transiently transfected with 1 μg of each pcDNA construct 
using LipofectAMINE Plus (Invitrogen) according to the manufacturer’s protocol.  The 
cells were lysed 18 hours post-transfection in 50 mM Tris, pH 7.6, 500 mM NaCl, 0.1 % 
SDS, 0.5 % sodium deoxycholate, 1 % Triton-X 100, 0.5 mM MgCl2 and protease 
inhibitors (Roche) prior to being used in the affinity purification assays described below. 
Affinity Purification Assays: 
GST and a GST-tagged version of the Tim SH3 domain (residues 434-519) were 
expressed in BL21 (DE3) E. coli and batch purified on glutathione sepharose beads 
(Amersham).  100 μg of immobilized protein was incubated with either 100 μg of 
purified Δ22 or Δ57 Tim or 1 mg of HEK 293T whole cell lysate for 1 hour at 4 ºC.  The 
beads were washed extensively in lysis buffer and analyzed by either SDS-PAGE or 
SDS-PAGE in combination with immunoblotting. 
Analytical Gel Filtration Chromatography and Ultracentrifugation: 
1 mg of purified full-length Tim was loaded onto a calibrated Superdex S-75 
column (Amersham) in buffer A containing 300 mM NaCl, and eluted at a flow rate of 
0.5 mL/min.  In addition, purified full-length Tim in the above buffer at several different 
concentrations (OD280 of 1.0. 0.8 and 0.6 at 1 cm pathlength) was analyzed by analytical 
ultracentrifugation (297) in a Beckman Optima XL-I ultracentrifuge equipped with a 
Ti60 rotor and a 6-sector cell (1.2 cm pathlength).  The samples were centrifuged at 
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11,000 rpm for 26 hours at 20 ºC.  The offset was determined by meniscus depletion, 
which was achieved by centrifugation at 45,000 rpm for 6 hours at 20 ºC.  The data were 
fit to a one-state model using the XL-A/XL-I Data Analysis Software package version 4.0 
(Beckman). 
Surface Plasmon Resonance (SPR) experiments: 
N-terminally biotinylated peptides corresponding to the poly-proline region of 
Tim (residues 39-54), a proline-rich region of Ngef (residues 223-233) and mNotch (298) 
were diluted to 0.1 μg/mL in BIA running buffer (10 mM Hepes, 150 mM NaCl, 10 mM 
MgCl2 and 0.005% NP-40).  These peptides were coupled to separate flow cells of a 
streptavadin-coated biosensor chip to a surface density of 1000 response units using the 
MANUAL INJECT command on a BIAcore 3000 (Biacore).  The resulting chip was used 
in surface plasmon resonance experiments as previously described (299).  In brief, 30 μL 
of Tim SH3, diluted to various concentrations in BIA running buffer, were 
simultaneously injected over all flow cells using the KINJECT command at a flow rate of 
10 μL/min, followed by 300 s of dissociation.  The surfaces were regenerated between 
titrations using a 10 μL pulse of 500 mM NaCl and 25 mM NaOH at a flow rate of 20 
μL/min.  Thermodynamic constants were calculated by normalizing the resulting 
sensorgrams using the BIAevaluation software package (Biacore), and plotting the 
response units at binding equilibrium versus the Tim SH3 concentration for that 
sensorgram using GraphPad Prizm (GraphPad) and these constants represent the results 
of two independent experiments. 
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Confocal Microscopy: 
NIH 3T3 cells transiently transfected with pcDNA-Tim constructs were plated 
onto glass coverslips and serum starved for 48 hours prior to being fixed in 3.8% 
paraformaldehyde and stained with anti-HA (Covance) and Alexa-488 conjugated anti-
mouse antibodies as well as Alexa-546 conjugated phalloidin.  Images were taken on a 
LEICA TCS-SL laser scanning confocal microscope. 
Results: 
Tim is auto-inhibited by a proline-containing region in its N-terminus. 
The N terminus of Tim consists of an extended region of low complexity and no 
known domain structure.  Truncation of the N-terminal 22 amino acids of Tim leads to a 
robust increase in its exchange activity in vitro (269).  To determine if additional regions 
of the Tim N terminus play a role in its regulation, we tested the exchange activity of Tim 
mutants in which the N-terminus had been further truncated.  A shorter version of Tim 
(Δ57, see Figure 24A) was able to catalyze exchange of guanine nucleotide bound to 
RhoA 45% more efficiently than the previously characterized Δ22 Tim.  Further N-
terminal truncations destabilized Tim upon over-expression in E.coli (data not shown), 
most likely reflecting the loss of important secondary structural elements necessary for 
the integrity of the extended DH domain, which begins at residue 70 in full-length Tim. 
Primary sequence analysis indicated that the region of Tim between residues 23 
and 57 contains a Type 1A poly-proline containing SH3 domain binding ligand.  To test 
if the integrity of this region was important for maintenance of Tim auto-inhibition, we 
mutated a key proline residue to alanine in the context of both full-length and Δ22 Tim 
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(P49A, Figure 24A, upper and lower panel).  Δ22 + P49A Tim, similar to Δ57 Tim, was 
approximately 45% more efficient at catalyzing nucleotide exchange than Δ22 Tim.  
Importantly, P49A Tim was itself 3-fold more efficient at catalyzing nucleotide 
exchange.  These data indicate that the poly-proline region of Tim, proline 49 in 
particular, is involved in the regulation of Tim by auto-inhibition. 
We have previously shown that stable expression of active forms of Tim promotes 
the transformation of NIH 3T3 cells (269).  Here, we show that expression of Δ22 and 
Δ57 Tim robustly induces the formation of foci relative to background levels (vector and 
wt, Figure 24B).  While Δ57 Tim expression does induce the formation of more foci then 
Δ22 expression, this difference is not statistically significant. 
The SH3 domain of Tim is involved in intramolecular auto-inhibitory interactions. 
Tim is a member of a subfamily of Dbl-family members that contain an SH3 
domain C-terminal to the DH and PH domains, which also includes Ngef, Sgef, Vsm-
RhoGEF, neuroblastoma and Wgef (269).  Because the poly-proline region in the N-
terminus was determined to be required for Tim auto-inhibition, we wanted to test the 
hypothesis that the C-terminal SH3 domain and the N-terminal poly-proline region are 
involved in an intramolecular SH3 domain/ligand interaction. 
First, we used affinity purification assays to test if the isolated SH3 domain of 
Tim was able to bind to portions of Tim.  The SH3 domain of Tim was able to interact 
with purified, recombinant Δ22 Tim, while GST alone was unable to interact with Δ22 
Tim in this assay.  Unexpectedly, Δ57 Tim, in which the poly-proline region has been 
truncated, was also affinity purified by the isolated SH3 domain of Tim, albeit to a lesser  
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Figure 24: An intramolecular interaction between the SH3 domain of Tim and its N-terminal poly-
proline region negatively regulates the exchange potential of Tim. 
(A)  Upper panel: The region of Tim between the auto-inhibitory motif and the DH domain contains a 
stretch of proline residues that conform to the consensus sequence of a Type 1A SH3 domain binding 
ligand.  Truncation of these residues (Δ57) or mutation of proline 49 to alanine in the context of a version 
of Tim lacking the auto-inhibitory helix (Δ22) is slightly activating with respect to Δ22 Tim.  The proteins 
used in the exchange assay are shown at right.  Lower panel: Mutation of proline 49 to alanine in the 
context of full length Tim is also activating.  Again, the proteins used in the exchange assay are shown at 
right.  (B)  N-terminally truncated forms of Tim potentiate transformation of NIH 3T3 cells.  Data represent 
the averages of three independent experiments carried out in duplicate.  Right panel verifies approximately 
equal expression of Tim variants used in the focus formation assays. 
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extent than Δ22 Tim (Figure 25A).  These data suggest that the SH3 domain of Tim is 
able to bind to portions of Tim in both a poly-proline region dependent and independent 
manner. 
To confirm that the isolated SH3 domain interacts with Tim, we performed 
affinity purification assays from HEK 293 T cell lysates.  GST-tagged SH3 Tim, but not 
GST itself, was able to affinity purify full-length Tim (Figure 25B).  Importantly, pre-
incubation of the GST-SH3 matrix with a peptide comprising the Tim poly-proline region 
did not abrogate the interaction between Tim and the SH3 domain, confirming that there 
are additional binding determinants for the SH3 domain in Tim besides the poly-proline 
region. 
In order to show that the SH3 domain of Tim is able to bind to the N-terminal 
poly-proline region, we performed surface plasmon resonance experiments (Figure 25C).  
The purified SH3 domain of Tim was able to interact with a surface composed of the Tim 
poly-proline region, but not a surface composed of the poly-proline region of its paralog, 
Ngef, or an unrelated peptide.  The interaction between the SH3 domain and the poly-
proline region was determined to be of modest affinity (35 μM), although this is a 
biologically relevant affinity for an intramolecular interaction in which the relative 
concentrations of the SH3 domain and its ligand would be very high.  In addition, GST 
alone was unable to interact with the surface composed of the Tim poly-proline region at 
a concentration of 100 μM (data not shown). 
To assess whether or not the interactions between the SH3 domain and various 
other regions of Tim were intramolecular, we attempted to determine if purified Tim is 
oligomeric in solution.  First, we performed sedimentation equilibrium experiments on  
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Figure 25: The SH3 domain of Tim interacts with the N-terminal poly-proline region. 
(A)  GST and a GST-tagged construct containing the SH3 domain of Tim (residues 434 - 519) was 
immobilized on glutathione-sepharose beads.  Purified Tim proteins were incubated with either GST or 
GST-SH3 beads for a period of 1 hour.  The beads were extensively washed and loaded onto an SDS-
PAGE gel (right lower panel).  Both Δ22 and to a lesser extent Δ57 Tim were affinity purified by GST-SH3 
beads, and not GST beads (right upper panel).  (B)  GST-SH3 beads were used to affinity purify full length 
Tim from lysates of transiently transfected HEK 293T cells.  Addition of 0.5 mM of the peptide used in 
panel C does not abrogate binding of the GST-SH3 to full length Tim, indicating that there are additional 
binding determinants for the SH3 domain besides the poly-proline region.  (C)  The isolated SH3 domain 
of Tim interacts with an isolated poly-proline containing peptide. Biotinylated peptides corresponding to 
the poly-proline region of Tim (residues 39 - 54), the poly-proline region of Ngef (residues 223-233), and a 
non-proline containing portion of an unrelated protein (mNotch) were synthesized commercially and 
immobilized to a streptavadin coated sensor chip.  Various concentrations of GST-SH3 were flowed over 
this surface using a BIAcore 3000.  The resulting binding isotherms were normalized to the signal achieved 
due to binding to the unrelated peptide.  The apparent kD for this interaction is 35 μM. 
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purified, recombinant, full-length Tim by analytical ultracentrifugation (Figure 26A).  
The molecular mass of Tim determined by this experiment (59.8 kDa) is smaller than the 
calculated molecular mass of Tim (60.0 kDa), indicating that Tim is 100% monomeric in 
solution.  To complement this result, we performed an analytical gel filtration 
chromatography experiment.  Tim eluted as a single peak from this column at a volume 
corresponding to 60 kDa.  In sum, these data indicate that the SH3 domain of Tim is 
involved in multiple auto-inhibitory intramolecular interactions. 
We were unable to assess the consequences of removal of the SH3 domain on the 
in vitro exchange activity of Tim, since both truncation of the SH3 domain and mutation 
of a conserved tryptophan (W470R) known to be critical for poly-proline ligand binding 
destabilized Tim upon over-expression in E. coli.  However, expression of Δ22+W470R 
Tim in NIH 3T3 cells did not induce formation of foci relative to background levels, 
despite the fact that Δ22 Tim did induce foci formation in the same experiment (Figure 
27A).  Indirect immunofluorescence experiments reveal that while Δ22 Tim co-localizes 
with the actin cytoskeleton in NIH 3T3 cells, Δ22+W470R Tim does not (Figure 27B).  
These data indicate that the SH3 domain of Tim may play a role in regulation of Tim 
localization in intact cells in addition to its maintenance of Tim auto-inhibition.   
Discussion: 
A model for the regulation of Tim by intramolecular and intermolecular 
interactions is depicted in Figure 28.  In the basal state the exchange potential of Tim is 
auto-inhibited by two sets of intramolecular interactions: the auto-inhibitory helix 
packing into a conserved pocket on the DH domain and the SH3 domain binding to the 
N-terminal poly-proline region.  This second interaction serves to both stabilize the auto- 
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Figure 26: Tim is monomeric in solution. 
(A)  Residuals (upper panel) and raw data (lower panel) for a sedimentation equilibrium data generated by 
analytical ultracentrifugation fit to a one-state model.  The molecular weight for Tim determined 
empirically by this experiment is 59.8 kDa.  (B)  Purified Tim elutes from an analytical gel filtration 
column as a single peak at a volume corresponding to a molecular weight of 60 kDa. 
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inhibitory helix on the DH domain and to partially occlude the DH domain.  Binding of 
another protein to the SH3 domain, with a higher affinity than that of the SH3 domain for 
the poly-proline region of Tim, could serve to remove the SH3 domain from that poly-
proline region (center).  This binding interaction could also localize Tim to the 
appropriate sub-cellular compartment for nucleotide exchange.  Interactions between 
another unidentified protein and the poly-proline region of Tim could also serve to 
modulate Tim exchange activity and localization.   
With interactions between the SH3 domain and the poly-proline region disrupted, 
the auto-inhibitory helix would be unstable in the DH domain pocket, increasing 
frequency of time that the auto-inhibitory helix is solvent-exposed.  Src could then 
phosphorylate the tyrosine residues in the auto-inhibitory helix as previously described 
(269), both preventing a rebinding event and fully activating the exchange potential of 
this Dbl-family GEF (Figure 28, right panel).  Further work is necessary to identify 
potential intermolecular binding partners for the Tim SH3 domain and poly-proline 
region, as well as to determine the molecular details of the intramolecular interaction 
between the SH3 domain and regions of Tim. 
Phenotypic diversity and complexity in biological systems arises from new 
combinations of proteins and independently-folding protein domains working together as 
a network, not from new protein functions (300).  In fact, multiple sequence analysis of 
Dbl-family proteins from diverse animal species revealed that GEFs that are composed of 
an N-terminal SH3 domain followed by a DH/PH cassette, such as Asef1, and GEFs that 
are composed of a DH/PH cassette followed by an SH3 domain, such as Tim, evolved 
from a common ancestor composed of only a DH/PH cassette through independent  
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Figure 27: Tim compromised in poly-proline binding is inactive in transformation assays and 
mislocalized in cells. 
(A)  Mutation of Tim in the ligand binding pocket of the SH3 domain (W470R) abrogates transformation 
by Δ22 Tim.  Data represent the averages of three independent experiments carried out in duplicate.  Right 
panel verifies approximately equal expression of Tim variants used in the focus formation assays.  (B)  
Indirect immunofluorescence experiments on transfected NIH 3T3 cells reveal that Δ22 Tim colocalizes 
with the actin cytoskeleton, but Δ22 + W470R Tim is cystosolic. 
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Figure 28: A model for the regulation of Tim by intramolecular and intermolecular interactions. 
In the basal state (left), the exchange potential of Tim is auto-inhibited by two sets of intramolecular 
interactions.  First, the auto-inhibitory helix (red) packs against a conserved pocket on the DH domain.  
Second, the SH3 domain binds to the N-terminal poly-proline region.  This second interaction serves to 
both stabilize the auto-inhibitory helix on the DH domain and to partially occlude the DH domain.  Binding 
of protein X (purple) to the SH3 domain, with a higher affinity than that of the SH3 domain for the poly-
proline region of Tim, could serve to remove the SH3 domain from that poly-proline region (center).  The 
auto-inhibitory helix would then be unstable in the DH domain pocket, increasing frequency of time that 
the auto-inhibitory helix is solvent-exposed.  The auto-inhibitory helix would then be able to be 
phosphorylated by Src, preventing a rebinding event, and fully activating the exchange potential of this 
Dbl-family GEF (right). 
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insertion of the SH3 domain (301).  Since the SH3 domains of both Tim and Asef1 
function to regulate the exchange potential of these GEFs by auto-inhibition, it is likely 
that the evolutionary pressure for the insertion of the SH3 domain was to achieve finer 
control of the exchange activity of these Dbl-family proteins. 
The stabilization of the auto-inhibitory motif on the DH domain of Tim by SH3 
domain/poly-proline region interaction, like the auto-inhibitory helix itself, is reminiscent 
of the mechanism of auto-inhibition of the Vav isozymes.  Recent structural 
characterization of full-length Vav3 by electron microscopy showed that the CH domain 
of this protein stabilizes the acidic region, including the auto-inhibitory helix, through an 
intramolecular interaction with the zinc finger domain (157).  For both Tim and Vav, 
then, multiple domains are functioning together to stabilize the inactive state of the 
catalytic DH domain.  While the first interaction, the auto-inhibitory helix, is conserved 
between Tim and Vav (269), the second interaction is divergent in primary and tertiary 
structure.  If auto-inhibition by interaction of the auto-inhibitory helix with the DH 
domain is a conserved mechanism of regulation among Dbl-family GEFs, perhaps the 
second, stabilizing interactions are the mechanism by which specificity of activation is 
achieved.  In fact, these two sets of auto-inhibitory interactions could enable Tim, and 
Vav, to approximate a logical AND gate (302).  In this way, full activation of Tim would 
not occur unless both sets of auto-inhibitory interactions were removed, thus allowing a 
large degree of spatiotemporal control of Tim activation.   
 
CHAPTER 5: GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
The studies described here identify a conserved mechanism for the basal auto-
inhibition and phosphorylation-dependent activation of the exchange potential of Tim and 
Ngef.  In particular, these Dbl proteins are auto-inhibited by a short N-terminal helix that 
directly interacts with a conserved surface of the DH domain to prevent the binding of 
GTPases necessary for guanine nucleotide exchange and GTPase activation.  
Phosphorylation of the auto-inhibitory helix disrupts interactions with the DH domain 
and frees the conserved surface of the DH domain for subsequent GTPase activation.  
This model of regulation has been borne out by several experimental lines of evidence.  
For example, using an in vitro guanine nucleotide exchange assay, cell-based GTPase 
activity assays, and assays for cellular transformation, we determined that auto-inhibition 
of Tim is relieved by truncation, mutation, and Src- or EphA4-mediated phosphorylation 
of the N-terminal helical motif.  Similar results are seen with the Tim homolog, Ngef.  
Finally, we show that Tim is constitutively activated by substitutions within their DH 
domains designed to disrupt interactions with the N-terminal auto-inhibitory helix while 
preserving intrinsic exchange activity.  Lines of experimentation that are designed to 
more fully characterize the function and regulation of Tim and Ngef are described in the 
following sections. 
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Extend the concept of auto-inhibition mediated by a small, conserved sequence 
motif to other Dbl-family GEFs. 
Several observations presented here suggest that other Dbl-family proteins may be 
regulated similarly to Tim.  First, one mechanism by which the distantly-related Vav 
isozymes are regulated is through phosphorylation of an auto-inhibitory helix 
homologous to that of Tim.  Second, while many of the conserved surface sites on DH 
domains overlap with sites known to contact GTPases in nucleotide-depleted complexes, 
several of the most conserved positions overlap instead to points of contact between the 
DH domain of Vav1 and its inhibitory helix as determined by NMR.  Indeed, the deep 
cavity used by Vav1 to sequester Tyr 174 of its auto-inhibitory helix is preserved in all of 
the other DH domain structures that have been solved to date (Figure 15A).  It seems 
extremely likely that other Dbl-family proteins also use this cavity to sequester large 
aromatic or hydrophobic residues that are part of similar auto-inhibitory motifs.  Finally, 
the guanine nucleotide exchange activities of a majority of Dbl-family proteins are 
increased upon N-terminal truncation (see Table 1).  Indeed, truncated forms of many 
Dbl-family proteins have been isolated as oncogenes capable of constitutively activating 
Rho-family GTPases, leading to cellular transformation (10).  It is likely that these 
truncation events involve the removal of short inhibitory sequences that would normally 
pack against the DH domain to prevent GTPase binding and activation.   
Identifying other Dbl family members that are regulated by auto-inhibition and 
phosphorylation in a manner similar to Tim, Ngef and the Vav isozymes is an important 
line of future research.  We would like to begin by confirming that other members of the 
Tim subfamily are regulated in this manner.  We have extended our analysis to include 
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Wgef.  Truncation of the auto-inhibitory helix of Wgef (Δ302) is activating in vitro and in 
affinity purification assays using nucleotide-free RhoA as the affinity matrix.  In addition, 
Wgef behaved similarly to Tim in that mutation of its auto-inhibitory helix (Y295E, 
analogous to Y19E in Tim) and its DH domain (S394A; analogous to S114A in Tim) 
activated a truncated form of Wgef (Δ285) containing the auto-inhibitory region (Figure 
29A).  Wgef, like Tim and Ngef, is inhibited by a peptide derived from the auto-
inhibitory helix of Tim (Figure 29C) and is activated by Src phosphorylation in vitro 
(Figure 29D). 
In order to establish that all of the members of the Tim subfamily are regulated by 
auto-inhibition, the regulation of the remaining members of that subfamily, Sgef, Vsm-
RhoGEF and neuroblastoma, must be studied.  Of these three remaining Tim subfamily 
members, we have attempted to study only Vsm-RhoGEF and Sgef thus far.  We have 
been unsuccessful at generating soluble Vsm-RhoGEF after expression in E. coli.  While 
we are able to express and purify Sgef, we are unable to detect Sgef activity in our in 
vitro exchange assay.  The regulation of these exchange factors will have to be studied in 
cellular assays, such as affinity purifications using nucleotide free forms of their cognate 
GTPases (RhoA for Vsm-RhoGEF and RhoG for Sgef). 
Ultimately, in order to establish the generality that auto-inhibition as well as 
catalytic nucleotide exchange activity is embedded within the most conserved surface of 
DH domains, we must identify a Dbl-family protein outside of the Tim and Vav 
subfamilies that is regulated in this manner.  We decided to target several Dbl-family 
proteins for scrutiny, namely: Tiam1, GEF-H1 and FRG.  These proteins fulfill several 
criteria required of this hypothesis.  Tiam1 (149) and FRG (46,47) are excellent  
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Figure 29: Wgef is regulated by auto-inhibition and phosphorylation.  
(A)  The exchange of GDP bound to RhoA and catalyzed by 50 nM Wgef was measured using a standard 
fluorescence-based assay (245,246).  Fold-activation is relative to the spontaneous loading of guanine 
nucleotide and represents the average of two independent reactions for each trace.  Equal amounts (2 µg) of 
purified proteins used in the exchange assays are shown at right following SDS-PAGE and staining with 
Coomassie brilliant blue.  (B)  The activity of Wgef constructs transiently expressed in quiescent COS7 
cells was assessed by a pulldown assay using GST-tagged nucleotide-free RhoA as the affinity purification 
matrix.  Levels of active Wgef were determined by immunoblotting the pulldown samples.  Immunoblots 
of the total cell lysate (2.5% input shown) show approximately equal expression of the Wgef constructs.  
(C)  Wgef (Δ302) was incubated with either a peptide corresponding to the N-terminal auto-inhibitory 
region of Tim (WT, biotin-SQLLYQEYSDV-amide) or a mutant peptide (MT, biotin-SQLLEQEYSDV-
amide) at room temperature for 20 minutes.  The resulting complexes were assayed for their ability to 
stimulate loading of mant-GTP onto RhoA.  The peptide concentrations were 100 μM, Wgef concentrations 
were 50 nM.  (D)  Phosphorylation of Wgef by Src (left) or EphA4 (right) promotes the capacity of Wgef 
to catalyze nucleotide exchange on RhoA.  Auto-inhibited Wgef (Δ285) was incubated with combinations 
of kinase and ATP as indicated for thirty minutes prior to addition of the mixtures to exchange reactions.   
 145
substrates for Src-family kinases and in both cases phosphorylation is associated with 
increased levels of activated GTPases.  The case for the physiological relevance of Src-
mediated phosphorylation is especially compelling for FRG since cell-cell adhesions 
initiated by homotypic clustering of nectins recruits and activates Src, which 
subsequently is required for the recruitment and phosphorylation of FRG.  
Phosphorylated FRG is then responsible for enhanced levels of GTP-bound Cdc42.  The 
case for Tiam1 phosphorylation by Src is less clear, although stimulation of cells with 
BNDF leads to an association of Tiam1 with the receptor for BNDF, TrkB.  TrkB directly 
phosphorylates Tiam1 at a tyrosine residue in the RBD, Y829, and this phosphorylation 
leads to an increase in Tiam1 exchange activity (150).  GEF-H1 is also phosphorylated in 
vivo, although it is not known if phosphorylation correlates with active GTPase levels 
(85).  The functional relationship between phosphorylation and GTPase activation is not 
understood for any of these Dbl-family GEFs.   
We have identified sequence motifs in all three proteins with high conservation to 
the regions in Vav and Tim required for regulated auto-inhibition (Figure 30A).  
Consistent with a general mode of inhibition typified by Vav and supported by our 
preliminary data with Tim, the short spans in Tiam1, GEF-H1 and FRG are: a) located N-
terminal to their respective DH domains, b) all predicted to be helical with high 
confidence, and c) predicted to be excellent substrates for tyrosine phosphorylation.  For 
Tiam1 (165) and GEF-H1 (131), N-terminal truncations that remove these putative auto-
inhibitory regions result in transforming phenotypes.  Tiam1 also has been shown to be 
phosphorylated within this motif (150).   
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Figure 30: Tiam1 is regulated by auto-inhibition. 
(A)  Regions in Vav1 and Tim responsible for auto-inhibition of exchange activity were aligned with 
ClustalX along with similar regions in Tiam1, FRG, and GEF-H1.  The asterisk above the alignment marks 
the tyrosines in Vav1 and Tim that when phosphorylated relieve inhibition and these positions are 
numbered to the right of the alignment.  Analogous tyrosines in the other GEFs are also numbered.  (B)  
Mutation of the Tiam1 DH domain (T1054A) is activating within a large fragment (PH-PH) of Tiam1; but 
has no effect on the DH-PH fragment.  The domain architecture of Tiam1 is presented below. Panel to the 
right indicates equal amounts (2 μg) of the assayed proteins submitted to SDS-PAGE followed by staining 
with Coomassie brilliant blue.  Also depicted is a schematic of the domain architecture of Tiam1. 
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Unfortunately, we have been unable to purify active forms of GEF-H1 and FRG 
to test the hypothesis that these Dbl-family proteins are regulated by the motifs identified 
in Figure 30A.  However, we have been able to establish that a long form of purified 
Tiam1 (PH-PH; similar to the well-studied version C1199) that includes all its known 
domains is auto-inhibited relative to the minimal DH-PH fragment necessary for guanine 
nucleotide exchange (Figure 30B).  We have been unable to show that introduction of a 
phosphomimetic mutation in the potential auto-inhibitory motif affects the exchange 
activity of Tiam1 (Y829E, data not shown).  However, introduction of T1054A, 
analogous to S114A in Tim, was partially activating in the auto-inhibited form of Tiam1, 
while having no effect on the exchange activity of the shorter fragment (Figure 30B).  
These analyses indicated that Tiam1 is also auto-inhibited and that this auto-inhibition 
can be partially relieved by mutation of the DH domain without affecting the intrinsic 
exchange mechanism.   
The cumulative data strongly suggest that the most conserved surface of DH 
domains serves two separable, but functionally linked purposes.  Most obviously, this 
conserved surface is designed to engage Rho GTPases to catalyze nucleotide exchange 
and consequent GTPase activation.  Second, and less obviously, this conservation appears 
built into DH domains in order to provide for auto-inhibition of guanine nucleotide 
exchange.  It remains to be determined how extensively these dual functions are linked, 
but the preliminary data presented here suggests that this linkage may be wide-spread 
throughout the family of Dbl proteins and will be useful in understanding the various 
processes, such as truncations and phosphorylations, that are known to activate many of 
the Dbl-family proteins.   
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Define the molecular details of the auto-inhibited form of Tim or a closely related 
Dbl-family member using protein crystallography. 
We have used site-directed mutagenesis coupled with in vitro and cellular 
functional assays to define the auto-inhibitory helix of Tim, as well as a region of the DH 
domain important for binding the auto-inhibitory helix to maintain a basal level of Tim 
activity.  However, the precise composition of the DH domain pocket that accepts the 
auto-inhibitory helix and the nature of the auto-inhibitory interactions involving the Tim 
SH3 domain will not be elucidated without determining the atomic-resolution crystal 
structure of the auto-inhibited form of Tim or one of its closely-related homologs.  
Unfortunately, Tim and its homologs have been recalcitrant to crystallize in initial 
screens.  Future crystallization experiments include attempting to improve crystallization 
by removing the loop region between the poly-proline region and the extended DH 
domain in these proteins.  This region has no identifiable secondary structure and is not 
part of a known consensus regulatory motif or phosphorylation site, and therefore 
deletion of this region is not expected to activate the exchange potential of these Dbl-
family proteins.  Additionally, we will attempt to improve crystallization by decreasing 
the conformational heterogeneity of surface residues by site-directed mutagenesis (303). 
Once preliminary diffraction experiments indicate that crystals are tractable, cryo-
cooling conditions will be found for collection of a complete data set from a single 
crystal.  Initial attempts to obtain phases associated with the diffraction data will involve 
molecular replacement using either the programs AMoRe (304) or Beast (305).  Search 
models for molecular replacement will include isolated DH and PH domains derived 
from structures previously determined in this lab (94,225,245) or others (306-308), as 
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well as the SH3 domain of Vav1(309).  If necessary, fragments encompassing both DH 
and PH domains will be used; however, these search models will not be favored given the 
unusually high degree of conformational flexibility originating from the hinge region 
between DH and PH domains (310).   
Should molecular replacement fail, phase information will be generated using 
conventional techniques including heavy atom derivatization of native crystals or 
production of seleno-methionine incorporated proteins to be used for MAD data 
collection (311).  Given the fact that all forms of Tim and its closely related members 
proposed for study in this application are currently being expressed and purified from 
bacteria, structure determination by MAD using seleno-methionine-incorporated proteins 
will be the favored route.  Model building and refinement will use the interactive 
molecular graphics program O (312) and the X-PLOR suite of crystallographic programs.  
Geometry and stereochemistry of the final model will be confirmed with PROCHECK 
(313).   
Establish the physiological relevance of Tim phosphorylation by Src. 
We have shown that Tim is directly phosphorylated by Src in vitro, as well as 
when co-expressed with a constitutively active mutant of Src in SYF cells.  However, 
whether endogenously expressed Tim is phosphorylated upon activation of endogenous 
tyrosine kinases has yet to be determined.  To attempt to answer this question, we created 
and characterized a polyclonal antibody directed at full-length Tim.  This antibody is 
capable of detecting over-expressed Tim protein in immunoblot, immunoprecipitation 
and indirect immunofluorescence experiments (Figure 31).  In addition, the anti-Tim  
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Figure 31: Characterization of a polyclonal antibody specific for Tim. 
(A)  A polyclonal antibody was generated using full-length Tim as the immunogen.  This antibody was 
capable of detecting HA-tagged Tim, but not the highly related Ngef, in 1 μg of COS7 cell lysate.  (B)  1 
μL of anti-Tim antibody was able to immunoprecipitate HA-Tim from 100 μg of COS7 cell lysate, but not 
HA-Ngef.  (C)  HA-tagged Tim was over-expressed in COS-7 cells and visualized by indirect 
immunofluorescence experiments.  The signal derived from the anti-HA primary antibody and Alexa 488-
conjugated anti-mouse secondary antibody overlapped completely with the signal derived from the anti-
Tim primary antibody and Alexa-546 conjugated anti-rabbit secondary antibody. 
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antibody was able to detect endogenously expressed Tim in HEK 293T cell lysates (data 
not shown). 
To establish if endogenously expressed Tim is phosphorylated in the context of an 
intact cell, we treated HEK 293T cells with 10 μM pervanadate for various time points, 
prior to lysing the cells.  We then immunoprecipitated Tim with the anti-Tim antibody 
and analyzed the immunoprecipitates by SDS-PAGE followed by immunoblotting with 
an anti-phosphotyrosine antibody.  As few as ten minutes of treatment with pervanadate, 
which inhibits cellular tyrosine phosphatases (314), led to an increase in the amount of 
tyrosine phosphorylation of Tim (Figure 32).  Tyrosine phosphorylation of Tim appeared 
to be Src-dependent, since treatment of the HEK 293T cells with PP2, a Src inhibitor, 
prior to the pervanadate treatment abrogated Tim tyrosine phosphorylation (Figure 32). 
Although the experiments described above establish that endogenously expressed 
Tim is tyrosine phosphorylated in a Src-dependent manner, they do not establish the 
upstream signaling pathways that lead to Tim phosphorylation.  Interestingly, fetal 
bovine serum does not contain any growth factor components that lead to Tim 
phosphorylation (data not shown).  The Tim homologs, ephexin and Vsm-RhoGEF, 
interact with and are tyrosine phosphorylated downstream of the EphA4 receptor tyrosine 
kinase (77,80), and we have previously shown that Tim is directly phosphorylated by the 
kinase domain of EphA4 in vitro.  Therefore, we anticipate that Tim phosphorylation is 
stimulated by an ephrin ligand binding to EphA4.  This hypothesis will be tested by 
transfecting HEK 293 cells with an HA-tagged version of EphA4, treating these cells 
with an ephrinA3-Fc fusion protein that has been pre-clustered by incubation with an ant-
Fc antibody, and performing immunoprecipitation and immunoblotting experiments as  
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Figure 32: Phosphorylation of endogenous Tim upon activation of endogenous tyrosine kinases. 
(A)  HEK 293 T cells, which express Tim endogenously, were treated with pervanadate for various time 
periods, prior to lysis and immunoprecipitation of Tim.  Immunoprecipitates were analyzed by Western 
blot using anti-phosphotyrosine and anti-Tim antibodies.  (B)  HEK 293 T cells were treated with various 
concentrations of the Src inhibitor, PP2, for two hours prior to treatment with pervanadate for 30 minutes.  
Tim was immunoprecipitated from the resulting cell lysates and the immunoprecipitates were analyzed as 
above. 
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were described above for pervanadate treatment.  Additionally, we will identify a cell line 
that expresses Tim, EphA4 and Src endogenously, treat these cells with pre-clustered 
ephrinA3-Fc and perform similar experiments.  Current candidate cell lines include the 
CaCo2 and MIA Paca2 cell lines, both of which are predicted to express all three proteins 
of interest. 
Identify mechanisms for down-regulating Tim activity. 
We have identified several mechanisms by which Tim exchange activity can be 
up-regulated, namely truncation or mutation of the auto-inhibitory helix, Src 
phosphorylation of the auto-inhibitory helix and mutation of the surface of the DH 
domain involved in binding to the auto-inhibitory helix.  However, we have yet to 
identify mechanisms by which Tim exchange activity can be down-regulated.  
Importantly, a tyrosine phosphatase that might remove phosphate groups from Tyr 19 and 
Tyr 22 has yet to be identified. 
Tim has recently been identified as a substrate for direct serine/threonine 
phosphorylation by Pak2 (A. Beeser and J. Chernoff, personal communication).  
Phosphorylation of an activated version of Tim (Y19E+Y22E) by Pak2 decreases its 
exchange activity in vitro (Figure 33).  Current studies are aimed at determining the 
specific residue(s) of Tim that are phosphorylated by Pak, in order to define a mechanism 
for this inhibition of exchange activity. 
Tim phosphorylation and inhibition by Pak2 would represent one of many 
mechanisms by which activation of Rac, for which Group I Pak family members are 
downstream effectors, leads to the inactivation of RhoA.  Indeed, many such examples of 
crosstalk between the signaling pathways of the Rho GTPases have been identified.  For  
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Figure 33: Tim is phosphorylated and inhibited by Pak2. 
15 μg of activated Tim (Y19E+Y22E) were incubated with ATP in the presence or absence of 6 μg of Pak2 
for 30 min at 30 degrees prior to analysis in a fluorescence-based guanine nucleotide exchange assay as 
indicated.  In the exchange assay, one fifth of the kinase assay reaction (a final [Tim] of 50 nM) was added 
to 200 nM RhoA, which had been pre-loaded with BODIPY-labeled GDP.  The rate of guanine nucleotide 
exchange was monitored as a decrease in fluorescence intensity over time as the labeled GDP is released 
into solution, where it is quenched.  The resulting curves were fit to an exponential decay model, and the 
rate of dissociation of guanine nucleotide is shown above (values represent the mean and standard error of 
the mean for three independent exchange assays from the same kinase assay). 
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example, Rac-mediated production of reactive oxygen species (ROS) leads to inhibition 
of low molecular weight protein tyrosine phosphatase, an increase in phosphorylation and 
activation of p190-RhoGAP and subsequent inhibition of RhoA (315).  Pak1 
phosphorylation of the Dbl-family GEF, GEF-H1, on Ser 885 leads to a decrease in its 
exchange activity towards RhoA due to an increase in its association with the phospho-
serine binding protein 14-3-3 (9).  Most recently, Rac has been shown to inhibit Rho 
activation in response to thrombin stimulation of endothelial cells through activation of 
Pak, which phosphorylates and inactivates p115-RhoGEF (118).  Interestingly, Rho 
activation can inhibit Rac activation in a similar manner.  The Rho effector, p160-ROCK, 
phosphorylates and decreases the activity of the Rac specific exchange factor, Tiam2 
(148).  Phosphorylation of Dbl-family proteins by the serine/threonine kinase effector 
proteins of Rho GTPases, then, may be a general mechanism by which activation of one 
Rho GTPase leads to a decrease in the activity level of another Rho GTPase. 
Identify a small molecule inhibitor of Tim. 
We have shown that Tim (Figure 12), as well as the highly related proteins Ngef 
(Figure 19) and Wgef (Figure 29), is effectively inhibited by high concentrations (100 
μM) of an 11-mer peptide based upon its auto-inhibitory helix.  However, substitution of 
a key tyrosine residue within this peptide renders the peptide inactive as an inhibitor of 
exchange activity.  In addition, this peptide inhibitor seems to be relatively selective for 
the Tim subfamily of exchange factors, since it is inactive on an unrelated protein, Trio 
(Figure 34A).  Finally, the inhibition of Tim by the 11-mer peptide is sensitive to the dose 
of peptide used, and the IC50 for the 11-mer is approximately 50 μM.  A 7-mer peptide 
derived from the original 11-mer sequence is 10-fold less active (Figure 34B). 
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Figure 34: The peptide inhibitor is specific for Tim subfamily GEFs. 
(A)  Trio (DHPH1) was incubated with the WT and MT peptides used in Figure 12.  The resulting 
complexes were assayed for their ability to stimulate loading of mant-GTP onto Rac1.  (B)  Tim (Δ22) was 
incubated with various concentrations of an 11-mer peptide (biotin-SQLLYQEYSDV-amide), or a 7-mer 
peptide (acetyl-QLLYQEY-amide).  The resulting complexes were assayed for their ability to stimulate 
loading of GTP on RhoA that had been pre-loaded with BODIPY-labeled GDP (left).  The exchange assay 
curves were fit to an exponential decay model.  The rates of dissociation were normalized and presented at 
right. 
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Alanine scanning mutagenesis experiments have revealed that Tim is regulated in 
a manner similar to the Vav isozymes, and the auto-inhibitory helix of Tim exhibits 
significant sequence identity to the auto-inhibitory helix of Vav1.  Importantly, the 
critical Vav residues Ile 173, Tyr 174 and Leu 177, which make hydrophobic contacts 
near the active site of Vav to sterically occlude the active site of the DH domain, are 
functionally conserved in the Tim auto-inhibitory helix by Ile 18, Tyr 19 and Tyr 22.  
These residues are present at positions 4, 5 and 8 of the inhibitory 11-mer peptide.  A 
synthetic agent able to reproduce the I Y x x Y (where X is any amino acid) sequence 
while maintaining the conformation of one turn of an α-helix has the potential to also 
function as an inhibitor of constitutively active Tim.   
Several candidate peptidomimetic compounds based on the auto-inhibitory helix 
of Tim were synthesized and tested for their ability to inhibit the exchange activity of 
Tim in vitro (Figure 3 A through G).  Of these, one compound in particular, 3,5-
benzyloxy-N-isobutyl benzamide (PW6_053) inhibited Tim in a dose-dependent manner 
with an IC50 of approximately 30 μM (Figure 35).  In this compound, the two benzyl 
groups function to mimic the two tyrosines in the auto-inhibitory helix (positions i+1 and 
i+4), with the isobutyl group mimicking the isoleucine (position i).  Experiments are 
currently underway to improve the water solubility and the efficacy of this potential Tim 
inhibitor. 
Establish a role for Tim in tumorigenesis. 
We have identified several mechanisms by which Tim is regulated, auto-
inhibition and tyrosine phosphorylation, however, the cellular functions of Tim are  
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Figure 35: PW6_053 is a peptidomimetic Tim inhibitor 
The ability of Tim (Δ22) to stimulate loading of GTP on RhoA that had been pre-loaded with BODIPY-
labeled GDP in the presence of various concentrations of compound PW6_053 was assessed.  The resulting 
curves were fit to an exponential decay model.  The rates of dissociation are presented at right.  Also 
depicted is the chemical structure of PW6_053.  The phenyl groups (purple) function as tyrosine mimetics, 
while the isobutyl group (blue) functions to mimic isoleucine. 
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largely unknown.  Importantly, although Tim was originally identified as an oncogene, its 
role in tumorigenesis has yet to be established.   
The EphA4 receptor tyrosine kinase was recently shown to be up-regulated in 
pancreatic ductal adenocarcinoma (PDAC) cells.  Knocking down expression of EphA4 
in these cells using siRNA decreased the viability of these cells, and conversely, over-
expressing EphA4 in these cells increased their growth rate.  Finally, it was also 
established that a ligand for EphA4, ephrin A3, is also over-expressed in these cells 
(316).  Since Tim is highly expressed in the pancreas (44), and since we believe Tim to 
be part of a signal transduction pathway downstream of EphA4, we would like to study 
the role of Tim in pancreatic cancer development. 
To this end, we would like to investigate whether Tim is expressed in PDAC cell 
lines and primary tumors using the anti-Tim antibody described above.  Affinity 
purification experiments using GST-tagged rhotekin could be used to ascertain the level 
of RhoA activity in these cell lines and tumor samples.  Additionally, we would like to 
use RT-PCR, using previously established primers for the Tim mRNA (244), coupled 
with direct nucleotide sequencing to determine if the Tim expressed in PDAC cell lines 
and tumors harbors mutations in the auto-inhibitory helix or DH domain that we would 
expect to be auto-activating based upon our understanding of the mechanism by which 
Tim is regulated.  Should we find a cell line that expresses Tim, we would like to 
determine if knocking down expression of Tim, or inhibition of Tim activity with a small 
molecule, affects the ability of this cell line to proliferate or grow in the absence of 
adherence to the extracellular matrix.   
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Identify the functional consequences of Ngef activation of Rac1 in neurons. 
We have used functional in vitro and cellular assays to show that truncation, 
mutation or phosphorylation of the auto-inhibitory helix of Ngef activates this Dbl-family 
GEF toward its entire repertoire of cognate GTPases, RhoA, Rac1 and Cdc42.  These 
data are in contrast with experiments describing the regulation of the mouse paralog of 
Ngef, ephexin.  Several lines of future experimentation are aimed at resolving this 
discrepancy.  We will study the spatio-temporal dynamics of Ngef localization in primary 
cortical neuron progenitor cells in order to determine if Ngef is properly localized in the 
cell to activate Cdc42 as well as RhoA.  We are working in collaboration with Dr. 
Prithwish Pal in the laboratory of Dr. Klaus Hahn to develop novel fluorescent biosensors 
for Ngef in the activated state.  These sensors will be used in conjunction with the 
biosensors for activated RhoA and Cdc42 previously developed in the Hahn lab (317), as 
well as with traditional immunofluorescence techniques to resolve the localization of the 
total pools of RhoA, Cdc42 and Ngef in these cells. 
In addition, it has been shown that ephrin induced growth cone collapse is 
dependent on Vav2 activation of Rac1.  Active Rac1 in this context promotes 
internalization of the membranes in which both the ligand ephrin and the receptor EphA4 
are localized via a unique endocytosis event (282).  Our future experiments include 
investigating if ephexin/Ngef activation of Rac1 can function in this pathway.  We will 
treat primary cortical neuron progenitor cells from ephexin -/- knockout mice with either 
pre-clustered ephrin A1-Fc or Fc alone prior to fixing the cells and blocking them in 
either the presence or absence of a permeabilizing agent, the detergent, TritonX-100.  We 
will then visualize the surface (unpermeabilized cells) or total (permeabilized cells) 
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ephrin A1-Fc by indirect immunofluorescence using a Cy3-conjugated anti-human Fc 
antibody.  We anticipate that the cells derived from the ephexin -/- mice will display 
more surface ephrin A1-Fc than cells derived from wild type mice due to impairment of 
activation of Rac1 and subsequent inhibition of Rac1-mediated endocytosis of the 
ephrin/Eph complex. 
Identify binding partners for the SH3 domain and poly-proline region of Tim. 
We have established that the exchange potential of Tim is auto-inhibited by two 
sets of intramolecular interactions: the auto-inhibitory helix packing into a conserved 
pocket on the DH domain and the SH3 domain binding to the N-terminal poly-proline 
region.  Binding of another protein to either the poly-proline region or the SH3 domain, 
could serve to activate the exchange potential of Tim.  The identification of such 
interacting proteins is an important future aim.   
We plan to transfect HEK 293T cells, which express Tim endogenously and 
therefore are likely to also express proteins that interact with Tim, with HA-tagged wild 
type Tim, or HA-tagged versions of Tim with mutations in the poly-proline region 
(P49A) or the SH3 domain (W470R) that are expected to prevent these regions from 
binding to proteins containing SH3 domains or poly-proline regions, respectively.  We 
will then affinity purify Tim-containing protein complexes on an anti-HA matrix, and 
analyze these protein complexes by SDS-PAGE followed by Coomassie or silver 
staining.  Bands present in the immunoprecipitates of HA-Tim, but not HA-Tim (P49A) 
or HA-Tim (W470R) will be trypsin digested and identified by liquid chromatography 
and mass spectrometry. 
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Summary: 
We have shown that the Dbl-family protein, Tim, is a RhoA, RhoB and RhoC-
specific GEF that is auto-inhibited by a putative helix N-terminal to the DH domain, 
which directly binds the DH domain to sterically exclude Rho GTPases and prevent their 
activation.  This auto-inhibition is relieved by truncation, mutation, or phosphorylation of 
the auto-inhibitory helix, or by mutation of the conserved surface of the DH domain to 
disrupt interactions with the auto-inhibitory helix.  Since inhibition of Tim can be 
restored by addition of the auto-inhibitory helix in trans, the auto-inhibitory helix is 
necessary and sufficient for maintenance of a basal state of Tim activation. 
We have also demonstrated that Ngef is activated towards its full repertoire of 
cognate GTPases, namely RhoA, Rac1 and Cdc42, by removal, substitution or Src-
dependent tyrosine phosphorylation of a small, conserved sequence N-terminal to its DH 
domain.  This work is in contrast to published studies, which show that phosphorylation 
of the mouse paralog of Ngef, ephexin, activates this GEF toward only RhoA.  Ngef 
exchange activity is inhibited by a peptide derived from the auto-inhibitory sequence of 
Tim, indicating that these two proteins are regulated in a near identical manner.  The 
exchange activity of Ngef, and its Rho-specific exchange activity in particular, functions 
to inhibit axon outgrowth in developing neurons. 
Finally, we have shown preliminary data that indicate that Tim is also auto-
inhibited by the SH3 domain binding to the N-terminal poly-proline region.  This second 
interaction serves to both stabilize the auto-inhibitory helix on the DH domain and to 
partially occlude the DH domain.  Future studies will identify other Dbl-family members 
regulated in a manner similar to Tim, define the precise molecular details of Tim auto-
 163
inhibition and rationally design small molecule inhibitors of Tim activity.  They will also 
define the intracellular signaling pathways regulating Tim under normal conditions and 
during tumorigenesis.  Finally, future studies will establish the physiological role for 
Ngef activation of multiple GTPases. 
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